AccessIDB# SEARCH REQUEST FORM 6 Scientific and Technical/Inf rmation Center Requester's Full Name: PATEL, S.U) HAKER Examiner #: 7.1018 Date: Phone Number 30 8 4709 Serial Number: Art Unit: 1624 006 92 Mail-Boxsand Bidg/Room Location CM1-4E17 Results Format Preferred (circle): (PAPER) DISK-2E-MAIL UE 11 more than one search is submitted; please prioritize searches in order of need. MEI Please provide:a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched Include a herelected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or a state utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract. USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ALTIVITY Title of Invention: STEPHEN THOM et al Inventors (please provide full names): Point of Contact SusaniHanley Technical/Into: Specialist CM1 6B05 Tel: 305-4053 8124/199 Earliest Priority Filing Date: *For Sequence Searches Only* Please include all partinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial numbe DE rocycle »زم مک ۵n Heterociel C AL (DAA) HI CO-MH AVAILABLE S. SS/STATHESIS, recer STAFF USE ON BY Type of Search Vendors and cost where applicab Searcher: -STN NA Sequence (#) Searcher Phone AA Sequence (# Dialog Questel/Orbit Structure (#) Searcher Location 53 101 3 Date Searcher Picked Up: Bibliographic Dr.Link Date Completed: Litigation Lexis/Nexis ÷. Fulltext Searcher Prep & Review Time: Sequence Syster WWW/Internet Clerical Prep Time: Patent Family Online Time: Other (specify) Other PTO=1590 (8-01)

=> d ibib abs hitstr 1-44

T-SE ANSWER R-OF 44 HOA	BLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:	2002:754995 HCAPLUS
DOCUMENT NUMBER:	137:268473
TITLE:	Porous drug matrices and methods of manufacture thereof
INVENTOR(S):	Straub, Julie; Altreuter, David; Bernstein, Howard; Chickering, Donald E.; Khattak, Sarwat; Randall, Greg
PATENT ASSIGNEE(S):	Acusphere Inc., USA
SOURCE :	U.S. Pat. Appl. Publ., 20 pp., Contin-part of U.S. 6,395,300. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	


PATENT NO.	KIND	DATE	APPLICATION NO. DATE
US 2002142050	A1	20021003	US 2002-53929 20020122 <
US 6395300	B1	20020528	US 1999-433486 19991104 <
PRIORITY APPLN. INFO.	:		US 1999-136323P P 19990527 <
			US 1999-158659P P 19991008
			US 1999-433486 A2 19991104


Drugs, esp. low aq. soly. drugs, are provided in a porous matrix form, AB preferably microparticles, which enhances dissoln. of the drug in aq. media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aq: soly., in a volatile solvent to form a drug soln., (ii) combining at least one pore forming agent with the drug soln. to form an emulsion, suspension, or second soln. and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystn., and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second soln. to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in cryst. form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystn. The pore forming agent can be either a volatile liq. that is immiscible with the drug solvent or a volatile solid compd., preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aq. medium and administered parenterally, or processed using std. techniques into tablets or capsules for oral administration. Thus, 5.46 g of PEG 8000, 0.545 g of prednisone, and 0.055 g of Span 40 were dissolved in 182 mL of methylene chloride. A soln. of 3.27 g of ammonium bicarbonate in 18.2 mL of water was added to the org. soln. (phase ratio 1:10) and homogenized for 5 min at 16,000 RPM. The resulting emulsion was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas. 120014-06-4, Donepezil IT

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (porous drug matrixes and methods of manuf. thereof)

```
RN 120014-06-4 HCAPLUS
```

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4piperidinyl]methyl]- (9CI) (CA INDEX NAME)





II

Searched by Susan Hanley 305-4053


NH2

- AB The title compds. [I; A = pyrrole; R1 = (un)substituted aryl or heteroaryl; R2 = (un)substituted nitrogen-contg. heteroaryl; R3 = XR4 (wherein X = a single bond, (un)substituted alkylene, alkenylene, alkynylene; R4 = substituted cycloalkyl, aryl, heterocyclyl, etc.); provided that said substituents R1 and R3 are bonded to the two atoms of said pyrrole ring which are adjacent to the atom of the pyrrole ring to which said substituent R2 is bonded] which have excellent inhibitory activity against the prodn. of inflammatory cytokines such as TNF.alpha. (biol. data given) and IL-1.beta., and are useful in treating arthritis, were prepd. and formulated. E.g., a multi-step synthesis of the pyrrole II was given.
- IT 321343-86-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of heteroaryl-substituted pyrroles having excellent inhibitory activity against the prodn. of inflammatory cytokines)


- RN 321343-86-6 HCAPLUS
- CN Pyridine, 4-[3-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1Hpyrrol-2-yl]- (9CI) (CA INDEX NAME)



L38 ANSWER 3 OF 44 HCAPLUS COPYRIGHT 2002 ACS 2001:31464 HCAPLUS ACCESSION NUMBER: 134:100762 DOCUMENT NUMBER: TITLE: Preparation of pyridine derivatives and medicinal use thereof Iino, Yukio; Fujita, Kohichi; Kodaira, Ariko; Hatanaka, Toshihiro; Takehana, Kenji; Kobayashi, Tsuyoshi; Konishi, Atsushi; Yamamoto, Takashi INVENTOR(S): Ajinomoto Co., Inc., Japan PATENT ASSIGNEE(S): PCT Int. Appl., 86 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent Japanese LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATEL 10/069,215


PATENT NO. KIND DATE								APPLICATION NO. DATE										
	10 2001	001002359 A1 200			2001	0010111 WO 2000-JP4298						20000629 <						
											, вG,						CN,	
											, FI,							
		нU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG	, KP	, KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	
											, MZ,							
											, TT,							
		YU,	ZA,	Z₩,	AM,	ΑZ,	ΒY,	KG,	ΚZ	, MD	, RU,	ТJ,	ТΜ					
	RW:	GH,	GM,	KΕ,	LS,	MW,	ΜZ,	SD,	SL	, SZ	, TZ,	UG,	ZW,	ΑT,	ΒE,	CH,	CY,	
		DE,	DK,	ES,	FΙ,	FR,	GB,	GR,	ΙE	, IT	, LU,	MC,	NL,	ΡT,	SE,	BF,	ΒJ,	
											, NE,							
E	CP 1193	3255		А	1	2002	0403			EP 2	000-9	4087	9	2000	0629	<		
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB	, GR	, IT,	LI,	LU,	NL,	SE,	MC,	PΤ,	
		IE,	SI,	LT,	LV,	FI,	RO											
E	3R 2000	0120	46	А		2002	0514		BR 2000-12046						20000629 <			
Ŭ	JS 2002	21330	05	А	1	2002	0919			US 2	001-2	9871		2001	1231	<		
PRIORI	TY APP	PLN.	INFO	.:					JP	1999	-1879	59	А	1999	0701	<		
									JP	2000	-7170	6	А	2000	0315			
									WO	2000	-JP42	98	W	2000	0629			
OTHER GI	SOURCE	E(S):			MAF	RPAT	134:	1007	62									




AB Heterocyclic compds. represented by the following general formula R1-CO-N(R2)-A-X-B-N(R3)-Y-(CH2)n-R4 [R1 = (un)substituted or cycloalkenyl; R2, R3 = H, alkyl; R4 = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, or heterocyclyl having .gtoreq.1 heteroatom(s); A = (un)substituted heterocyclic ring; B = (un)substituted arom. or heterocyclic ring; n = 0-6; Y = a bond between atoms, CO, CO2, CONR5, C(S)NR5, SO, SO2 (wherein R5 = H, alkyl); X = a bond between atoms, O, OCHR7, CHR80, O2C, CO2, OC(S), C(S)O, S, SO, SO2, SCHR9, CHR10S, SC(O), C(O)S, SC(S), C(S)S, SO2 NR11, NR12SO2, NR13, etc.; R7 - R10 = H, alkyl; R11 - R13 = H, alkyl, acyl] or pharmacol. acceptable salts thereof are prepd. These compds. have inhibitory effects on AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor, etc. and are usable as drugs such as antiinflammatory, antirheumatic, antiviral agents, immunosuppressants, cancer metastasis inhibitors, and antiarteriosclerotics. Thus, 2-mercapto-5-nitropyridine was treated with NaH in DMF and then alkylated by 1-bromomethyl-4-nitrobenzene at room temp. for 1.5 h to give 2-(4-nitrobenzylthio)-5-nitropyridine which was reduced by Zn/AcOH in THF at room temp. for 16 h to 2-(4-aminobenzylthio)-5-aminopyridine and then acylated by 2,2-dimethylcyclopropanecarbonyl chloride in the presence of Et3N in CH2Cl2 at room temp. for 17 h to give 2-(4-(2,2-dimethylcyclopropanecarbonylamino)benzylthio)-5-(2,2dimethylcyclopropanecarbonylamino)pyridine (I). I in vitro inhibited NF-kappa B activity with IC50 of 0.015 .mu.g/mL in an assay measuring .beta.-galactosidase activity expressed in HUVEC cells and driven by

NF-kappa B-binding sequence-fused SV40 T antigen min. promoter.

- IT 318967-28-1P 318967-29-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B
 activity, inflammatory cytokine prodn., matrix metalloprotease prodn.,
 expression of inflammatory cell adhesion factor)
- RN 318967-28-1 HCAPLUS
- CN Cyclopropanecarboxamide, N-[1-[[4-[[(2,2-dimethylcyclopropyl)carbonyl]amin o]phenyl]methyl]-4-piperidinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



- RN 318967-29-2 HCAPLUS
- CN Cyclopropanecarboxamide, N-[1-[2-[4-[[(2,2-dimethylcyclopropyl)carbonyl]am ino]phenyl]ethyl]-4-piperidinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



10

REFERENCE COUNT:

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 4 OF 44 HCA ACCESSION NUMBER: DOCUMENT NUMBER:	APLUS COPYRIGHT 2002 ACS 2000:861473 HCAPLUS 134:32972
TITLE:	Porous drug matrixes containing polymers and sugars and methods of their manufacture
INVENTOR(S):	Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg
PATENT ASSIGNEE(S):	Acusphere, Inc., USA
SOURCE:	PCT Int. Appl., 45 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT: PATENT INFORMATION:	2

APPLICATION NO. DATE PATENT NO. KIND DATE _____ _____ ____ WO 2000-US14578 20000525 <--20001207 WO 2000072827 A2 20010125 WO 2000072827 AЗ W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,


PATEL 10/069,215

		SK,	SL,	тJ,	ΤM,	TR,	ΤT,	ΤZ,	UA	, UG,	UΖ,	VN,	YU,	ZA,	ZW,	AM,	AZ,
		BY,	KG,	KΖ,	MD,	RU,	тJ,	ΤM									
	RW:	GH,	GM,	KΕ,	LS,	MW,	MZ,	SD,	SL	, SZ,	ΤZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE	, IT,	LU,	MC,	NL,	ΡT,	SE,	BF,	BJ,
		CF,	CG,	CI,	CM,	GA,	GN,	G₩,	ML	, MR,	NE,	SN,	ΤD,	ΤG			
US	6395	300		В	1	2002	0528		1	US 19	99-4	3348	6	1999	1104	<	
EP	1180	020		A	2	2002	0220			EP 20	00-9	3936	5	2000	0525	<	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB	, GR,	IT,	LI,	LU,	NL,	SE,	MC,	ΡT,
		IE,	SI,	LT,	LV,	FI,	RO										
BR	2000	0109	84	А		2002	0430			BR 20	00-1	0984		2000	0525	<	
US	2002	0418	96	А	1	2002	0411			US 20	01-7	9882	4	2001	0302		
. NO	2001	0057	53	А		2002	0128			NO 20	01-5	753		2001	1126	<	
PRIORIT								1	US	1999-	1363	23P	Р	1999	0527	<	
								1	US	1999-	1586	59P	Р	1999	1008		
								1	US	1999-	4334	86	А	1999	1104		
								1	US	2000-	1863	10P	Р	2000	0302		
								ļ	WO	2000-	US14	578	W	2000	0525		

AB Drugs, esp. low aq. soly. drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aq. media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aq. soly., in a volatile solvent to form a drug soln., (ii) combining at least one pore forming agent with the drug soln. to form an emulsion, suspension, or second solns., and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second soln. to yield the porous matrix of drug. The pore forming agent can be either a volatile liq. that is immiscible with the drug solvent or a volatile solid compd., preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aq. medium and administered parenterally, or processed using std. techniques into tablets or capsules for oral Paclitaxel or docetaxel can be provided in a porous administration. matrix form, which allows the drug to be formulated without solubilizing agents and administered as a bolus. For example, a nifedipine-loaded org. soln. was prepd. by dissolving 9.09 g of PEG 3350, 2.27 g of nifedipine, and 0.009 g of lecithin in 182 mL of methylene chloride. An aq. soln. was prepd. by dissolving 3.27 g of NH4HCO3 and 0.91 g of PEG 3350 in 1.82 mL of water. The aq. and org. solns. were homogenized and resulting emulsion was spray dried. A suspension of the porous nifedipine drug matrix was prepd. in 5% dextrose soln. at a concn. of 2.5 mg/mL. A bolus injection of the suspension was tolerated when administrated to dogs.


IT 120014-06-4, Donepezil
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
use); BIOL (Biological study); PROC (Process); USES (Uses)
 (prepn. of porous matrixes contg. hydrophilic polymers and sugars for
 enhancement of drug dissoln.)

- RN 120014-06-4 HCAPLUS
- CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4piperidinyl]methyl]- (9CI) (CA INDEX NAME)



HCAPLUS COPYRIGHT 2002 ACS L38 ANSWER 5 OF 44 2000:814466 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 133:362714 Preparation of cyclic compounds having antagonism TITLE: against .beta.-beta chemokine receptor (CCR5) Shiraishi, Mitsuru; Baba, Masanori; Seto, Masaki; INVENTOR(S): Kanzaki, Naoyuki; Nishimura, Osamu Takeda Chemical Industries, Ltd., Japan PATENT ASSIGNEE(S): PCT Int. Appl., 282 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent Japanese LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

DATE APPLICATION NO. DATE PATENT NO. KIND ______ ____ ____ _____ _____ 20000428 <--WO 2000-JP2825 20001116 WO 2000068203 A1 W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 20010130 JP 2000-134249 20000428 <--JP 2001026586 A2 EP 2000-921096 20000428 <--EP 1182195 20020227 A1 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, R: IE, SI, LT, LV, FI, RO PRIORITY APPLN. INFO.: JP 1999-127724 А 19990507 <--WO 2000-JP2825 Ŵ 20000428 OTHER SOURCE(S): MARPAT 133:362714 GI



Compds. of general formula R1-X1-W-X2-Z1-Z2-R2 or salts thereof [wherein AB R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or divalent group having 1-4 C atoms in the straight chain moiety; W is a divalent group represented by general formula Q, Q1, or Q2 (wherein A and B are each an optionally substituted five- to seven-membered ring; E1 and E4 are each optionally substituted carbon or N; E2 and E3 are each optionally substituted carbon or N, O, or optionally oxidized S; and a and b are each a single bond or a double bond); X2 is a divalent group constituting a C1-4 straight chain moiety; Z1 is a single bond or a divalent cyclic group; Z2 is a free valency or divalent group having 1-4 C atoms in the straight chain moiety; and R2 is (1) optionally substituted, quaternized, or oxidized amino, (2) optionally substituted N-contg. heterocyclyl optionally contg. S or O and optionally quaternized or oxidized at the N atom, (3) group bonding through S atom, etc.] are These compds. exhibit preventive and therapeutic effects against prepd. HIV infections or AIDS. Thus, chlorination of 7-[(2-propoxybenzyl)oxy]-1,1-dioxo-2,3-dihydro-1-benzothiepin-4-carboxylic acid by SOCl2 in the presence of one drop of DMF at room temp. for 1 h followed by condensation with 4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]aniline in the presence of Et3N in THF at room temp. for 2 days gave N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-7-[(2-propoxybenzyl)oxy]-1,1dioxo-2,3-dihydro-1-benzothiepin-4-carboxamide (I). I in vitro inhibited the binding of 125I-RANTES to recombinant CCR5 receptor by 98%. A capsule and a tablet formulation contg. I were prepd.


IT 307301-68-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of cyclic compds. having antagonism against CCR 5 receptor for preventives and therapeutics for HIV and AIDS) 202201 (C. 4. UCAPUUC)

RN 307301-68-4 HCAPLUS

CN


1-Benzoxepin-4-carboxamide, 2,3-dihydro-7-(4-methylphenyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




14

REFERENCE COUNT:

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT





•

AB The title compds. I [one of T and U is N+R5 and R5 = alkyl, haloalkyl, amidoalkyl, etc., and the other is CH; X- = counterion; R1, R2 = H, alkyl; m = 0-3; Ar, Ar1 = aryl, heteroaryl; F = alkylene, alkenylene, bond; R = H, alkyl; R3, R4 = H, alkyl, cycloalkyl, etc.; E = CONR6, SO2NR6, etc.; q = CO, alkylene optionally interrupted by CO, NR8, O, etc.], CCR-3 receptor antagonists, were prepd. E.g., 4-(3,4-dichlorobenzyl)-1-methyl-1-{3methyl-2R-[3-(3,4,5-trimethoxyphenyl)ureido]butyl}piperidinium iodide was prepd.


IT 270572-41-3P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic

PATEL 10/069,215

use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of piperidine quaternary salts as CCR-3 receptor antagonists)

- RN 270572-41-3 HCAPLUS
- CN Piperidinium, 4-[(3,4-dichlorophenyl)methyl]-1-[(2R)-3-methyl-2-[[[(3,4,5trimethoxyphenyl)amino]carbonyl]amino]butyl]-1-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



) I-

L38 ANSWER 7 OF 44 HC ACCESSION NUMBER: DOCUMENT NUMBER:	CAPLUS COPYRIGHT 2002 ACS 2000:646008 HCAPLUS 133:207890
TITLE:	Preparation of N-piperidinylbenzothiazolylthioacetamid e derivatives and analogs thereof as chemokine receptor antagonists
INVENTOR(S):	Naya, Akira; Kobayashi, Kensuke; Ishikawa, Makoto; Saeki, Toshihiko; Ohwaki, Kenji; Otake, Norikazu; Noguchi, Kazuhito
PATENT ASSIGNEE(S): SOURCE:	Banyu Pharmaceutical Co., Ltd., Japan PCT Int. Appl., 50 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT: PATENT INFORMATION:	1


PATENT NO. KIND DATE APPLICATION NO. DATE _____ _____ _____ _____ ____ 20000914 WO 2000-JP1479 20000310 <--WO 2000053600 A1 AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, W : CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG JP 1999-64194 A 19990311 <--PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 133:207890 GI




- The title compds. I [m is 0 or 1; n is an integer of from 1 to 3; R1 and AB R2 are the same or different and each represents hydrogen, halogeno, amino, etc.; R3 and R4 are the same or different and each represents hydrogen, halogeno, nitro, etc.; and X and Y are the same or different and each represents oxygen or sulfur] are prepd. These compds. specifically inhibit, for example, binding of a chemokine to a chemokine receptor such as CCR3 and regulate the selective migration and activation of leukocytes. Due to this effect, these compds. are useful in treating, for example, acute and chronic inflammatory diseases such as sepsis, pneumonia, arthritis and allergic diseases, cancer, reperfusion injury, arteriosclerosis, rejection reaction in assocn. with organ transplantation, human immunol. deficiency syndrome, etc., in particular, acute and chronic inflammatory diseases and human immunol. deficiency syndrome. In an in vitro test for CCR3 antagonism, N-[1-(3,4-dichlorobenzyl)-4-piperidyl]-(6-amino-2benzothiazolylthio)acetamide showed IC50 of 68 nM.
- IT 290363-19-8P 290363-23-4P 290363-29-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation); cf N=piperidipylbenzotbiazolyltbioacetamide derives and analogs)

(prepn. of N-piperidinylbenzothiazolylthioacetamide derivs. and analogs thereof as **chemokine** receptor antagonists)


- RN 290363-19-8 HCAPLUS
- CN Acetamide, 2-(2-benzothiazolylthio)-N-[1-[(4-chloro-3-nitrophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




- RN 290363-23-4 HCAPLUS
- CN Acetamide, 2-[(6-amino-2-benzothiazolyl)thio]-N-[1-[(3,4dichlorophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




- RN 290363-29-0 HCAPLUS
- CN 6-Benzothiazolecarboxylic acid, 2-[[2-[[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]amino]-2-oxoethyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



- IT 290363-00-7P 290363-02-9P 290363-05-2P 290363-07-4P 290363-10-9P 290363-21-2P 290363-25-6P 290363-27-8P 290363-31-4P 290363-33-6P 290363-35-8P 290363-37-0P 290363-39-2P 290363-41-6P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N-piperidinylbenzothiazolylthioacetamide derivs. and analogs thereof as chemokine receptor antagonists) RN 290363-00-7 HCAPLUS
- CN Acetamide, 2-(2-benzothiazolylthio)-N-[1-(phenylmethyl)-4-piperidinyl]-
 - (9CI) (CA INDEX NAME)




RN 290363-02-9 HCAPLUS CN Acetamide, 2-(2-benzothiazolylthio)-N-[1-[(4-cyanophenyl)methyl]-4piperidinyl]- (9CI) (CA INDEX NAME)




RN 290363-05-2 HCAPLUS CN Acetamide, 2-(2-benzothiazolylthio)-N-[1-[(3,4-dichlorophenyl)methyl]-4-


piperidinyl]- (9CI) (CA INDEX NAME)




- RN 290363-07-4 HCAPLUS
- CN Acetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2-[(6-ethoxy-2benzothiazolyl)thio]- (9CI) (CA INDEX NAME)




- RN 290363-10-9 HCAPLUS
- CN Acetamide, 2-.(2-benzothiazolyloxy)-N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]- (9CI) (CA INDEX NAME)




RN 290363-21-2 HCAPLUS CN Acetamide, N-[1-[(3-amino-4-chlorophenyl)methyl]-4-piperidinyl]-2-(2benzothiazolylthio)- (9CI) (CA INDEX NAME)




- RN 290363-25-6 HCAPLUS
- CN Acetamide, 2-[[6-(acetylamino)-2-benzothiazolyl]thio]-N-[1-[(3,4dichlorophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 290363-27-8 HCAPLUS CN Benzamide, N-[2-[[2-[[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]amino]-2-oxoethyl]thio]-6-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 290363-31-4 HCAPLUS CN 6-Benzothiazolecarboxamide, 2-[[2-[[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]amino]-2-oxoethyl]thio]-N,N-dimethyl- (9CI) (CA INDEX NAME)




- RN 290363-33-6 HCAPLUS
- CN 6-Benzothiazolecarboxamide, 2-[[2-[[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]amino]-2-oxoethyl]thio]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




- RN 290363-35-8 HCAPLUS
- CN 6-Benzothiazolecarboxamide, 2-[[2-[[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]amino]-2-oxoethyl]thio]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




- RN 290363-39-2 HCAPLUS
- CN 6-Benzothiazolecarboxamide, 2-[[2-[[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]amino]-2-oxoethyl]thio]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



PRIORITY APPLN. INFO.:	JP	1999-33367	А	19990210 <
	JP	1999-198473	А	19990713 <
	WO	2000-JP767	W	20000210
OTHER SOURCE(S):	MARPAT 133:177164			


OTHER SOURCE(S): N GI



AB The title compds. I [R1 represents substituted aryl, heteroaryl, etc.; R2 and R3 represent each hydrogen, alkyl, halogeno, hydroxy, etc.; Q represents N, CH, etc.; W represents hydrogen, alkyl, hydroxycarbonylalkyl, etc.; X represents halogeno, cyano, nitro, amino, etc.; X' represents hydrogen, halogeno, cyano or nitro; and Y represents alkyl, hydroxy, alkoxy, etc.] are prepd. For example, pyrazolecarboxamide deriv. II was prepd. The title compds. are said to show significant inhibiting activity against the proliferation of activated lymphocytes in in vitro tests. A formulation is given.

IT 288251-43-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyrazolecarboxamides and pyrrolecarboxamides as inhibitors
 of the proliferation of activated lymphocytes and as remedies for
 autoimmune disease.)


- RN 288251-43-4 HCAPLUS CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-[3-cyano-4-[[4-(4
 - morpholinyl)-1-piperidinyl]methyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 2-A

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS .



9

REFERENCE COUNT:

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L38 ANSWER 9 OF 44 HCAPLUS COPYRIGHT 2002 ACS 2000:455294 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 133:74017 Preparation of 5-phenyl-2-piperidinyl-4-TITLE: pyridylimidazoles and related compounds having anticancer and cytokine inhibitory activity. Liverton, Nigel J.; Claiborne, Christopher F.; INVENTOR(S): Claremon, David A.; Selnick, Harold G. Merck and Co., Inc., USA PATENT ASSIGNEE(S): U.S., 46 pp., Cont.-in-part of U.S. 5,717,100. CODEN: USXXAM SOURCE: DOCUMENT TYPE: Patent LANGUAGE: English


Searched by Susan Hanley 305-4053

Page 18

FAMILY ACC. NUM. COUNT: 3 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION N	о.	DATE
US 6083949	А	20000704	US 1998-13527		19980126 <
US 5717100	А	19980210	US 1996-71795	5	19960923 <
PRIORITY APPLN. IN	FO.:	US	1995-5059P	Р	19951006 <
		US	1995-5063P	Ρ	19951006 <
		US	1996-717955	A2	19960923 <
OTHER SOURCE(S):	MA	ARPAT 133:74017			


GI



- AB Title compds. [I; Ar = aryl; X, X1 = (CH2)mY(CH2)n; m, n = 0-4; m+n = 0-6; Y = bond, O, S, SO, SO2, CO, CO2, etc.; Het = nonarom. N-heterocyclyl; R, R2 = 1-3 of halo, OH, cyano, CONH2, (substituted) alkyl, alkoxy, cycloalkyl, etc.; R1 = 1-3 of OH, cyano, (substituted) alkyl, cycloalkyl, alkoxy, heterocyclyl, etc.; R3 = H, (substituted) alkyl, alkoxy, alkylcarbonyl], were prepd. Thus, 4-pyridylcarbinol tertbutyldimethylsilyl ether and then 4-fluorophenyl N, Odimethylbenzhydroxamide were added to LDA in THF at -20.degree. to give 1-(4-fluorophenyl)-2-hydroxy-2-pyridin-4-ylethanone tertbutyldimethylsilyl ether. The latter was refluxed with N-tert-butoxycarbonylpiperidine-4-carboxaldehyde, NH4OAc, and Cu acetate in HOAc to give tert-Bu 4-[5-(4-fluorophenyl)-4-pyridin-4-yl-1H-imidazol-2yl]piperidine-1-carboxylate. I showed IL-8 inhibitory activity with IC50 = 0.001-1.5 mM.
- IT 189442-12-4P 189442-26-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 5-phenyl-2-piperidinyl-4-pyridylimidazoles and related compds. having anticancer and cytokine inhibitory activity)

- RN 189442-12-4 HCAPLUS
- CN Pyridine, 4-[5-(4-fluorophenyl)-2-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-4-yl]- (9CI) (CA INDEX NAME)




```
RN 189442-26-0 HCAPLUS
```

```
CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-(phenylmethyl)-4-piperidinyl]-1H-
imidazol-4-yl]- (9CI) (CA INDEX NAME)
```



THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 16 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT HCAPLUS COPYRIGHT 2002 ACS L38 ANSWER 10 OF 44 2000:420964 HCAPLUS ACCESSION NUMBER: 133:43445 DOCUMENT NUMBER: Preparation of N-ureidoalkyl-piperidines as modulators TITLE: of chemokine receptor activity Ko, Soo S.; Duncia, John V. K.; Santella, Joseph B., INVENTOR(S): III; Wacker, Dean A.; Kim, Ui Tae Du Pont Pharmaceuticals Company, USA PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 351 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 5 PATENT INFORMATION:

PAT	KIND DATE				I	APPLI	CATI	э. 	DATE								
WO	2000	0354	54	A	1	2000	0622		V	10 19	99-U	s303	36	1999:	1217	<	
	W:	AL,	AU,	BR,	CA,	CN,	CZ,	ΕE,	HU,	IL,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	ΤR,	UA,	VN,	ZA,	AM,	AZ,	ΒY,	KG,	KΖ,
		MD,	RU,	ТJ,	ΤM												
	RW:	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		PT,															
EP	1140	087		A	1	2001	1010		E	EP 19	99-9	6532	2	1999	1217	<	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PΤ,
		IE,	SI,	LT,	LV,	FI,	RO										
US	6331	541		B	1	2001	1218		τ	JS 19	99-4	6528	8	1999	1217	<	
PRIORITY	APP	LN.	INFO	. :					US 1	1998-	1127	17P	Р	1998	1218	<	
									US 1	1999-	1611	84P	Р	1999	1022		
									US 1	1999-	1612	22P	Р	1999:	1022		
								1	WO 1	L999-1	US30	336	W	1999	1217		
OTHER SC GI	DURCE	(S):			MAR	PAT	133:	4344	5								




- AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepd. and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/da (oral dosage).
- 275810-47-4P 275810-48-5P 275810-49-6P ΙT 275810-58-7P 275810-59-8P 275810-60-1P 275810-61-2P 275810-62-3P 275810-63-4P 275810-64-5P 275810-65-6P 275810-66-7P 275810-67-8P 275810-68-9P 275810-69-0P 275810-70-3P 275810-71-4P 275810-72-5P 275810-73-6P 275810-74-7P 275810-80-5P 275810-81-6P 275810-83-8P 275810-84-9P 275810-86-1P 275810-87-2P 275810-88-3P 275810-92-9P 275810-93-0P 275810-94-1P 275810-95-2P 275810-96-3P 275810-97-4P 275810-98-5P 275810-99-6P 275811-00-2P 275811-01-3P 275811-05-7P 275811-06-8P 275811-07-9P 275811-08-0P 275811-09-1P 275811-10-4P 275811-11-5P 275811-12-6P 275811-13-7P 275811-14-8P 275811-15-9P 275811-16-0P 275811-17-1P 275811-18-2P 275811-20-6P 275811-24-0P 275811-25-1P 275811-26-2P 275811-27-3P 275811-28-4P 275811-29-5P 275811-30-8P 275811-31-9P 275811-32-0P 275811-33-1P 275811-34-2P 275811-35-3P 275811-36-4P 275811-39-7P 275811-40-0P 275811-41-1P 275811-42-2P 275811-43-3P 275811-44-4P 275811-45-5P 275811-46-6P 275811-47-7P 275811-48-8P 275811-49-9P 275811-50-2P 275811-51-3P 275811-52-4P 275811-53-5P 275811-54-6P 275811-55-7P 275811-61-5P 275811-69-3P 275811-70-6P 275811-71-7P 275811-72-8P 275811-74-0P 275811-75-1P 275811-76-2P 275811-78-4P 275811-79-5P 275815-82-2P 275815-83-3P 275815-84-4P 275815-85-5P


PATEL 10/069,215

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)


- 275810-47-4 HCAPLUS RN
- Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[2-[[4-(phenylmethyl)-1-CN piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- 275810-48-5 HCAPLUS RN
- Urea, N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1-CN piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-49-6 HCAPLUS
- Urea, N-(2,5-difluorophenyl)-N'-[[3-[[4-(phenylmethyl)-1-CN piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275810-58-7 HCAPLUS CN piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)
 - Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[3-[[4-(phenylmethyl)-1-




- RN 275810-59-8 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)







- RN 275810-60-1 HCAPLUS
- CN Urea, N-(3-hydroxypropyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-61-2 HCAPLUS
- CN Urea, N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[2-(1piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 275810-62-3 HCAPLUS CN Urea, N-[2-(dimethylamino)ethyl]-N'-[2-[[4-(phenylmethyl)-1-




RN 275810-63-4 HCAPLUS
CN 1-Piperazinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-64-5 HCAPLUS
CN 1-Piperidinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- PII CH2
- RN 275810-65-6 HCAPLUS
- CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-66-7 HCAPLUS CN Urea, N-(2,2-diphenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)







RN 275810-67-8 HCAPLUS CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-69-0 HCAPLUS
CN 1-Piperidinecarboxamide, 4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-70-3 HCAPLUS CN Urea, N-1H-indazol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-71-4 HCAPLUS
- CN Urea, N-1H-indazol-6-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-72-5 HCAPLUS CN Urea, N-(phenylmethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-73-6 HCAPLUS CN Urea, N-1,3-benzodioxol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-74-7 HCAPLUS
- CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[6-[[4-(phenylmethyl)-1piperidinyl]methyl]-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)




- RN 275810-80-5 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)







- RN 275810-81-6 HCAPLUS
- CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



- RN 275810-83-8 HCAPLUS
- CN Urea, N-1H-indazol-5-yl-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-84-9 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




----2


- RN 275810-86-1 HCAPLUS
- CN Urea, N-phenyl-N'-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-(9CI) (CA INDEX NAME)




RN 275810-87-2 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-88-3 HCAPLUS CN Urea, N-(3-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-92-9 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



- RN 275810-93-0 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-94-1 HCAPLUS
- CN Urea, N-(4-methoxyphenyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-95-2 HCAPLUS
- CN Urea, N-(2-phenylethyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


RN 275810-96-3 HCAPLUS CN Benzoic acid, 3-[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- RN 275810-97-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-98-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)




- RN 275810-99-6 HCAPLUS
- CN Urea, N'-phenyl-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-00-2 HCAPLUS
- CN Urea, N'-(3-cyanophenyl)-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-01-3 HCAPLUS CN Urea, N-(2-phenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-05-7 HCAPLUS CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)



RN 275811-06-8 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-07-9 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-08-0 HCAPLUS
- CN Urea, N-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI)


(CA INDEX NAME)

Relative stereochemistry.




RN 275811-09-1 HCAPLUS CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-4-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-11-5 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-12-6 HCAPLUS CN Urea, N-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




- RN 275811-13-7 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 275811-14-8 HCAPLUS
CN Benzoic acid, 4-[[((3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX
NAME)







- RN 275811-15-9 HCAPLUS
- CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-16-0 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







- RN 275811-17-1 HCAPLUS
- CN Benzamide, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)






RN 275811-18-2 HCAPLUS CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[[3-(1-hydroxyethyl)phenyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)






RN 275811-20-6 HCAPLUS


```
CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-
[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)
```



RN 275811-24-0 HCAPLUS CN Benzoic acid, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-

fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)









RN 275811-25-1 HCAPLUS


```
CN Benzoic acid, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester,
monohydrochloride (9CI) (CA INDEX NAME)
```









- RN 275811-26-2 HCAPLUS
- CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



- RN 275811-27-3 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




- RN 275811-28-4 HCAPLUS
- CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



- RN 275811-29-5 HCAPLUS
- CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)


Searched by Susan Hanley 305-4053


.




RN 275811-30-8 HCAPLUS


CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-31-9 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







RN 275811-32-0 HCAPLUS
CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N-methyl- (9CI) (CA INDEX NAME)







RN 275811-33-1 HCAPLUS
CN Benzoic acid, 3-[[((3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX
NAME)






- RN 275811-34-2 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







```
RN 275811-35-3 HCAPLUS
```


```
CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)
```







- RN 275811-36-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-[(4-fluorophenyl)methyl]-1piperidinyl]methyl]-4-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-39-7 HCAPLUS
- CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)







```
RN 275811-40-0 HCAPLUS
```


```
CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX
NAME)
```





- RN 275811-41-1 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)







RN 275811-42-2 HCAPLUS


ŧ


CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-(hydroxymethyl)phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 275811-43-3 HCAPLUS CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)






- RN 275811-44-4 HCAPLUS
- CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

```
RN 275811-45-5 HCAPLUS
```

CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)







• HCl


RN 275811-46-6 HCAPLUS

```
CN Benzamide, 3-[[((3-acetylphenyl)amino]carbonyl]amino]-N-[2-
(dimethylamino)ethyl]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-
(9CI) (CA INDEX NAME)
```







- RN 275811-47-7 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-cyclopropyl-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-48-8 HCAPLUS CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)






- RN 275811-49-9 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

.







RN 275811-50-2 HCAPLUS


ó

CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)






- RN 275811-51-3 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-52-4 HCAPLUS


CN Urea, N-(3-cyanophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-53-5 HCAPLUS CN Benzoic acid, 3-[[{[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]meth yl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- RN 275811-54-6 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-55-7 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275811-61-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-(hydroxymethyl)phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 275811-69-3 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-70-6 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)







- RN. 275811-71-7 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)





RN 275811-72-8 HCAPLUS
CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'(3-methoxyphenyl)- (9CI) (CA INDEX NAME)







- RN 275811-74-0 HCAPLUS
- CN Urea, N-(3-acetylphenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-75-1 HCAPLUS
- CN Urea, N-(4-fluorophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






RN 275811-76-2 HCAPLUS CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)




RN 275811-78-4 HCAPLUS
CN Piperidinium, 1-[[2-[[((3-cyanophenyl)amino]carbonyl]amino]-5hydroxyphenyl]methyl]-1-methyl-4-(phenylmethyl)-, chloride (9CI) (CA
INDEX NAME)



• c1-


RN 275811-79-5 HCAPLUS CN Piperidinium, 1-[[2-[[((3-cyanophenyl)amino]carbonyl]amino]-5-[(tetrahydro-

2H-pyran-2-yl)oxy]phenyl]methyl]-1-methyl-4-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)





• I-

RN 275815-82-2 HCAPLUS CN Urea, N-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)




RN 275815-83-3 HCAPLUS
CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-N-[2 (dimethylamino)ethyl]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl] (9CI) (CA INDEX NAME)






- RN 275815-84-4 HCAPLUS
- CN Benzamide, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-N-cyclopropyl-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



- RN 275815-85-5 HCAPLUS
- CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N-2-pyridinyl- (9CI) (CA INDEX NAME)


.



Searched by Susan Hanley 305-4053

GI

Page 53




- AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepd. and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).
- 275810-47-4P 275810-48-5P 275810-49-6P ΙT 275810-58-7P 275810-59-8P 275810-60-1P 275810-61-2P 275810-62-3P 275810-63-4P 275810-64-5P 275810-65-6P 275810-66-7P 275810-67-8P 275810-68-9P 275810-69-0P 275810-70-3P 275810-71-4P 275810-72-5P 275810-73-6P 275810-74-7P 275810-80-5P 275810-81-6P 275810-83-8P 275810-84-9P 275810-86-1P 275810-87-2P 275810-88-3P 275810-92-9P 275810-93-0P 275810-94-1P 275810-95-2P 275810-96-3P 275810-97-4P 275810-98-5P 275810-99-6P 275811-00-2P 275811-01-3P 275811-05-7P 275811-06-8P 275811-07-9P 275811-08-0P 275811-09-1P 275811-10-4P 275811-11-5P 275811-12-6P 275811-13-7P 275811-14-8P 275811-15-9P 275811-16-0P 275811-17-1P 275811-18-2P 275811-20-6P 275811-24-0P 275811-25-1P 275811-26-2P 275811-27-3P 275811-28-4P 275811-29-5P 275811-30-8P 275811-31-9P 275811-32-0P 275811-33-1P 275811-34-2P 275811-35-3P 275811-36-4P 275811-39-7P 275811-40-0P 275811-41-1P 275811-42-2P 275811-43-3P 275811-44-4P 275811-45-5P 275811-46-6P 275811-47-7P 275811-48-8P 275811-49-9P 275811-50-2P 275811-51-3P 275811-52-4P 275811-53-5P 275811-54-6P 275811-55-7P 275811-61-5P 275811-69-3P 275811-70-6P 275811-71-7P 275811-72-8P 275811-74-0P 275811-75-1P 275811-76-2P 275811-78-4P 275811-79-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological


PATEL 10/069,215

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)


- 275810-47-4 HCAPLUS RN
- Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[2-[[4-(phenylmethyl)-1-CN piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- 275810-48-5 HCAPLUS RN
- CN Urea, N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- 275810-49-6 HCAPLUS RN
- Urea, N-(2,5-difluorophenyl)-N'-[[3-[[4-(phenylmethyl)-1-CN piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- 275810-58-7 HCAPLUS RN
- CNUrea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-59-8 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275810-60-1 HCAPLUS
- CN Urea, N-(3-hydroxypropyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



- RN 275810-61-2 HCAPLUS
- CN Urea, N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[2-(1piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




- RN 275810-62-3 HCAPLUS
- CN Urea, N-[2-(dimethylamino)ethyl]-N'-[2-[[4-(phenylmethyl)-1-


PATEL 10/069,215

•

piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-63-4 HCAPLUS CN 1-Piperazinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



Ph-CH2


RN 275810-64-5 HCAPLUS
CN 1-Piperidinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




Ph-CH2


RN 275810-65-6 HCAPLUS CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[2-[[4-(phenylmethyl)-1-

```
piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)
```




RN 275810-66-7 HCAPLUS CN Urea, N-(2,2-diphenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)







RN 275810-67-8 HCAPLUS CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-68-9 HCAPLUS CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 275810-69-0 HCAPLUS
CN 1-Piperidinecarboxamide, 4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-70-3 HCAPLUS CN Urea, N-1H-indazol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-71-4 HCAPLUS CN Urea, N-1H-indazol-6-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


.




RN 275810-72-5 HCAPLUS CN Urea, N-(phenylmethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-73-6 HCAPLUS CN Urea, N-1,3-benzodioxol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-74-7 HCAPLUS
- CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[6-[[4-(phenylmethyl)-1piperidinyl]methyl]-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)




- RN 275810-80-5 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)







- RN 275810-81-6 HCAPLUS
- CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




- RN 275810-83-8 HCAPLUS
- CN Urea, N-1H-indazol-5-yl-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-84-9 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-86-1 HCAPLUS CN Urea, N-phenyl-N'-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-(9CI) (CA INDEX NAME)




RN 275810-87-2 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-88-3 HCAPLUS CN Urea, N-(3-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 275810-92-9 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-93-0 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




Ph-CH2


- RN 275810-94-1 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[4-[[4-(phenylmethyl)-1-
- piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-95-2 HCAPLUS
- CN Urea, N-(2-phenylethyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-96-3 HCAPLUS
- CN Benzoic acid, 3-[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- RN 275810-97-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-98-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)




- RN 275810-99-6 HCAPLUS
- CN Urea, N'-phenyl-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-00-2 HCAPLUS
- CN Urea, N'-(3-cyanophenyl)-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-01-3 HCAPLUS CN Urea, N-(2-phenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-05-7 HCAPLUS
- CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)



- RN 275811-06-8 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



- RN 275811-07-9 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-
 - 1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-08-0 HCAPLUS


```
CN Urea, N-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1-
piperidinyl]methyl]phenyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI)
```

(CA INDEX NAME)


Relative stereochemistry.




RN 275811-09-1 HCAPLUS CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-4-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 275811-10-4 HCAPLUS
CN Benzoic acid, 3-[[((3-methoxyphenyl)amino]carbonyl]amino]-4-[[4 (phenylmethyl)-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




- RN 275811-11-5 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-12-6 HCAPLUS
- CN Urea, N-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




- RN 275811-13-7 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 275811-14-8 HCAPLUS CN Benzoic acid, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-15-9 HCAPLUS
- CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-16-0 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







- RN 275811-17-1 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)






RN 275811-18-2 HCAPLUS
CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[[3 (1-hydroxyethyl)phenyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA
 INDEX NAME)





RN 275811-20-6 HCAPLUS
CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)





RN 275811-24-0 HCAPLUS CN Benzoic acid, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-

Searched by Susan Hanley 305-4053

Page 69


fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)









- RN 275811-25-1 HCAPLUS
- CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)









- RN 275811-26-2 HCAPLUS
- CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-[[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




- RN 275811-27-3 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




- RN 275811-28-4 HCAPLUS
- CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




- RN 275811-29-5 HCAPLUS
- CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)





- RN 275811-30-8 HCAPLUS
- CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-31-9 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3-methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







RN 275811-32-0 HCAPLUS CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N-methyl- (9CI) (CA INDEX NAME)







RN 275811-33-1 HCAPLUS
CN Benzoic acid, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX
NAME)






- RN 275811-34-2 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







```
RN 275811-35-3 HCAPLUS
```


```
CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)
```







- RN 275811-36-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-[(4-fluorophenyl)methyl]-1piperidinyl]methyl]-4-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-39-7 HCAPLUS
- CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)







```
RN 275811-40-0 HCAPLUS
```


```
CN Benzamide, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX
NAME)
```







```
RN 275811-41-1 HCAPLUS
CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX
NAME)
```







- RN 275811-42-2 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-(hydroxymethyl)phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 275811-43-3 HCAPLUS
CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX
NAME)







RN 275811-44-4 HCAPLUS CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


- RN 275811-45-5 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)







• HCl

- RN 275811-46-6 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-[2-(dimethylamino)ethyl]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-(9CI) (CA INDEX NAME)







- RN 275811-47-7 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-cyclopropyl-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)





RN 275811-48-8 HCAPLUS
CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)







- RN 275811-49-9 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)






RN 275811-50-2 HCAPLUS CN Benzamide, 3-[[{(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)






- RN 275811-51-3 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-52-4 HCAPLUS


CN Urea, N-(3-cyanophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-53-5 HCAPLUS
CN Benzoic acid, 3-[[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]meth
yl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- RN 275811-54-6 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-55-7 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275811-61-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-(hydroxymethyl)phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 275811-69-3 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-70-6 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)







RN 275811-71-7 HCAPLUS

CN Urea, N-(3-methoxyphenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)





RN 275811-72-8 HCAPLUS CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)







- RN 275811-74-0 HCAPLUS
- CN Urea, N-(3-acetylphenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-75-1 HCAPLUS
- CN Urea, N-(4-fluorophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






RN 275811-76-2 HCAPLUS CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)




RN 275811-78-4 HCAPLUS
CN Piperidinium, 1-[[2-[[((3-cyanophenyl)amino]carbonyl]amino]-5hydroxyphenyl]methyl]-1-methyl-4-(phenylmethyl)-, chloride (9CI) (CA
INDEX NAME)



• c1-

RN 275811-79-5 HCAPLUS CN Piperidinium, 1-[[2-[[[(3-cyanophenyl)amino]carbonyl]amino]-5-[(tetrahydro-

2H-pyran-2-yl)oxy]phenyl]methyl]-1-methyl-4-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)





I-I


REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT HCAPLUS COPYRIGHT 2002 ACS L38 ANSWER 12 OF 44 2000:420962 HCAPLUS ACCESSION NUMBER: 133:43443 DOCUMENT NUMBER: Preparation of N-ureidoalkyl-piperidines as modulators TITLE: of chemokine receptor activity Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, INVENTOR(S): Ui Tae; Santella, Joseph B. Iii; Wacker, Dean A. K. Du Pont Pharmaceuticals Company, USA PATENT ASSIGNEE(S): PCT Int. Appl., 388 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 5 PATENT INFORMATION:

P	PATENT NO.				KIND		DATE		APPLICATION NO. DATE									
W	10	> 2000035452			 A1		20000622			WO 1999-US30334			34	1999	1217	<		
		W:			•	•					•		•		LT,			•
							SG,	SI,	SK,	ΤR,	UA,	VN,	ZA,	AM,	ΑΖ,	BY,	KG,	ΚZ,
		DIAT .		RU,			DF	אח	FS	БT	FR	GB	CR	ТF	IT,	T.II	MC	NT.
		1744.	PT,	•	cn,	CI,		DR,	60,	,	1 1.7	ΟΔ,	ыл ,	10,	11,	цо,	10,	N Ш,
E					A1 20011212				EP 1999-963107					7	19991217 <			
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
			,		•	•	FI,							_				
							2001			L	JS 19	99-4	6528	8	1999	1217	<	
							2002			E	BR 19	99-1	7038		1999	1217	<	
U	JS	6444	686		B	1	2002	0903		τ	JS 19	99-4	6644	2	1999	1217	<	
J	JP 2	2002	53242	27	T	2	2002	1002			JP 20	00-5	8777	2	1999	1217	<	
N	10	2001	0029 [.]	77	А		2001	0820		Ν	10 20	01-2	977		2001	0615	<	
PRIORI	TY	APP	LN. I	INFO	. :					US 1	.998-	1127	17P	Р	1998	1218	<	
										US 1	.999-	1612	21P	P	1999	1022		
										US 1	.999-	1612	22P	Р	1999	1022		

OTHER SOURCE(S): GI








AB	The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepd. and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).
IT	275810-47-4P 275810-48-5P 275810-49-6P
	275810-58-7P 275810-59-8P 275810-60-1P
	275810-61-2P 275810-62-3P 275810-63-4P
	275810-64-5P 275810-65-6P 275810-66-7P
	275810-67-8P 275810-68-9P 275810-69-0P
	275810-70-3P 275810-71-4P 275810-72-5P
	275810-73-6P 275810-74-7P 275810-80-5P
	275810-81-6P 275810-83-8P 275810-84-9P
	275810-86-1P 275810-87-2P 275810-88-3P
	275810-92-9P 275810-93-0P 275810-94-1P
	275810-95-2P 275810-96-3P 275810-97-4P 275810-98-5P 275810-99-6P 275811-00-2P
	275810-98-59 275810-99-69 275811-00-29 275811-01-39 275811-05-79 275811-06-89
	275811-07-9P 275811-08-0P 275811-09-1P
	275811-10-4P 275811-11-5P 275811-12-6P
	275811-13-7P 275811-14-8P 275811-15-9P
	275811-16-0P 275811-17-1P 275811-18-2P
	275811-20-6P 275811-24-0P 275811-25-1P
	275811-26-2P 275811-27-3P 275811-28-4P
	275811-29-5P 275811-30-8P 275811-31-9P
	275811-32-0P 275811-33-1P 275811-34-2P
	275811-35-3P 275811-36-4P 275811-39-7P
	275811-40-0P 275811-41-1P 275811-42-2P
	275811-43-3P 275811-44-4P 275811-45-5P
	275811-46-6P 275811-47-7P 275811-48-8P
	275811-49-9P 275811-50-2P 275811-51-3P
	275811-52-4P 275811-53-5P 275811-54-6P 275811-55-7P 275811-61-5P 275811-69-3P
	275811-55-7P 275811-61-5P 275811-69-3P 275811-70-6P 275811-71-7P 275811-72-8P
	2/3011-10-0F 2/3011-11-1E 2/3011-12-0F


.

275811-74-0P 275811-75-1P 275811-76-2P 275811-78-4P 275811-79-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)


- RN 275810-47-4 HCAPLUS
- CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-48-5 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-49-6 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275810-58-7 HCAPLUS CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-59-8 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)







- RN 275810-60-1 HCAPLUS
- CN Urea, N-(3-hydroxypropyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-61-2 HCAPLUS
- CN Urea, N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[2-(1piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




- RN 275810-62-3 HCAPLUS
- CN Urea, N-[2-(dimethylamino)ethyl]-N'-[2-[[4-(phenylmethyl)-1-



RN 275810-63-4 HCAPLUS
CN 1-Piperazinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-64-5 HCAPLUS CN 1-Piperidinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)





Ph-CH2

- RN 275810-65-6 HCAPLUS
- CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-66-7 HCAPLUS CN Urea, N-(2,2-diphenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)







RN 275810-67-8 HCAPLUS CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-68-9 HCAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-69-0 HCAPLUS
CN 1-Piperidinecarboxamide, 4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-70-3 HCAPLUS CN Urea, N-1H-indazol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-71-4 HCAPLUS
- CN Urea, N-1H-indazol-6-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-72-5 HCAPLUS CN Urea, N-(phenylmethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-73-6 HCAPLUS CN Urea, N-1,3-benzodioxol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-74-7 HCAPLUS
- CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[6-[[4-(phenylmethyl)-1piperidinyl]methyl]-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)




RN 275810-80-5 HCAPLUS CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275810-81-6 HCAPLUS
- CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 275810-83-8 HCAPLUS

CN Urea, N-1H-indazol-5-yl-N'-[3-[[4-(phenylmethyl)-1-


piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-84-9 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-86-1 HCAPLUS CN Urea, N-phenyl-N'-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-(9CI) (CA INDEX NAME)




RN 275810-87-2 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-88-3 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-92-9 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-93-0 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-94-1 HCAPLUS
- CN Urea, N-(4-methoxyphenyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-95-2 HCAPLUS
- CN Urea, N-(2-phenylethyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-96-3 HCAPLUS CN Benzoic acid, 3-[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- RN 275810-97-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-98-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-l-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)




- RN 275810-99-6 HCAPLUS
- CN Urea, N'-phenyl-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-00-2 HCAPLUS
- CN Urea, N'-(3-cyanophenyl)-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-01-3 HCAPLUS CN Urea, N-(2-phenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




```
RN 275811-05-7 HCAPLUS
CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-
phenyl- (9CI) (CA INDEX NAME)
```



- RN 275811-06-8 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-07-9 HCAPLUS CN Urea, N-(3-methoxyphenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




```
RN 275811-08-0 HCAPLUS
CN Urea, N-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1-
piperidinyl]methyl]phenyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI)
```


(CA INDEX NAME)

Relative stereochemistry.







RN 275811-10-4 HCAPLUS
CN Benzoic acid, 3-[[((3-methoxyphenyl)amino]carbonyl]amino]-4-[[4 (phenylmethyl)-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




- RN 275811-11-5 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-12-6 HCAPLUS CN Urea, N-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




- RN 275811-13-7 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)





- RN 275811-14-8 HCAPLUS
- CN Benzoic acid, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-15-9 HCAPLUS
- CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-16-0 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







- RN 275811-17-1 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)






RN 275811-18-2 HCAPLUS CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[[3-(1-hydroxyethyl)phenyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)





- RN 275811-20-6 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 275811-24-0 HCAPLUS CN Benzoic acid, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-

Searched by Susan Hanley 305-4053


Page 100


fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)






- RN 275811-25-1 HCAPLUS
- CN Benzoic acid, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)






• HCl


- RN 275811-26-2 HCAPLUS
- CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-l-piperidinyl]methyl]-4-[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




- 275811-27-3 HCAPLUS RN
- Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME) CN




- RN
- 275811-28-4 HCAPLUS Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-3-CN[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




- 275811-29-5 HCAPLUS RN
- CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)





- RN 275811-30-8 HCAPLUS
- CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-31-9 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







RN 275811-32-0 HCAPLUS
CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N-methyl- (9CI) (CA INDEX NAME)







RN 275811-33-1 HCAPLUS
CN Benzoic acid, 3-[[((3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX
NAME)







- RN 275811-34-2 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







```
RN 275811-35-3 HCAPLUS
CN Benzamide, 3-[[((3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)
```







- RN 275811-36-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-[(4-fluorophenyl)methyl]-1piperidinyl]methyl]-4-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-39-7 HCAPLUS
- CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)







```
RN 275811-40-0 HCAPLUS
```


```
CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX
NAME)
```






RN 275811-41-1 HCAPLUS CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)







RN 275811-42-2 HCAPLUS

CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-(hydroxymethyl)phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 275811-43-3 HCAPLUS
CN Benzamide, 4-[[((3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX
NAME)



- RN 275811-44-4 HCAPLUS
- CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)





HCl

Page 107

```
RN 275811-45-5 HCAPLUS
```


CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)







• HCl

- RN 275811-46-6 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-[2-(dimethylamino)ethyl]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-(9CI) (CA INDEX NAME)







- RN 275811-47-7 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-cyclopropyl-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-48-8 HCAPLUS
CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)







- RN 275811-49-9 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




- RN 275811-50-2 HCAPLUS
- CN Benzamide, 3-[[((3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)






- RN 275811-51-3 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-52-4 HCAPLUS


CN Urea, N-(3-cyanophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-53-5 HCAPLUS CN Benzoic acid, 3-[[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]meth yl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- RN 275811-54-6 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-55-7 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275811-61-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-(hydroxymethyl)phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 275811-69-3 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-70-6 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)







- RN 275811-71-7 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)





RN 275811-72-8 HCAPLUS CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)







- RN 275811-74-0 HCAPLUS
- CN Urea, N-(3-acetylphenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-75-1 HCAPLUS
- CN Urea, N-(4-fluorophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-76-2 HCAPLUS CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'-
- tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)




RN 275811-78-4 HCAPLUS
CN Piperidinium, 1-[[2-[[[(3-cyanophenyl)amino]carbonyl]amino]-5hydroxyphenyl]methyl]-1-methyl-4-(phenylmethyl)-, chloride (9CI) (CA
INDEX NAME)




• c1-

RN 275811-79-5 HCAPLUS CN Piperidinium, 1-[[2-[[((3-cyanophenyl)amino]carbonyl]amino]-5-[(tetrahydro-




2H-pyran-2-yl)oxy]phenyl]methyl]-1-methyl-4-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)



• I-

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT HCAPLUS COPYRIGHT 2002 ACS L38 ANSWER 13 OF 44 2000:420961 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 133:43442 Preparation of N-ureidoalkyl-piperidines as modulators TITLE: of chemokine receptor activity Ko, Soo S.; Delucca, George V.; Duncia, John V.; INVENTOR(S): Santella, Joseph B., III; Wacker, Dean A.; Watson, Paul S.; Varnes, Jeffrey G. Du Pont Pharmaceuticals Company, USA PATENT ASSIGNEE(S): PCT Int. Appl., 394 pp. SOURCE: CODEN: PIXXD2 Patent DOCUMENT TYPE: English LANGUAGE: FAMILY ACC. NUM. COUNT: 5 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE -----____ -------_____ 20000622 WO 1999-US30332 19991217 <--WO 2000035451 A1 W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE EP 1999-964297 EP 1140086 A1 20011010 19991217 <--AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, R : IE, SI, LT, LV, FI, RO US 1999-465288 US 6331541 B1 20011218 19991217 <--PRIORITY APPLN. INFO.: US 1998-112717P P 19981218 <--US 1999-161243P P 19991022 US 1999-161222P P 19991022 WO 1999-US30332 W 19991217 MARPAT 133:43442 OTHER SOURCE(S): GΙ




AB	The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepd. and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).	
ΙT	275810-47-4P 275810-48-5P 275810-49-6P	
	275810-58-7P 275810-59-8P 275810-60-1P	
	275810-61-2P 275810-62-3P 275810-63-4P	
	275810-64-5P 275810-65-6P 275810-66-7P	
	275810-67-8P 275810-68-9P 275810-69-0P	
	275810-70-3P 275810-71-4P 275810-72-5P 275810-73-6P 275810-74-7P 275810-80-5P	
	275810-81-6P 275810-83-8P 275810-84-9P	
	275810-86-1P 275810-87-2P 275810-88-3P	
	275810-92-9P 275810-93-0P 275810-94-1P	
	275810-95-2P 275810-96-3P 275810-97-4P	
	275810-98-5P 275810-99-6P 275811-00-2P	
	275811-01-3P 275811-05-7P 275811-06-8P	
	275811-07-9P 275811-08-0P 275811-09-1P	
	275811-10-4P 275811-11-5P 275811-12-6P	
	275811-13-7P 275811-14-8P 275811-15-9P	
	275811-16-0P 275811-17-1P 275811-18-2P	
	275811-20-6P 275811-24-0P 275811-25-1P	
	275811-26-2P 275811-27-3P 275811-28-4P	
	275811-29-5P 275811-30-8P 275811-31-9P	
	275811-32-0P 275811-33-1P 275811-34-2P	
	275811-35-3P 275811-36-4P 275811-39-7P	
	275811-40-0P 275811-41-1P 275811-42-2P	
	275811-43-3P 275811-44-4P 275811-45-5P	
	275811-46-6P 275811-47-7P 275811-48-8P	
	275811-49-9P 275811-50-2P 275811-51-3P	
	275811-52-4P 275811-53-5P 275811-54-6P	
	275811-55-7P 275811-61-5P 275811-69-3P	
	275811-70-6P 275811-71-7P 275811-72-8P	
	275811-74-0P 275811-75-1P 275811-76-2P	
	275811-78-4P 275811-79-5P 276243-13-1P	


PATEL 10/069,215

276243-14-2P 276243-18-6P 276243-81-3P 276243-82-4P 276243-83-5P 276243-84-6P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)


- RN 275810-47-4 HCAPLUS
- CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-48-5 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-49-6 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275810-58-7 HCAPLUS
- CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-59-8 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275810-60-1 HCAPLUS
- CN Urea, N-(3-hydroxypropyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-61-2 HCAPLUS
- CN Urea, N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[2-(1piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 275810-62-3 HCAPLUS CN Urea, N-[2-(dimethylamino)ethyl]-N'-[2-[[4-(phenylmethyl)-1Ľ

PATEL 10/069,215

piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




275810-63-4 HCAPLUS RN 1-Piperazinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1-CN piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




```
Ph-CH2
```

```
275810-64-5 HCAPLUS
RN
     1-Piperidinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1-
CN
     piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)
```





Ph-CH2

- RN 275810-65-6 HCAPLUS Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[2-[[4-(phenylmethyl)-1-CN
 - piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-66-7 HCAPLUS CN Urea, N-(2,2-diphenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)







RN 275810-67-8 HCAPLUS CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



- RN 275810-68-9 HCAPLUS
- CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-69-0 HCAPLUS
CN 1-Piperidinecarboxamide, 4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



```
RN 275810-70-3 HCAPLUS
CN Urea, N-1H-indazol-5-yl-N'-[2-[[4-(phenylmethyl)-1-
```

piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-71-4 HCAPLUS


•

CN Urea, N-1H-indazol-6-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


.




RN 275810-72-5 HCAPLUS CN Urea, N-(phenylmethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 275810-73-6 HCAPLUS CN Urea, N-1,3-benzodioxol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-74-7 HCAPLUS
- CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[6-[[4-(phenylmethyl)-1piperidinyl]methyl]-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)




- RN 275810-80-5 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Searched by Susan Hanley 305-4053

Page 122







- RN 275810-81-6 HCAPLUS
- CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




- RN 275810-83-8 HCAPLUS
- CN Urea, N-1H-indazol-5-yl-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-84-9 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-86-1 HCAPLUS CN Urea, N-phenyl-N'-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-(9CI) (CA INDEX NAME)




RN 275810-87-2 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-88-3 HCAPLUS CN Urea, N-(3-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-92-9 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



- RN 275810-93-0 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- 275810-94-1 HCAPLUS RN
- Urea, N-(4-methoxyphenyl)-N'-[4-[[4-(phenylmethyl)-1-CN piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- 275810-95-2 HCAPLUS RN
- Urea, N-(2-phenylethyl)-N'-[4-[[4-(phenylmethyl)-1-CN piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


- 275810-96-3 HCAPLUS RN
- CNBenzoic acid, 3-[[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- 275810-97-4 HCAPLUS RN
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-98-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)




- RN 275810-99-6 HCAPLUS
- CN Urea, N'-phenyl-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-00-2 HCAPLUS CN Urea, N'-(3-cyanophenyl)-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-01-3 HCAPLUS CN Urea, N-(2-phenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-05-7 HCAPLUS CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)



- RN 275811-06-8 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 275811-07-9 HCAPLUS CN Urea, N-(3-methoxyphenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-08-0 HCAPLUS
- CN Urea, N-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI)

Searched by Susan Hanley 305-4053


.


(CA INDEX NAME)

Relative stereochemistry.




RN 275811-09-1 HCAPLUS CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-4-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-11-5 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-12-6 HCAPLUS
- CN Urea, N-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




- RN 275811-13-7 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)





- RN 275811-14-8 HCAPLUS CN Benzoic acid, 4-[[[(3-cyanopher
- CN Benzoic acid, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-15-9 HCAPLUS
- CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-16-0 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







- RN 275811-17-1 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)






RN 275811-18-2 HCAPLUS CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[[3-(1-hydroxyethyl)phenyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-20-6 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 275811-24-0 HCAPLUS CN Benzoic acid, 3-[[((3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-


fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)









- RN 275811-25-1 HCAPLUS
- CN Benzoic acid, 3-[[((3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)






• HCl


- RN 275811-26-2 HCAPLUS CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-
 - [[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




- RN 275811-27-3 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



- RN 275811-28-4 HCAPLUS
- CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)





- RN 275811-29-5 HCAPLUS
- CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 275811-30-8 HCAPLUS


CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)





- RN 275811-31-9 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







RN 275811-32-0 HCAPLUS
CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N-methyl- (9CI) (CA INDEX NAME)


Searched by Susan Hanley 305-4053


.







RN 275811-33-1 HCAPLUS Benzoic acid, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-CN fluorophenyl)methyl]-l-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)






- RN 275811-34-2 HCAPLUS CN
- Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







```
RN 275811-35-3 HCAPLUS
```


```
CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)
```







- RN 275811-36-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-[(4-fluorophenyl)methyl]-1piperidinyl]methyl]-4-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-39-7 HCAPLUS
- CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)







```
RN 275811-40-0 HCAPLUS
```


```
CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX
NAME)
```






```
RN 275811-41-1 HCAPLUS
CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX
NAME)
```







RN 275811-42-2 HCAPLUS


CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-(hydroxymethyl)phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 275811-43-3 HCAPLUS CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)






- RN 275811-44-4 HCAPLUS
- CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




HC1

```
RN 275811-45-5 HCAPLUS
```

CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)







• HCl


RN 275811-46-6 HCAPLUS

```
CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-[2-
(dimethylamino)ethyl]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-
(9CI) (CA INDEX NAME)
```







- RN 275811-47-7 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-cyclopropyl-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)





- RN 275811-48-8 HCAPLUS CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3
 - methoxyphenyl)amino]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)







- RN 275811-49-9 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)






RN 275811-50-2 HCAPLUS CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)





- RN 275811-51-3 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




Searched by Susan Hanley 305-4053


Page 141

RN 275811-52-4 HCAPLUS


CN Urea, N-(3-cyanophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-53-5 HCAPLUS
CN Benzoic acid, 3-[[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]meth
yl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- RN 275811-54-6 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-55-7 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275811-61-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-(hydroxymethyl)phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 275811-69-3 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-70-6 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)







- RN 275811-71-7 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-72-8 HCAPLUS CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


,







- RN 275811-74-0 HCAPLUS
- CN Urea, N-(3-acetylphenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1-
- piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-75-1 HCAPLUS
- CN Urea, N-(4-fluorophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-76-2 HCAPLUS
- CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)




RN 275811-78-4 HCAPLUS CN Piperidinium, 1-[[2-[[[(3-cyanophenyl)amino]carbonyl]amino]-5hydroxyphenyl]methyl]-1-methyl-4-(phenylmethyl)-, chloride (9CI) (CA INDEX NAME)



• c1-


```
RN 275811-79-5 HCAPLUS
CN Piperidinium, 1-[[2-[[[(3-cyanophenyl)amino]carbonyl]amino]-5-[(tetrahydro-
```

2H-pyran-2-yl)oxy]phenyl]methyl]-1-methyl-4-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)




• I-

RN 276243-13-1 HCAPLUS
CN Piperidinium, 1-[3-[[[(3-methoxyphenyl)amino]carbonyl]amino]propyl]-1,4bis(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)






- RN 276243-14-2 HCAPLUS
- CN Piperidinium, 1-[3-[[[(3-cyanophenyl)amino]carbonyl]amino]propyl]-1,4bis(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)




RN 276243-18-6 HCAPLUS
CN Piperidinium, 1-[3-[[[(4-fluorophenyl)amino]carbonyl]amino]propyl]-1,4bis(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)





🖲 Br-

RN 276243-81-3 HCAPLUS CN Ethanone, 1-[3-[[1-[[2-[[4-[(4-fluorophenyl)methyl]-1piperidinyl]methyl]phenyl]amino]-2-nitroethenyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 276243-82-4 HCAPLUS
CN Benzamide, 3-[{(cyanoamino)[(3,5-diacetylphenyl)amino]methylene]amino]-2[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA
INDEX NAME)






RN 276243-83-5 HCAPLUS
CN Benzamide, 3-[[[(3-acetylphenyl)amino](cyanoamino)methylene]amino]-2-[[4[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX

NAME)






RN 276243-84-6 HCAPLUS

```
CN Benzamide, 3-[[(cyanoamino)[[3-(1-methyl-1H-tetrazol-5-
yl)phenyl]amino]methylene]amino]-2-[[4-[(4-fluorophenyl)methyl]-1-
```

```
piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)
```




THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS **REFERENCE COUNT:** 8 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L38 ANSWER 14 OF 44 HCAPLUS COPYRIGHT 2002 ACS 2000:420959 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 133:43441 Preparation of N-ureidoalkyl-piperidines as modulators TITLE: of chemokine receptor activity Ko, Soo S.; Delucca, George V.; Duncia, John V.; INVENTOR(S): Santella, Joseph B., III; Gardner, Daniel S. PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA PCT Int. Appl., 327 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 5 PATENT INFORMATION: APPLICATION NO. DATE PATENT NO. KIND DATE -----____ _____ _____

PATEL 10/069,215

WO 2000035449				A1 20000622					WO 1999-US30292 19991217 <									
	W:	AL,	AU,	BR,	CA,	CN,	CZ,	ΕE,	HU	, I	L,	IN,	JP,	KR,	LT,	LV,	MK,	MX,
		NO,	NZ,	PL,	RO,	SG,	SI,	SK,	ΤR	ι, Ο	JA,	VN,	ZA,	AM,	ΑZ,	BY,	KG,	KΖ,
		MD,	RU,	ΤJ,	ТΜ													
	RW:	ΑT,	BE,	CH,	CY,	DE,	DK,	ΕS,	FΙ	, F	'R,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
		ΡT,	SE															
EP	1156807			A1 20011128					EP 1999-968144 1						1999:	1217	<	
	R:	ΑT,	ΒE,	CH,	DE,	DK,	ES,	FR,	GE	3, G	GR,	IΤ,	LI,	LU,	NL,	SE,	MC,	ΡT,
		IE,	SI,	LT,	LV,	FI,	RO											
US 6331541			B1 20011218						US	199	9-4	65288	3	1999	1217	<		
US	6444	686		B	1	2002	0903			US	199	9-4	66442	2	1999	1217	<	
PRIORIT	Y APP	LN. 1	INFO	.:					US	199	8-1	.127	17P	Ρ	1998	1218	<	
									US	199	9–1	612	21P	Р	1999:	1022		
									US	199	9-1	612	22P	Р	1999:	1022		
								•	WO	199	9-U	JS 30	292	W	1999	1217		
OTHER SOURCE(S): MARPAT 133:43441 GI																		

 $\begin{array}{c} J-M R^{4} \\ K N-E-N N^{-R^{3}} \\ L-Q R^{1} R^{2} I \\ R^{2} I \\ R^{2} I \end{array}$




AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc.; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepd. and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

```
IT 275810-47-4P 275810-48-5P 275810-49-6P
275810-58-7P 275810-59-8P 275810-60-1P
275810-61-2P 275810-62-3P 275810-63-4P
275810-64-5P 275810-65-6P 275810-66-7P
275810-67-8P 275810-68-9P 275810-69-0P
275810-70-3P 275810-71-4P 275810-72-5P
275810-73-6P 275810-74-7P 275810-80-5P
275810-81-6P 275810-83-8P 275810-84-9P
275810-86-1P 275810-87-2P 275810-88-3P
275810-92-9P 275810-93-0P 275810-94-1P
275810-95-2P 275810-96-3P 275810-97-4P
275810-98-5P 275810-99-6P 275811-00-2P
275811-01-3P 275811-05-7P 275811-06-8P
```


Page 149

```
275811-07-9P 275811-08-0P 275811-09-1P
275811-10-4P 275811-11-5P 275811-12-6P
275811-13-7P 275811-14-8P 275811-15-9P
275811-16-0P 275811-17-1P 275811-18-2P
275811-20-6P 275811-24-0P 275811-25-1P
275811-26-2P 275811-27-3P 275811-28-4P
275811-29-5P 275811-30-8P 275811-31-9P
275811-32-0P 275811-33-1P 275811-34-2P
275811-35-3P 275811-36-4P 275811-39-7P
275811-40-0P 275811-41-1P 275811-42-2P
275811-43-3P 275811-44-4P 275811-45-5P
275811-46-6P 275811-47-7P 275811-48-8P
275811-49-9P 275811-50-2P 275811-51-3P
275811-52-4P 275811-53-5P 275811-54-6P
275811-55-7P 275811-61-5P 275811-69-3P
275811-70-6P 275811-71-7P 275811-72-8P
275811-74-0P 275811-75-1P 275811-76-2P
275811-78-4P 275811-79-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
   (prepn. of N-ureidoalkyl-piperidines as modulators of chemokine
   receptor activity)
275810-47-4 HCAPLUS
Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[2-[[4-(phenylmethyl)-1-
piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)
```




RN CN


RN 275810-48-5 HCAPLUS CN Urea, N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-49-6 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275810-58-7 HCAPLUS
- CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-59-8 HCAPLUS CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275810-60-1 HCAPLUS
- CN Urea, N-(3-hydroxypropyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-61-2 HCAPLUS


CN Urea, N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[2-(1piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 275810-62-3 HCAPLUS CN Urea, N-[2-(dimethylamino)ethyl]-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-63-4 HCAPLUS
- CN 1-Piperazinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




Ph-CH2

RN 275810-64-5 HCAPLUS


CN 1-Piperidinecarboxamide, 4-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-65-6 HCAPLUS CN Urea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-66-7 HCAPLUS
- CN Urea, N-(2,2-diphenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275810-67-8 HCAPLUS
- CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




```
RN 275810-68-9 HCAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-
piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)
```


C1




RN 275810-69-0 HCAPLUS CN 1-Piperidinecarboxamide, 4-phenyl-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-70-3 HCAPLUS CN Urea, N-1H-indazol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-71-4 HCAPLUS CN Urea, N-1H-indazol-6-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



- RN 275810-72-5 HCAPLUS
- CN Urea, N-(phenylmethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-73-6 HCAPLUS
- CN Urea, N-1,3-benzodioxol-5-yl-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 275810-74-7 HCAPLUS

```
CN Urea, N-[1-(phenylmethyl)-4-piperidinyl]-N'-[6-[[4-(phenylmethyl)-1-
piperidinyl]methyl]-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)
```




- RN 275810-80-5 HCAPLUS
- CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275810-81-6 HCAPLUS
- CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




- RN 275810-83-8 HCAPLUS
- CN Urea, N-1H-indazol-5-yl-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-84-9 HCAPLUS CN Urea, N-[2-(4-fluorophenyl)ethyl]-N'-[3-[[4-(phenylmethyl)-1-

PATEL 10/069,215


piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-86-1 HCAPLUS CN Urea, N-phenyl-N'-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-(9CI) (CA INDEX NAME)




- RN 275810-87-2 HCAPLUS
- CN Urea, N-(4-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-88-3 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 275810-92-9 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[3-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275810-93-0 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




Ph-CH2

- RN 275810-94-1 HCAPLUS
- CN Urea, N-(4-methoxyphenyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




Ph-CH2


RN 275810-95-2 HCAPLUS CN Urea, N-(2-phenylethyl)-N'-[4-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-96-3 HCAPLUS CN Benzoic acid, 3-[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 275810-97-4 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275810-98-5 HCAPLUS CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)




- RN 275810-99-6 HCAPLUS
- CN Urea, N'-phenyl-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-00-2 HCAPLUS CN Urea, N'-(3-cyanophenyl)-N-(phenylmethyl)-N-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-01-3 HCAPLUS CN Urea, N-(2-phenylethyl)-N'-[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-05-7 HCAPLUS
- CN Urea, N-[4-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]-N'phenyl- (9CI) (CA INDEX NAME)



RN 275811-06-8 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[4-hydroxy-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-07-9 HCAPLUS CN Urea, N-(3-methoxyphenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-




PATEL 10/069,215

1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 275811-08-0 HCAPLUS CN Urea, N-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




- RN 275811-09-1 HCAPLUS
- CN Benzoic acid, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-4-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




- RN 275811-10-4 HCAPLUS
- CN Benzoic acid, 3-[[[(3-methoxyphenyl)amino]carbonyl]amino]-4-[[4-(phenylmethyl)-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




- RN 275811-11-5 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[4-[(methylsulfonyl)oxy]-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-12-6 HCAPLUS
- CN Urea, N-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 275811-13-7 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[5-(hydroxymethyl)-2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)





RN 275811-14-8 HCAPLUS
CN Benzoic acid, 4-[[((3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX
NAME)







- RN 275811-15-9 HCAPLUS
- CN Benzoic acid, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)







- RN 275811-16-0 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)










CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)






- RN 275811-18-2 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[[3-(1-hydroxyethyl)phenyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)






- RN 275811-20-6 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




Page 164

```
RN 275811-24-0 HCAPLUS
```

```
CN Benzoic acid, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester,
monohydrochloride (9CI) (CA INDEX NAME)
```







• HCl

RN 275811-25-1 HCAPLUS


```
CN Benzoic acid, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4-
fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester,
monohydrochloride (9CI) (CA INDEX NAME)
```









```
RN 275811-26-2 HCAPLUS
CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-
[((phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)
```




- 275811-27-3 HCAPLUS RN CN
 - Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



- RN 275811-28-4 HCAPLUS
- Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-3-CN [[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)





- RN 275811-29-5 HCAPLUS
- Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-CN[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 275811-30-8 HCAPLUS


CN Benzoic acid, 3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)





- RN 275811-31-9 HCAPLUS
- CN Benzoic acid, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)







RN 275811-32-0 HCAPLUS
CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N-methyl- (9CI) (CA INDEX NAME)


Searched by Susan Hanley 305-4053


Page 167







RN 275811-33-1 HCAPLUS Benzoic acid, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-CN fluorophenyl)methyl]-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)






- RN
- 275811-34-2 HCAPLUS Benzamide, 3-[[((3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-CN fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)







```
RN 275811-35-3 HCAPLUS
```


```
CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)
```





- RN 275811-36-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[[4-[(4-fluorophenyl)methyl]-1piperidinyl]methyl]-4-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)







RN 275811-39-7 HCAPLUS


*


CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)







- RN 275811-40-0 HCAPLUS
- CN Benzamide, 3-[[[(3-cyanophenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)





RN 275811-41-1 HCAPLUS CN Benzamide, 3-[[((3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)







RN 275811-42-2 HCAPLUS


.


- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-4-
- (hydroxymethyl)phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 275811-43-3 HCAPLUS CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)





RN 275811-44-4 HCAPLUS


CN Benzamide, 4-[[[(3-cyanophenyl)amino]carbonyl]amino]-3-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




HC1

```
RN 275811-45-5 HCAPLUS
```


CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)







• HCl

- RN 275811-46-6 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-[2-(dimethylamino)ethyl]-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-(9CI) (CA INDEX NAME)







- RN 275811-47-7 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-cyclopropyl-2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)





RN 275811-48-8 HCAPLUS CN Benzamide, 2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-[[[(3methoxyphenyl)amino]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)







- RN 275811-49-9 HCAPLUS
- CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)






RN 275811-50-2 HCAPLUS CN Benzamide, 3-[[[(3-acetylphenyl)amino]carbonyl]amino]-2-[[4-[(4fluorophenyl)methyl]-1-piperidinyl]methyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)







- RN 275811-51-3 HCAPLUS
- CN Urea, N-(2,5-difluorophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275811-52-4 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-53-5 HCAPLUS
CN Benzoic acid, 3-[[[[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]meth
yl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




- RN 275811-54-6 HCAPLUS
- CN Urea, N-(3-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 275811-55-7 HCAPLUS CN Urea, N-(4-methoxyphenyl)-N'-[[2-[[4-(phenylmethyl)-1piperidinyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




- RN 275811-61-5 HCAPLUS
- CN Urea, N-[2-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]methyl]-3-(hydroxymethyl)phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 275811-69-3 HCAPLUS CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 275811-70-6 HCAPLUS
- CN Urea, N-(3-cyanophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)







RN 275811-71-7 HCAPLUS

CN Urea, N-(3-methoxyphenyl)-N'-[2-[2-[4-(phenylmethyl)-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)





RN 275811-72-8 HCAPLUS CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)







- RN 275811-74-0 HCAPLUS
- CN Urea, N-(3-acetylphenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-75-1 HCAPLUS
- CN Urea, N-(4-fluorophenyl)-N'-[2-[2-[4-[(4-fluorophenyl)methyl]-1piperidinyl]ethyl]phenyl]- (9CI) (CA INDEX NAME)






- RN 275811-76-2 HCAPLUS
- CN Urea, N-[2-[2-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]phenyl]-N'tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 275811-78-4 HCAPLUS CN Piperidinium, 1-[[2-[[[(3-cyanophenyl)amino]carbonyl]amino]-5hydroxyphenyl]methyl]-1-methyl-4-(phenylmethyl)-, chloride (9CI) (CA INDEX NAME)


L



• c1-

RN 275811-79-5 HCAPLUS CN Piperidinium, 1-[[2-[[((3-cyanophenyl)amino]carbonyl]amino]-5-[(tetrahydro-

2H-pyran-2-yl)oxy]phenyl]methyl]-1-methyl-4-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)



• I-

REFERENCE COUNT:

16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

HCAPLUS COPYRIGHT 2002 ACS L38 ANSWER 15 OF 44 2000:349214 HCAPLUS ACCESSION NUMBER: 133:4602 DOCUMENT NUMBER: Preparation of arylcarbonylaminoalkylpiperidinio salts TITLE: as CCR-3 receptor antagonists. Hirschfeld, Donald Roy; Smith, David Bernard; Kertesz, INVENTOR(S): Denis John F. Hoffmann La Roche A.-G.; Switz. PATENT ASSIGNEE(S): SOURCE: Ger. Offen., 32 pp. CODEN: GWXXBX DOCUMENT TYPE: Patent LANGUAGE: German FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE _____ ____ _____ _____ _____ DE 1999-19955793 19991119 <--20000525 DE 19955793 A1 20000602 WO 1999-EP8554 19991108 <--WO 2000031033 A1 AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, W: DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG BR 9915735 20010904 BR 1999-15735 19991108 <--А 20010912 EP 1999-960962 19991108 <---EP 1131290 A1 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, R: IE, SI, LT, LV, FI, RO т2 20020917 JP 2000-583861 19991108 <--JP 2002530375 US 6342509 Β1 20020129 US 1999-442799 19991118 <--

Searched by Susan Hanley 305-4053

Page 179


FR 2786179 ES 2158813	A1 A1	20000526 20010901 20020316	FR 1999-14562 ES 1999-2546	19991119 < 19991119 <
ES 2158813 IT 1308657	B1 B1	20020316	IT 1999-TO1021	19991122 <
PRIORITY APPLN. INFO.:				19981120 < 19991108
OTHER SOURCE(S): GI	MA	RPAT 133:4602		



- Title compds. [I; 1 of T, U = NR5, the other = CH; X- = pharmaceutically AB acceptable counterion; R1, R2 = H, alkyl; m = 0-3; Ar, Ar1 = aryl, heteroaryl; G = alkylene, alkenylene, bond; R = H, alkyl; RR3, RR4 = atoms to form a carbocyclyl or heterocyclyl; R3, R4 = H, QCOZ; Q = alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, etc.; Z = amino, aryl, aralkyl, aryloxy, heteroaryl, etc.; E = CONR6, SO2NR6, NR7CONR6, etc.; R6, R7 = H, alkyl, acyl, haloalkyl, cycloalkyl, aryl, aralkyl, etc.; Q = CO, alkylene, etc.], were prepd. Thus, 3,4,5-trimethoxyphenyl isocyanate was stirred with 1(R)-[4-(3,4dichlorobenzyl)piperidin-1-ylmethyl]-2-methylpropylamine (prepn. given) in dichlorobenzyl)piperidin-1-ylmethyl]-2-methylpropyl]-3-(3,4,5trimethoxyphenyl)urea. This was heated with EtI at 68.degree. overnight to give 4-(3,4-dichlorobenzyl)-1-ethyl-1-[3-methyl-2-[3-(3,4,5trimethoxyphenyl)ureido]butyl]piperidinium iodide. The latter inhibited binding of 125I-eotaxin to CCR-3-L1.2-transfected cells with IC50 = 0.21 .mu.M.
- IT 270572-41-3P

- RN 270572-41-3 HCAPLUS
- CN Piperidinium, 4-[(3,4-dichlorophenyl)methyl]-1-[(2R)-3-methyl-2-[[[(3,4,5trimethoxyphenyl)amino]carbonyl]amino]butyl]-1-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




) I-

ð

HCAPLUS COPYRIGHT 2002 ACS L38 ANSWER 16 OF 44 2000:133684 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 132:166252 Preparation of novel thiazolopyrimidines as modulators TITLE: of chemokine receptor activity Austin, Rupert; Baxter, Andrew; Bonnert, Roger; Hunt, INVENTOR(S): Fraser; Kinchin, Elizabeth; Willis, Paul Astra Pharmaceuticals Ltd., UK; Astra AB PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 155 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PA	TENT	NO.		KI	ND	DATE			A	PPLI	CATI	ON NO	э.	DATE			
wo	2000	0095	11	A	1	2000	0224		W	0 19	99-SI	E133	3	1999	0803	<	
	W:	AE,	AL,	AM,	ΑT,	AU,	AZ,	ΒA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,
		DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,
		JP.	KE.	KG.	KP.	KR.	κz.	LC.	LK.	LR.	LS.	LT.	LU,	LV,	MD.	MG.	MK.
			•			•			•		•	•		SI,	•		
		•	•	•	•			•			•			AZ,			
		,	RU,	•		00,	007	01,	,	10,	2,	2,	,	,	21,	,	,
	₽M.					MW	SD	SI.	57	UG	2.W	ልጥ	BE	CH,	CY	DE	אס
	1/14													BF,			
						GW,							56,	ы,	во,	Cr,	00,
C 7	2338	•		•	•	•		-	•	•	•		00	1000	0003	<	
	9956																
EP	1104																
	R:							FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	РΤ,
						FI,											
JP	2002	5225	44	Т													
PRIORIT	Y APP	LN.	INFO	.:					SE 1	998-	2729		А	1998	0813	<	
								1	WO 1	999-	SE13	33	W	1999	0803	<	
OTHER S GI	OURCE	(S):			MAR	PAT	132:	1662	52								



AB The title compds. [I; R1 = H, NR3R4 (wherein R3, R4 = H, 4-piperidinyl, alkyl, etc.; NR3R4 = (un)substituted 4-7 membered satd. heterocyclic ring); X = OH, NR13R14 (R13, R14 = H, 4-piperidinyl, etc.; NR13R14 = (un)substituted 4-7 membered satd. heterocyclic ring); R2 = alkyl, alkenyl optionally substituted by (un) substituted Ph or PhO], useful for treating a chemokine mediated disease wherein the chemokine binds to a CXCR2 receptor such as an inflammatory disease (e.g. psoriasis), were prepd. Thus, treating 2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one with POC13 and N,N-dimethylaniline followed by reacting the resulting 7-chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-amine with (R)-2-amino-1-butanol in THF afforded the title thiazolopyrimidine (2R)-II. Exemplified compds. I were found to have IC50 of < 10 .mu.M against hrCXCR2 binding.


IΤ 259102-87-9P

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of novel thiazolopyrimidines as modulators of chemokine

```
receptor activity)
```

```
259102-87-9 HCAPLUS
RN
```

Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-(2-phenoxyethyl)-N7-[1-CN (phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


HCAPLUS COPYRIGHT 2002 ACS L38 ANSWER 17 OF 44 2000:133679 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 132:180573

10

TITLE:	Preparation of imidazopyridine derivatives as TNF and IL-1 production inhibitors
INVENTOR(S):	Kato, Hideo; Sakaguchi, Jun; Aoyama, Makoto; Izumi, Tomoyuki; Kato, Ken-ichi
PATENT ASSIGNEE(S):	Hokuriku Seiyaku Co., Ltd., Japan
SOURCE:	PCT Int. Appl., 111 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	
PATENT NO. KI	ND DATE APPLICATION NO. DATE

									•								
WC	2000	0095	06	A	1	2000	0224		I.	NO 19	999-J	P438	1	1999	0812	<	
	W:	AE,	AL,	AM,	ΑT,	AU,	ΑZ,	ΒA,	BB	, вG,	BR,	ΒY,	CA,	CH,	CN,	CR,	CU,
		CZ,	DE,	DK,	DM,	ΕE,	ES,	FI,	GB	, GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,
		IN,	IS,	KE,	KG,	KR,	KΖ,	LC,	$\mathbf{L}\mathbf{K}$, LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,
		MN,	MW,	MX,	NO,	ΝZ,	ΡL,	ΡT,	RO	, RU,	SD,	SE,	SG,	SI,	SK,	SL,	тJ,
		ΤM,	ΤR,	ΤT,	UA,	UG,	US,	UΖ,	VN	, YU,	ZA,	ZW,	ΑM,	ΑZ,	BY,	KG,	KΖ,
		•	•	тJ,													
	RW:										ZW,						
											NL,		SE,	BF,	вJ,	CF,	CG,
											ΤD,		_				
	2000																
	2339																
	9951								1	AU 19	999-5	1974		1999	0812	<	
	7443												_	1			
EF	1104																
	R:	•	•	•				FR,	GB	, GR,	IT,	ьi,	LU,	ΝL,	SE,	MC,	РΤ,
	0014			LT,						DD 1(000 1	1200		1000	0010		
	9914										999-1						
	2001										01-6	-		2001			
PRIORIT	Y APP	LN.	TNEO	.:							-2410						
											-2161						
OWUED C		(0)				שענו	122.			т Э Э Э Э -	-JP43	01	W	т Э Э Э Э	0012		
OTHER S	OURCE	(S):			MAR	PAT	132:	1902	13								


GI



- AB The title compds. I [A1 = (CH2)m; R1 is hydrogen, hydroxyl, alkyl, cycloalkyl, styryl or aryl; R2 is hydrogen, alkyl, halogeno, hydroxyl, amino, cyclic amino or phenoxy; ring A is an optionally substituted homocycle or heterocycle; R3 is a satd. nitrogenous heterocyclic group; and m is an integer of 0 to 3] are prepd. In an in vitro test using cells, the title compd. II.CF3CO2H at 0.001 .mu.mol gave 79% inhibition of TNF-.alpha. prodn.
- IT 259178-25-1P 259178-92-2P 259178-94-4P


.

259178-96-6P 259179-04-9P 259180-47-7P 259180-48-8P 259180-50-2P 259180-51-3P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of imidazopyridine derivs. as TNF and IL-1 prodn. inhibitors)




CN 1H-Imidazo[4,5-c]quinoline, 4-chloro-1-[2-[1-(phenylmethyl)-4piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

ŧ




RN 259178-92-2 HCAPLUS CN 4H-Imidazo[4,5-c]quinolin-4-one, 8-chloro-1,5-dihydro-1-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



CN 4H-Imidazo[4,5-c]quinolin-4-one, 1,5-dihydro-1-[[1-(phenylmethyl)-4piperidinyl]methyl]- (9CI) (CA INDEX NAME)




```
RN 259178-96-6 HCAPLUS
CN 1H-Imidazo[4,5-c]quinoline, 4-phenoxy-1-[2-[1-(phenylmethyl)-4-
piperidinyl]ethyl]- (9CI) (CA INDEX NAME)
```



RN 259179-04-9 HCAPLUS
CN 1H-Imidazo[4,5-c]quinolin-4-amine, 1-[2-[1-(phenylmethyl)-4piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




```
RN 259180-47-7 HCAPLUS
CN 1H-Imidazo[4,5-c]quinoline, 4,8-dichloro-1-[2-[1-(phenylmethyl)-4-
piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)
```





RN 259180-48-8 HCAPLUS


CN 1H-Imidazo[4,5-c]quinoline, 4-chloro-1-[[1-(phenylmethyl)-4piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl


- RN 259180-50-2 HCAPLUS
- CN 1H-Imidazo[4,5-c]quinoline, 1-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

.



●2 HC1

- RN 259180-51-3 HCAPLUS
- CN 1H-Imidazo[4,5-c]quinoline, 1-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS **REFERENCE COUNT:** 17 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L38 ANSWER 18 OF 44 HCAPLUS COPYRIGHT 2002 ACS 2000:117025 HCAPLUS ACCESSION NUMBER: 132:166125 DOCUMENT NUMBER: TITLE: Preparation of heteroarylcarboxamides as inhibitors of the production of cytokines Brown, Dearg Sutherland; Brown, George Robert INVENTOR(S): Zeneca Limited, UK PATENT ASSIGNEE(S): PCT Int. Appl., 118 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE _____ ____ _____ ______ _____ WO 2000007991 A1 20000217 WO 1999-GB2489 19990729 <--AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, W: DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 1999-2338121 19990729 <--20000217 CA 2338121 AA AU 1999-51788 A1 20000228 19990729 <--AU 9951788 20010502 BR 1999-12729 19990729 <--BR 9912729 А 20010530 A1 EP 1999-936810 19990729 <--EP 1102750 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO JP 2002522421 T2 20020723 JP 2000-563625 19990729 <--NO 2001000534 А 20010315 NO 2001-534 20010131 <--

US 6432949	B1 200	20813	US 2001-76210	7	20010202 <
PRIORITY APPLN. INFO.:		GB	1998-16838	А	19980804 <
		GB	1998-24939	А	19981113 <
		WO	1999-GB2489	W	19990729 < - -
OTHER SOURCE(S):	MARPAT	132:166125			

GI




AB The title compds. [I; R3 = alkyl, halo; Q1 = (un)substituted heteroaryl; p = 0-2; R2 = OH, halo; q = 0-4; Q2 = (un)substituted aryl, cycloalkyl, heteroaryl, heterocyclyl], useful in the treatment of diseases or medical conditions mediated by cytokines, were prepd. and formulated. Thus, reacting 6-chloropyridine-3-carbonyl chloride with N-(3-amino-4methylphenyl)-3-dimethylaminobenzamide (prepn. given) in the presence of K2CO3 in DMF/CH2Cl2 afforded I [R3 = Me; R2 = H; Q1 = 6-chloropyrid-3-yl; q = 0; Q2 = 3 - (Me2N)C6H4]. Biol. data (e.g., inhibition of p38 kinase and TNF.alpha. prodn.) for compds. I were given.

258503-19-4P IΤ RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of heteroarylcarboxamides as inhibitors of the prodn. of cytokines)

```
RN
     258503-19-4 HCAPLUS
```

3-Pyridinecarboxamide, N-[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]-6-[[1-CN (phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



7

Ι

REFERENCE COUNT:

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 19 OF 44 ACCESSION NUMBER: DOCUMENT NUMBER:	HCAPLUS COPYRIGHT 2002 ACS 1999:659372 HCAPLUS 131:286397
TITLE:	Preparation of fused thiophene derivatives as
INVENTOR (S) :	interleukin-6 and interleukin-12 production inhibitors Konishi, Mikio; Katsube, Nobuo; Konno, Mitoshi;
PATENT ASSIGNEE(S):	Kishimoto, Tadamitsu Ono Pharmaceutical Co., Ltd., Japan
SOURCE:	PCT Int. Appl., 717 pp.


CODEN: PIXXD2 DOCUMENT TYPE: Patent Japanese LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ ----_____ -----_____ WO 1999-JP1648 19990331 <--Al 19991014 WO 9951587 W: AU, BR, CA, CN, HU, JP, KR, MX, NO, NZ, RU, TR, US, ZA RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE AU 9930531 19991025 AU 1999-30531 19990331 <--A1 EP 1067128 A1 20010110 EP 1999-912051 19990331 <--R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI 20020716 US 2000-647430 20001002 <--US 6420391 B1 PRIORITY APPLN. INFO.: JP 1998-104210 A 19980401 <--A 19990119 <--JP 1999-46887 W 19990331 <--WO 1999-JP1648 OTHER SOURCE(S): MARPAT 131:286397 GI

 $CH_2 - O \qquad 0 \\ N = \qquad CH_2 - O \qquad 0 \\ N = \qquad N =$


- AB The title compds. I [dotted line indicates single or double bond; T = S(O)n; Y = H, etc.; ring A = benzene ring, etc.; Rl = alkyl, nitro, etc.; m = 0, or 1 4; n = 0 or 1 or 2] are prepd. The fused thiophene derivs. represented by general formula I are useful as preventives and/or remedies for various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell cancer, Kaposi's sarcoma, chronic rheumatoid arthritis, hypergammaglobulinemia, Curschmann's disease, intraatrial myxoma, diabetes, autoimmune diseases, hepatitis, multiple sclerosis, colon inflammation, graft-vs.-host disease and infectious diseases. Formulations contg. I are given. In an in vitro test using cells, the title compd. II showed IC50 of 4.4 .mu.M against interleukin-6 prodn.
- IT 246171-62-0P 246171-63-1P 246172-37-2P 246172-38-3P 246172-39-4P 246174-51-6P 246177-07-1P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of fused thiophene derivs. as interleukin-6 and interleukin-12 prodn. inhibitors)
- RN 246171-62-0 HCAPLUS

Ι

CN Benzo[b]thiophene-4-carboxamide, N-[1-(phenylmethyl)-4-piperidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



- 246171-63-1 HCAPLUS RN Benzo[b]thiophene-4-carboxamide, N-[1-(phenylmethyl)-4-piperidinyl]-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME) CN







RN 246172-37-2 HCAPLUS

= 0

Benzo[b]thiophene-4-carboxamide, 2,3-dihydro-N-[1-(phenylmethyl)-4-piperidinyl]-3-(phenylsulfonyl)-, 1,1-dioxide (9CI) (CA INDEX NAME) CN



- 246172-38-3 HCAPLUS RN CN
- Benzo[b]thiophene-4-carboxamide, 2,3-dihydro-N-[1-(phenylmethyl)-4-piperidinyl]-3-(phenylsulfonyl)-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)







246172-39-4 HCAPLUS RN

Benzo[b]thiophene-4-carboxamide, 2,3-dihydro-N-[1-(phenylmethyl)-4-piperidinyl]-3-(phenylsulfonyl)-, 1,1-dioxide, monomethanesulfonate (9CI) CN(CA INDEX NAME)

1 СМ

CRN 246172-37-2 CMF C27 H28 N2 O5 S2







Searched by Susan Hanley 305-4053

Page 194

IE, Fl				
PRIORITY APPLN. INFO.:	JP	1998-92431	А	19980320 <
	WO	1999-JP1422	W	19990319 <
OTHER SOURCE(S):	MARPAT 131:257570			

GI






AB The title compds. I [R1, R2 and R3 independently represent each H, C1-5 alkyl or C1-5 alkoxy; R4 represents H, hydroxymethyl, alkyl, etc.; Z is phenylene, etc.; and n is 0 to 6] are prepd. The title compd. II showed IC50 of 21 .mu.M against TNF-.alpha. prodn. in RAW 264.7 cells stimulated by lipopolysaccharide. (Stimulation of cells by lipopolysaccharide causes the activation NF-.kappa.B, followed by prodn. of TNF-.alpha.).
IT 245087-13-2P

```
245087-13-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylmethylbenzoquinones as NF-.kappa.B inhibitors)
```

- RN 245087-13-2 HCAPLUS
- CN Benzenepropanamide, 4-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT:6THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMATL38ANSWER 21 OF 44HCAPLUSCOPYRIGHT 2002 ACS
1999:495295ACCESSION NUMBER:1999:495295HCAPLUSDOCUMENT NUMBER:131:129983TITLE:Preparation of 1-cycloalkyl-1,8-naphthyridin-4-one


Searched by Susan Hanley 305-4053

Page 195

derivatives with phosphodiesterase IV inhibitory activitv INVENTOR(S): Shimamoto, Tetsuo; Inoue, Hidekazu; Hayashi, Yasuhiro Suntory Limited, Japan PATENT ASSIGNEE(S): PCT Int. Appl., 165 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE -----_____ _ _ _ _ ______ WO 9938867 A1 19990805 WO 1999-JP404 19990129 <--W: AU, CA, CN, HU, JP, KR, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE AU 9921856 A1 19990816 AU 1999-21856 19990129 <--EP 978516 20000209 EP 1999-901925 19990129 <--A1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI US 6331548 Β1 20011218 US 1999-402142 19990929 <--19980129 <--PRIORITY APPLN. INFO.: JP 1998-17009 А WO 1999-JP404 19990129 <--W OTHER SOURCE(S): MARPAT 131:129983 GI



Ι



AB 1-Cycloalkyl-1,8-naphthyridin-4-one derivs. represented by formula (I) or pharmacol. acceptable salts or solvates thereof (wherein Rl represents optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; R2, R3, and R4 each independently represents hydrogen, optionally substituted lower alkyl, or halogeno; and X represents NR5R6 or OR7 (wherein R5 and R6 each independently represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl); and R7 represents hydrogen, optionally substituted lower alkyl, or optionally substituted cycloalkyl) are prepd. These compds. selectively inhibit phosphodiesterase IV and prodn. of tumor necrosis factor TNF-.alpha. and are useful for the prevention and treatment of phosphodiesterase IV-assocd. diseases such as respiratory disease (bronchial asthma and chronic bronchitis), nerve functional disorders (depression, schizophrenia, Alzheimer's disease or Parkinson's disease-related learning, memory, and cognition disorders), inflammatory diseases (atopic dermatitis, conjunctivitis, or AIDS), general or local joint diseases (knee arthritis deformans and chronic rheumatoid arthritis) and

cytokine-assocd. diseases such as psoriasis, septicemia, Crohn's disease, cardiac infarction, arteriosclerosis, and nephritis. Thus, 1-cyclopentyl-1,4-dihydro-1,8-naphthyridine-4-one-3-carboxylic acid was refluxed with SOCl2 in toluene for 1.5 h, evapd. in vacuo, and then condensed with 4-amino-3,5-dichloropyridine in the presence of NaH in THF to give the title compd., N-(3,5-dichloropyridin-4-yl)-cyclopentyl-1,4dihydro-1,8-naphthyridine-4-one-3-carboxamide (II). II showed IC50 of 0.0003 .mu.M against phosphodiesterase IV.


IT 233762-90-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of cycloalkylnaphthyridinone derivs. with phosphodiesterase inhibitory activity and inhibition of tumor necrosis factor-.alpha. prodn. as therapeutics)

RN 233762-90-8 HCAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-1,4-dihydro-4-oxo-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



6

REFERENCE COUNT:

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 22 OF 44 H	CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:	1999:421672 HCAPLUS
DOCUMENT NUMBER:	131:73571
TITLE:	Preparation of benzoxepinecarboxamides,
	benzocycloheptenecarboxamides,
	naphthalenecarboxamides, and related compounds as
	MCP-1 receptor antagonists.
INVENTOR(S):	Shiraishi, Mitsuru; Kitayoshi, Takahito; Aramaki,
	Yoshio; Honda, Susumu; Oda, Tsuneo
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Japan
SOURCE:	PCT Int. Appl., 513 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:


 PATENT NO.
 KIND
 DATE
 APPLICATION NO.
 DATE

 WO
 9932468
 A1
 19990701
 WO
 1998-JP5707
 19981217 <--</td>


 W:
 AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD,

		MG,	MK,	MN,	MX,	NO,	NZ,	PL,	RO,	RU,	SG,	SI,	SK,	SL,	ТJ,	ΤM,	TR,
		ΤT,	UA,	UZ,	VN,	YU,	AM,	AZ,	ΒY,	KG,	KΖ,	MD,	RU,	тJ,	ТМ		
	RW:	GH,	GM,	KΕ,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	ΡT,	SE,	BF,	BJ,	CF,	CG,	CI,
		CM,	GA,	GN,	G₩,	ML,	MR,	NE,	SN,	ТD,	ΤG						
BR	9813	686		А		2000	1010		E	SR 19	98-1	3686		1998	1212	<	
CA	2311					19990	0701		C	A 19	98-2	3114:	28	1998	1217	<	
AU	9916	830		A	1	1999	0712		P	U 19	99-1	6830		1998	1217	<	
AU	7420	77		B	2	2001	1213										
ZA	9811	576		А		2000	0619		Z	IA 19	98-1	1576		1998	1217	<	
EP	1040	103		A	1	2000	1004		E	CP 19	98-9	6138	3	1998	1217	<	
	R:	AT,	ΒE,	CH,	DE,	DK,	ΕS,	FR,	GB,	GR,	IT,	LI,	LU,	.NL,	SE,	MC,	PΤ,
		IE,	FI														
US	6166	006		A		2000	1226		U	JS 19	98-2	1337	9	1998	1217	<	
JP	1126	3764		A	2	1999	0928		Ċ	VP 19	98-3	6078	0	1998	1218	<	
NO	2000	0031	33	A		2000	0809		N	10 20	00-3	133		2000	0616	<	
US	6413	947		B	1	2002	0702		τ	JS 20	00-6	6119	4	2000	0913	<	
PRIORITY	Y APP	LN.	INFO	.:					JP 1	.997-	3514	81	А	1997	1219	<	
								1	US 1	.998-	2133	79	AЗ	1998	1217	<	
								۱	WO 1	.998-	JP57	07	W	1998	1217	<	
OTHER SC	DURCE	(S):			MAR	PAT	131:	7357	1								

GI



- AB Title compds. I [R1 = (substituted) 5-6 membered ring; W = Q1, Q2; A = atoms to form a (substituted) 5-6 membered arom. ring; X = S, O, (substituted) C, N; B = atoms to form a (substituted) 5-7 membered ring; Z = bond, divalent group; R2 = (substituted) amino, ammonio, heterocyclyl, S-bonded group, P(O)kR5R6; k = 0, 1; R5, R6 = (substituted) hydrocarbyl, amino; PR5R6 = cyclic group], were prepd. Thus, 7-(4-methylphenyl)-2, 3-dihydro-1-benzoxepine-4-carboxylic acid in CH2Cl2 was treated with (COCl)2 and DMF to give a residue which was stirred with 4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]aniline and Et3N in THF to give N-[4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]phenyl]-7-(4-methylphenyl)-2, 3-dihydro-1-benzoxepine-4-carboxamide (II). II at 1 .mu.M inhibited MCP-1 induced chemotaxis in CHO cells by 89%. A II capsule compn. is given.
- IT 229003-70-7P 229003-71-8P
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor
 - antagonists)
- RN 229003-70-7 HCAPLUS
- CN 2-Naphthalenecarboxamide, 3,4-dihydro-7-(4-methylphenyl)-N-[4-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



Searched by Susan Hanley 305-4053


Page 199

AU	7480	64		B	2	2002	0530											
ZA	9811	574		А		2000	0619		:	ZA 1	998	-11	574		1998	1217	<	
EP	1039	899		A	2	2000	1004]	EP 1	998	-96	1384	4	1998	1217	<	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	, GF	λ, I	т,	LI,	LU,	NL,	SE,	MC,	PΤ,
		IE,	FI															
BR	9813	691		А		2000	1010		l	BR 1	998	-13	691		1998	1217	<	
JP	2000	1287	82	A	2	2000	0509		ı	JP 1	998	-36	0820	0	1998	1218	<	
US	6096	780		А		2000	0801		I	US 1	999	-37	7040	0	1999	0819	<	
US	6376	536		B	L	2002	0423		τ	US 2	2000	÷58	0270	0	2000	0526	<	•
NO	2000	0031	79	А		2000	0619		1	NO 2	2000	-31	79		2000	0619	<	
US	6268	354		B	L	2001	0731		I	US 2	2000	-66	1320	0	2000	0913	<	
PRIORITY	APP	LN.	INFO	. :					JP :	1997	7-35	148	0	А	1997	1219	<	
									JP :	1998	3-21	887	5	А	1998	0803	<	
									JP :	1998	3-23	438	8	А	1998	0820	<	
								1	US 3	1998	3-10	484	5P	Р	1998	1016	<	
								1	US :	1998	3-10	484	7P	Р	1998	1116	<	
								1	US :	1998	3-21	337	7	A3	1998	1217	<	
								Ţ	WO	1998	3-JP	570	8	W	1998	1217	<	
								1	US :	1999	9-37	704	0	A3	1999	0819		
OTUED CO		191.			MAR	ידעס	121.9	2783	٨									


OTHER SOURCE(S):



-



- AB A pharmaceutical compn. for antagonizing CCR5 comprises I [R1 = (substituted) 5-6 membered ring; W = Q1, Q2; A = atoms to form a (substituted) 5-6 membered arom. ring; X = S, O, (substituted) C, N; B = atoms to form a (substituted) 5-7 membered ring; Z = bond, divalent group; R2 = (substituted) amino, ammonio, heterocyclyl, S-bonded group, P(O)kR5R6; k = 0, 1; R5, R6 = (substituted) hydrocarbyl, amino; PR5R6 = cyclic group]. Thus, 7-(4-methylphenyl)-2, 3-dihydro-1-benzoxepine-4-carboxylic acid in CH2Cl2 was treated with (COCl)2 and DMF to give a residue which was stirred with 4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]aniline and Et3N in THF to give N-[4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]phenyl]-7-(4-methylphenyl)-2, 3-dihydro-1-benzoxepine-4-carboxamide (II). A II capsule compn. is given.
 IT 229003-70-7P 229003-71-8P
 PL: PRC (Piological activity or effector except adverse): BSU (Piological
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)
- RN 229003-70-7 HCAPLUS
- CN 2-Naphthalenecarboxamide, 3,4-dihydro-7-(4-methylphenyl)-N-[4-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




prophylactic treatment, or management of excessive, undesired or inappropriate uterine activity, such as contractions, in a mammal in need thereof. An example of a cytokine-prodn. blocker is SKF 86002 [6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo[2,1-b]thiazole], a CSBP/p38 protein kinase RK inhibitor.

IT 165806-47-3 165806-49-5 186314-81-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cytokine prodn. blockers for the management of uterine contractions) RN 165806-47-3 HCAPLUS


CN Pyridine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-5-yl]- (9CI) (CA INDEX NAME)








```
RN 165806-49-5 HCAPLUS
CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-
1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)
```



RN 186314-81-8 HCAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1Himidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 9917773	Al 19990415	WO 1998-US21125	19981007 <
W: AL, AU,	BA, BB, BG, BR, CA,	CN, CZ, EE, GE, HU,	ID, IL, IS, JP,
KP, KR,	LC, LK, LR, LT, LV,	MG, MK, MN, MX, NO,	NZ, PL, RO, SG,
SI, SK,	SL, TR, TT, UA, US,	UZ, VN, YU, AM, AZ,	BY, KG, KZ, MD,
RU, TJ,	TM		
RW: GH, GM,	KE, LS, MW, SD, SZ,	UG, ZW, AT, BE, CH,	CY, DE, DK, ES,
FI, FR,	GB, GR, IE, IT, LU,	MC, NL, PT, SE, BF,	BJ, CF, CG, CI,
CM, GA,	GN, GW, ML, MR, NE,	SN, TD, TG	
ZA 9809083	A 19990407	ZA 1998-9083	19981006 <
CA 2305805	AA 19990415	CA 1998-2305805	19981007 <
AU 9897901	Al 19990427	AU 1998-97901	19981007 <
EP 1037635	A1 20000927	EP 1998-952132	19981007 <
R: BE, CH,	DE, ES, FR, GB, IT,	LI, NL	
JP 2001518505	T2 20011016	JP 2000-514644	19981007 <
US 6476028	B1 20021105	US 2000-529338	20000808 <


PRIORITY APPLN. INFO.:

	US	1997-61217P	Ρ	19971007	<
	WO	1998-US21125	W	19981007	<
MARPAT	130:281994				


OTHER SOURCE(S): GI




- The title compds. [I; X = H, alkyl, CF3, etc.; R1-R3 = H, alkyl; A = [C(R'')2]mCR''R4R5, [C(R'')2]nCR'':CR4R5; R'' = H, alkyl; m = 0-3; n = 1-2; R4 = Ph, biphenyl, naphthyl, etc.; R5 = R'', Ph, naphthyl] which are AB modulators, agonists or antagonists, of the CCR5 receptor, were prepd. E.g., a 3-step synthesis of the title compd. II, starting with 5-benzyloxyindole and 1-benzyl-4-piperidone, was given. Compds. I show CCR5 receptor modulator activity having IC50 of 0.0001-100 .mu.M. In addn., this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, by the use of substituted 3-(4-piperidinyl) indoles which are CCR5 receptor modulators. Furthermore, since CD8+ T cells have been implicated in Chronic Obstructive Pulmonary Disease ("COPD"), CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of Human Immunodeficiency Virus ("HIV") into cells, receptor modulators may be useful in the treatment of HIV infection.
- IT 222635-69-0P 222635-70-3P 222635-72-5P
 222635-73-6P 222635-74-7P 222635-75-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 3-(4-piperidinyl or 1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol 5-ols for treating a CCR5-mediated diseases)
- RN 222635-69-0 HCAPLUS
- CN 1H-Indol-5-ol, 3-[1-([1,1'-biphenyl]-2-ylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




- RN 222635-70-3 HCAPLUS CN 1H-Indol-5-ol, 3-[1-([1,1'-bip}
- CN 1H-Indol-5-ol, 3-[1-([1,1'-biphenyl]-4-ylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 222635-72-5 HCAPLUS
CN 1H-Indol-5-ol, 3-[1-(3-phenylpropyl)-4-piperidinyl]- (9CI) (CA INDEX
NAME)




RN 222635-73-6 HCAPLUS CN 1H-Indol-5-ol, 3-[1-(4-phenylbutyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 222635-74-7 HCAPLUS CN 1H-Indol-5-ol, 3-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



- RN 222635-75-8 HCAPLUS
- CN 1H-Indol-5-ol, 3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-piperidinyl]-(9CI) (CA INDEX NAME)



4

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Searched by Susan Hanley 305-4053


Page 205

L38 ANSWER 26 OF 44 HC ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:	CAPLUS COPYRIGHT 2002 ACS 1999:166498 HCAPLUS 130:223295 Preparation of imidazoquinoxaline protein tyrosine kinase inhibitors
INVENTOR (S):	Barrish, Joel C.; Chen, Ping; Das, Jagabandhu; Iwanowicz, Edwin J.; Norris, Derek J.; Padmanabha, Ramesh; Roberge, Jacques Y.; Schieven, Gary L.
PATENT ASSIGNEE(S): SOURCE:	Bristol-Myers Squibb Company, USA PCT Int. Appl., 315 pp. CODEN: PIXXD2
DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:	Patent English 1

PATENT NO. KIND DATE					APPLICATION NO. DATE												
 WO	9909	845		 A	1	1999	0304		N	10 19	98U	s160	 27	1998	0803	<	
	W:	AL,	AM,	AT,	AU,	ΑZ,	ΒA,	BB,	ΒG,	BR,	ΒY,	CA,	CH,	CN,	CU,	CZ,	DE,
		DK,	EE,	ΕS,	FI,	GB,	GE,	GH,	GΜ,	HU,	ID,	IL,	IS,	JP,	KΕ,	KG,	KΡ,
•		KR,	ΚΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MX,	NO,
		ΝZ,	ΡL,	PΤ,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	ΤM,	ΤR,	ΤT,	UA,
		UG,	UΖ,	VN,	YU,	ZW,	AM,	AZ,	ΒY,	KG,	KΖ,	MD,	RU,	ΤJ,	ТМ		
	RW:	GH,	GM,	KΕ,	LS,	MW,	SD,	SZ,	ŪG,	ZW,	ΑT,	ΒE,	CH,	CY,	DE,	DK,	ES,
		FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	ΡT,	SE,	BF,	ΒJ,	CF,	CG,	CI,
		CM,	GA,	GN,	GW,	ML,	MR,	NE,	SN,	ΤD,	ΤG						
US	6235	740		B	1	2001	0522		U	JS 19	98-9	7338		1998	0615	<	
AU	9886	817		A	1	1999	0316		P	U 19	98-8	6817		1998	0803	<	
ZA	9807	649		A		2000	0224		Z	IA 19	98-7	649		1998	0824	<	
PRIORITY	Y APP	LN.	INFO	.:					US 1	.997-	5677	ΟP	Р	1997	0825	<	
									US 1	.997-	6915	9P	Р	1997	1209	<	
								1	WO 1	.998-	US16	027	W	1998	0803	<	
OTHER SO GI	OURCE	(S):			MAR	PAT	130:	2232	95								

Searched by Susan Hanley 305-4053

·



AB Novel imidazoquinoxalines I and salts thereof are disclosed [wherein: n = 0-4; R1, R2, R3 = H, R6, OH, OR6, SH, SR6, CO2H, SO3H, halo, cyano, NO2, etc.; R1-R3 may form ring(s); R4, R5 = H, R6, COR6; or NR4R5 forms (un)substituted 3- to 8-membered heterocyclic ring; R6 = (un)substituted alk(en/yn)yl, cycloalk(en)yl(alkyl), aryl, aralkyl, heterocyclo(alkyl)]. Also disclosed are pharmaceutical compns. contg. the compds., and methods of their use in the treatment of various protein tyrosine kinase-assocd. disorders, such as immunol. disorders (no data). Over 500 synthetic examples are given. For instance, the nitroimidazoloquinoxalinone II (prepd. in 4 steps) was treated with POC13 to give 78% of the corresponding chloro compd., which reacted with NaN(SiMe3)2 and 2-chloro-6-methylaniline in THF to give 86% title compd. III.

III


C1

IT 221065-44-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of imidazoquinoxalines as protein tyrosine kinase inhibitors)

- RN 221065-44-7 HCAPLUS
- CN Imidazo[1,5-a]quinoxaline-4,7-diamine, N4-(2-chloro-6-methylphenyl)-N7-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L38 ANSWER 27 OF 44 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1999:64782 HCAPLUS DOCUMENT NUMBER: 130:139366

Preparation of 6-azauracil derivatives as IL-5 TITLE: biosynthesis inhibitors Lacrampe, Jean Fernand Armand; Freyne, Eddy Jean INVENTOR(S): Edgard; Venet, Marc Gaston; Boeckx, Gustaaf Maria Janssen Pharmaceutica N.V., Belg. PATENT ASSIGNEE(S): PCT Int. Appl., 83 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PAT	rént	NO.		KII	KIND DATE APPLICATION NO. D						DATE							
WO	9902	505		A	1	1999	0121		W	0 19	98-E	P419	1	1998	0707	<		
	W:	AL,	AM,	AT,	AU,	ΑZ,	ΒA,	BB,	ΒG,	BR,	ΒY,	CA,	CH,	CN,	CU,	CZ,	DE,	
		DK,	ΕE,	ΕS,	FI,	GB,	GE,	GH,	GM,	GW,	HR,	ΗU,	ID,	IL,	IS,	JP,	KΕ,	
		KG,	KΡ,	KR,	ΚΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	
		MX,	NO,	ΝZ,	ΡL,	ΡT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	ΤM,	ΤR,	
		ΤT,	UA,	UG,	US,	ŪΖ,	VN,	YU,	ZW,	AM,	ΑZ,	ΒY,	KG,	ΚZ,	MD,	RU,	ΤJ,	ΤM
	RW:	GH,	GM,	KΕ,	LS,	MW,	SD,	SΖ,	UG,	ZW,	ΑT,	ΒE,	CH,	CY,	DE,	DK,	ES,	
		FI,	FR,	GB,	GR,	IE,	ΙT,	LU,	MC,	NL,	ΡT,	SE,	BF,	ВJ,	CF,	CG,	CI,	
						MR,												
AU	9889	738		A	1	1999	0208		A	U 19	98-8	9738		1998	0707	<		
		45																
EP	1000	040		A	1	2000	0517		E	P 19	98-9	4129	9	1998	0707	<		
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	ΡT,	IE,	
				LV,														
		680								A 19	98-6	089		1998	0709	<		
		678								R 19	98-1	1678		1998	0710	<		
		0000								O 20	00-6	3		2000				
US	2002	0726	03	A	1	2002	0613					9188	-	2001				
PRIORITY	Y APF	LN.	INFO	.:					EP 1	997-	2021	18	А	1997	0710	<		
									WO 1	998-	EP41	91	W	1998	0707	<		
									US 2	000-	4623	20	В1	2000	0105			
OTHER SO	OURCE	:(S):			MAF	RPAT	130:	1393	66									




- AB RZCR1(XR2)R3 [I; R= 3,5-dioxo-1,2,4-triazin-2(3H)-yl; R1 = H, halo; alkyl, alkoxy, etc.; R2 = CONH2, (un)substituted alkyl, (hetero)aryl, etc.; R3 = (un)substituted Ph; X = bond, O, s, (alkyl)imino; Z = (un)substituted phenylene] were prepd. Thus, title compd. II (R4 = C1) was etherified by Me2CHCH2OH to give II (R4 = OCH2CHMe2). Data for biol. activity of I were given.
- IT 219979-02-9P 219979-22-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 6-azauracil derivs. as IL-5 biosynthesis inhibitors)

RN 219979-02-9 HCAPLUS

CN 5-Thiazolecarboxamide, 2-[(4-chlorophenyl)]2,6-dichloro-4-(4,5-dihydro-3,5dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]-4-phenyl-N-[1-(phenylmethyl)-4piperidinyl]- (9CI) (CA INDEX NAME)



RN 219979-22-3 HCAPLUS CN 5-Thiazoleacetamide, 2-[(4-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5dioxo-1,2,4-triazin-2(3H)-yl)phenyl]methyl]-4-phenyl-N-[1-(phenylmethyl)-4piperidinyl]- (9CI) (CA INDEX NAME)




THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L38 ANSWER 28 OF 44 HC ACCESSION NUMBER: DOCUMENT NUMBER:	APLUS COPYRIGHT 2 1999:45153 HCAPL 130:110263		·					
TITLE:	Substituted imida activity	zoles having cyto	kine inhibitory					
INVENTOR(S):	Liverton, Nigel J W.; Bilodeau, Mar		d A.; Butcher, John					
PATENT ASSIGNEE(S):	Merck and Co., In	c., USA						
SOURCE:	U.S., 40 pp.							
	CODEN: USXXAM							
DOCUMENT TYPE:	Patent							
LANGUAGE:	English							
FAMILY ACC. NUM. COUNT:	1							
PATENT INFORMATION:								
PATENT NO. KI	ND DATE	APPLICATION NO.	DATE					
US 5859041 A	19990112	US 1997-871382	19970609 <					

OTHER SOURCE (S): MARPAT 130:110263


GI



- AB The title compds. I [HETCy = 4-10 membered nonarom. heterocycle contg. at least one N atom; X, X' = (CH2)mY(CH2)n and m and n = 0-4 and m + n = 0-6 and Y = bond, O, CO, etc.; Rx = H, alkyl, cycloalkyl, etc.; R = halo, OH, etc.; R' = CONH2, SO2NH2, alkynyl, etc.; R'' = halo, alkyl, CN, CONH2, etc.], were prepd. as cytokine inhibitors (no data). E.g., benzyl 4-[5-(2-methylaminopyrimidin-4-yl)-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylate was prepd.
- IT 200801-44-1P 200801-78-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and cytokine inhibitory activity of imidazoles)
- RN 200801-44-1 HCAPLUS
- CN 2-Pyrimidinamine, N-[(4-methoxyphenyl)methyl]-4-[2-[1-(phenylmethyl)-4piperidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



- RN 200801-78-1 HCAPLUS
- CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-[2-[1-(phenylmethyl)-4piperidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 29 OF 44 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1998:789126 HCAPLUS DOCUMENT NUMBER: 130:38291 TITLE: Preparation and formulation of phthalimide derivatives as inhibitors of IgE and IL-5 production INVENTOR(S): Kawasaki, Hisashi; Shinagawa, Yuko; Mimura, Takayuki PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

PCT Int. Appl., 143 pp. SOURCE: CODEN: PIXXD2 Patent DOCUMENT TYPE: Japanese LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: DATE APPLICATION NO. DATE KIND PATENT NO. ____ ----------_____ A1 19981126 WO 1998-JP2217 19980520 <--WO 9852919 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, CM, GA, GN, ML, MR, NE, SN, TD, TG 19980519 <--JP 11035559 A2 19990209 JP 1998-153777 JP 2921760 В2 19990719 AU 9874491 A1 19981211 AU 1998-74491 19980520 <--PRIORITY APPLN. INFO .: JP 1997-147174 19970521 <--WO 1998-JP2217 19980520 <--OTHER SOURCE(S): MARPAT 130:38291


GI



AB The title phthalimide derivs. I [R1, R3, and R4 represent each a hydrogen atom or the like; X = (B2)A(CH2)t(Y1)m(Z1)nCy; R2 represents a carboxyl group or the like; A represents a carbon atom or the like; B2 represents an optionally substituted aryl group or the like; Y1 represents an oxygen atom or the like; Z1 represents an alkylene group having 1 to 4 carbon atoms or the like; t is 0 or an integer of 1 to 4; m and n each independently represents 0 or 1; and Cy represents an optionally substituted aryl group or the like] are prepd. The title compd. II in vivo showed ED50 of 6 mg/kg against IgE prodn.

```
IT 216680-86-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (prepn. of phthalimide derivs. as inhibitors of IgE and IL-5 prodn.)
RN 216680-86-3 HCAPLUS
```

CN 1H-Isoindole-5-carboxylic acid, 2,3-dihydro-1,3-dioxo-2-[4-phenyl-1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



Gerald S.; Selnick, Harold G.; Mantlo, Nathan B. LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5792778 OTHER SOURCE(S):	А ма	19980811 RPAT 129:161495	00 1000 000000	19960808 <
GI				


$$R^4$$
 R^3
 R^5 N R^2
 I R^1

Ι


Title compds. [I; R1 = H, alkyl, heterocyclyl, aryl, etc.; R2 = alk(en)yl, AB alkynyl, heterocyclyl, etc.; R3 = H, halo, alkyl, heterocyclyl, etc.; R4 = (un)substituted heteroaryl; R5 = ZR; R = 1-3 of halo, alkyl, acyl, (hetero)aryl, etc.; Z = (hetero)arylene] were prepd. Thus, R5COCH2R4 (R4 = 4-pyridyl, R5 = 4-FC6H4) was .alpha.-alkylated by ClCH2COR2 (R2 = 1-benzyloxycarbonyl-4-piperidinyl) (prepn. each given) and the product cyclocondensed with NH4Ac to give, after redn., I (R1 = R3 = H, R2 = 1-methyl-4-piperidinyl, R4 = 4-pyridyl, R5 = 4-FC6H4). Data for biol. activity of I were given. IT 188344-17-4P 188344-44-7P RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of arylpyrroles as cytokine inhibitors) 188344-17-4 HCAPLUS

```
RN
     Pyridine, 4-[5-[1-(phenylmethyl)-4-piperidinyl]-2-[3-
CN
     (trifluoromethyl)phenyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)
```



RN 188344-44-7 HCAPLUS CN Ethanone, 1-[5-(4-fluorophenyl)-2-[1-(phenylmethyl)-4-piperidinyl]-4-(4pyridinyl)-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:	18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
ACCESSION NUMBER: DOCUMENT NUMBER:	128:282837 Preparation of imidazoles as cytokine inhibitors
PATENT ASSIGNEE(S): SOURCE:	
DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUN PATENT INFORMATION:	English
PATENT NO.	KIND DATE APPLICATION NO. DATE
US 5739143 US 5658903 ZA 9604723 ZA 9711092 WO 9825619 W: AL, AU, KP, KR,	A19980414US1996-76400319961211<A19970819US1996-65910219960603<

Searched by Susan Hanley 305-4053

Page 214

.

RW:	GH, GM, FR, GB,	GR, I	Ξ, ΙΤ,	LU,	MC,	NL,					DE, CF,			
		ML, M						00 F			1007	1011		
AU 98570)33	A1	1998	0703			U 19				1997			
EP 96161	18	A1	1999	1208		E	P 19	97-9	53242	L	1997	1211	<	
R:	BE, CH,	DE, E	S, FR,	GB,	IT,	LI,	NL							
JP 20015	506239	т2	2001	0515		J	P 19	98-5	2704	5	1997	1211	<	
US 58696	660	А	1999	0209		U	S 19	98-1	2946		1998	0123	<	
US 63690	068	B1	2002	0409		U	S 19	99-3	19859	9	1999	0611	<	
PRIORITY APPI	•).:			τ	US 1	995-	4733	96	B2	1995	0607	<	
					τ	US 1	996-	6367	79	B2	1996	0419	<	
					τ	US 1	996-	6591	02	A2	1996	0603	<	
					ĩ	US 1	996-	3276	6P	Ρ	1996	1211	<	
					τ	US 1	996-	7640	03	А	1996	1211	<	
					7	WO 1	997-	US23	157	W	1997	1211	<	
OTHER SOURCE	(S):	М	ARPAT	128:	28283	37								

GI

 R^1 R^4 Ι


AB The title compds. [I; R1 = 4-pyridyl, pyrimidinyl, quinolinyl, etc.; R2 = heterocyclyl, C2-10 alkenyl, C3-7 cycloalkyl, etc.; R4 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, heteroaryl], useful in treatment, e.g., inflammation and osteoporosis as cytokine inhibitors, were prepd. Thus, reaction of 4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-5-(2-methylsulfinyl-4-pyrimidinyl)imidazole (prepn. described) with PhCH2NH2 afforded 82% I [R1 = 2-benzylamino-4-pyrimidinyl; R2 = 1-methyl-4-piperinyl; R4 = 4-fluorophenyl] which showed IC50 of < 50 .mu.M in cytokine specific binding protein assay.</p>


IT 186314-81-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of imidazoles as cytokine inhibitors)

- RN 186314-81-8 HCAPLUS
- CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1Himidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)









AB The title compds. [I; AR = 6-10 membered aryl; X, X1 = (CH2)mY(CH2)n (wherein n, m = 0-4; n + m = 0-6; Y = a direct bond, O, S(O)y, etc.; y = 0-2); HETCy = 4-6 membered non-arom. heterocyclyl contg. only N atom; R, R2 = halo, OH, CONH2, etc.; R1 = OH, CN, CF3, etc.; R3 = H, C1-6 alkyl, etc.], useful for treating cancer, cytokine mediated diseases, inflammation, osteoporosis, bone resorption and Crohn's disease, were prepd. Thus, treatment of 4-pyridylcarbinol tert-butyldimethylsilyl ether with BuLi/hexanes and (iPr)2NH in THF followed by addn. of 4-fluoro-N,O-dimethyl benzhydroxamide, and reaction of the resulting 1-(4-fluorophenyl)-2-hydroxy-2-pyridin-4-ylethanone tertbutyldimethylsilyl ether with N-tert-butoxycarbonyl-4piperidinecarbaldehyde in the presence of CuOAc and NH4OAc in AcOH afforded the title compd. II. Compds. I are effective in the treatment of cancer at 0.01-100 mg/kg.

IT 189442-12-4P 189442-26-0P 189442-60-2P
189442-61-3P 189442-70-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted imidazoles having anti-cancer and cytokine
 inhibitory activity)
RN 189442-12-4 HCAPLUS


CN Pyridine, 4-[5-(4-fluorophenyl)-2-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-4-yl]- (9CI) (CA INDEX NAME)




- RN 189442-26-0 HCAPLUS
- CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-4-yl]- (9CI) (CA INDEX NAME)




- RN 189442-60-2 HCAPLUS
- CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-(2-phenylethyl)-4-piperidinyl]-1Himidazol-4-yl]- (9CI) (CA INDEX NAME)



- RN 189442-61-3 HCAPLUS
- CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-(3-phenylpropyl)-4-piperidinyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 189442-70-4 HCAPLUS CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-[[4-(phenylmethoxy)phenyl]methyl]-4-piperidinyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)





L38 ANSWER 33 OF 44 H ACCESSION NUMBER: DOCUMENT NUMBER:	HCAPLUS COPYRIGHT 2002 ACS 1998:13957 HCAPLUS 128:88925
TITLE:	Preparation of pyrimidinylimidazoles as cytokine inhibitors
INVENTOR(S):	Liverton, Nigel J.; Butcher, John W.; Claremon, David A.; Bilodeau, Mark T.
PATENT ASSIGNEE(S):	Merck + Co., Inc., USA; Liverton, Nigel J.; Butcher, John W.; Claremon, David A.; Bilodeau, Mark T.
SOURCE:	PCT Int. Appl., 115 pp. CODEN: PIXXD2
DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT:	Patent English 1

PATENT INFORMATION:

PATENT NO.		KII	ND	DATE			A	PPLI	CATI	ON NC	э.	DATE			
WO 9747618		A	1	1997	1218		W	D 19	97–U	S988	8	1997	0606	<	
W: AL,	AM,	AU,	ΑZ,	ΒA,	BB,	BG,	BR,	BY,	CA,	CN,	CU,	CZ,	ΕE,	GE,	HU,
IL,	IS,	JP,	KG,	KR,	KΖ,	LC,	LK,	LR,	LT,	LV,	MD,	MG,	MK,	MN,	MX,
NO,	NZ,	PL,	RO,	RU,	SG,	SI,	SK,	ΤJ,	ΤM,	ΤR,	ΤT,	UA,	US,	UΖ,	VN,
YU,	AM,	ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ΤJ,	ΤM						
RW: GH,	KE,	LS,	MW,	SD,	SZ,	UG,	AT,	BE,	CH,	DE,	DK,	ΕS,	FI,	FR,	GB,
GR,	IE,	IT,	LU,	MC,	NL,	ΡT,	SE,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GA,	GN,
ML,	MR,	NE,	SN,	ΤD,	ΤG										
CA 2257200		A	A	1997	1218		C	A 19	97-2	2572	00	1997	0606	<	

AU 9733809 AU 708883	A1 1998010 B2 1999081		19970606 <
EP 906307	A1 1999040		3 19970606 <
R: AT, BE,	CH, DE, DK, ES	FR, GB, GR, IT, LI,	LU, NL, SE, PT, IE, FI
JP 2000515125	T2 2000111	JP 1998-50172	23 19970606 <
PRIORITY APPLN. INFO	.:	US 1996-19487P	P 19960610 <
		GB 1996-14190	A 19960705 <
		US 1996-23312P	P 19960731 <
		GB 1996-17897	A 19960828 <
		WO 1997-US9888	W 19970606 <
OTHER SOURCE(S): GI	MARPAT 128	88925	






AB Title compds. [tautomeric or isomeric I; R = H, (cyclo)alkyl, alkoxy, alkanoyl; R1 = (un)substituted 4-pyrimidinyl; R2 = (CH2)mY(CH2)nR21; R3 = (CH2)mY(CH2)nR31; R21 = (un)substituted Ph; R31 = (un)substituted heterocyclyl; Y = bond, O, SOO-2, (alkyl)imino, CO, etc.; m, n = 0-4] were prepd. as cytokine inhibitors (no data). Thus, 1-(2-methylthio-4pyrimidinyl)-(3-trifluoromethylphenyl)ethanone-1-oxime (prepn. given) was cyclocondensed with 1-tert-butoxycarbonylpiperidine-4-carboxaldehyde and the product converted in 2 steps to title compd. II (R4 = SO2Me, R5 = CO2CMe3) which was aminated by 4-(MeO)C6H4CH2NH2 and the product deprotected to give II (R4 = NHC6H4(OMe)-4, R5 = H).

IT 200801-44-1P 200801-78-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyrimidinylimidazoles as cytokine inhibitors)

```
RN 200801-44-1 HCAPLUS
```

CN 2-Pyrimidinamine, N-[(4-methoxyphenyl)methyl]-4-[2-[1-(phenylmethyl)-4piperidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 200801-78-1 HCAPLUS
CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-[2-[1-(phenylmethyl)-4piperidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]- (9CI)
INDEX NAME)

(CA

- Ph-CH2 N N H F3C
- L38 ANSWER 34 OF 44 HCAPLUS COPYRIGHT 2002 ACS 1997:650347 HCAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 127:314828 1,4,5-Substituted imidazole compounds for treatment of TITLE: CNS injuries to the brain Feuerstein, Giora Z. INVENTOR(S): Smithkline Beecham Corporation, USA; Feuerstein, Giora PATENT ASSIGNEE(S): Ζ. PCT Int. Appl., 40 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO.	KIND DATE	A	PPLICATION NO.	DATE	
WO 9735856 W: JP, US	A1 1997:	1002 W	D 1997-US5820	19970324 <	
•			GB, GR, IE, IT, P 1997-917899		
R: AT, BE, IE, SI,		ES, FR, GB,	GR, IT, LI, LU,	NL, SE, M	С, РТ,
JP 2000507558	T2 2000	0620 J	P 1997-534693	19970324 <	
US 6096739	A 2000	0801 U	5 1998-142877	19980918 <	
US 6387898	B1 2002	0514 U	S 2000-627940	20000728 <	
PRIORITY APPLN. INFO	• •	US 1	996-14137P P		
		WO 1	997-US5820 W	19970324 <	

Searched by Susan Hanley 305-4053


US 1998-142877 A3 19980918 <--

OTHER SOURCE(S):

AB 1,4,5-Substituted imidazole compds. and compns. are used for the treatment of CNS injuries to the brain. The preferred method of inhibition is the the inhibition of the CSBP/p38/RK kinase pathway. Compds. of the invention were active (IC50<50 .mu.M) in a cytokine specific binding protein (CSBP) assay.


MARPAT 127:314828

- IT 165806-47-3 165806-49-5 186314-81-8
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological
 process); BSU (Biological study, unclassified); THU (Therapeutic
 use); BIOL (Biological study); PROC (Process); USES (Uses)
 (imidazole derivs. for treatment of CNS injuries to brain)
- RN 165806-47-3 HCAPLUS
- CN Pyridine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-5-yl]- (9CI) (CA INDEX NAME)






RN 165806-49-5 HCAPLUS CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)




```
RN 186314-81-8 HCAPLUS
CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-
imidazol-5-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)
```



L38 ANSWER 35 OF 44 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1997:636196 HCAPLUS 127:307383 DOCUMENT NUMBER: Pyridyl imidazole compounds, useful as cytokine TITLE: inhibitors, and their compositions INVENTOR(S): Adams, Jerry Leroy; Garigipati, Ravi Shanker; Boehm, Jeffrey Charles Smithkline Beecham Corporation, USA PATENT ASSIGNEE(S): U.S., 39 pp., Cont.-in-part of U.S. Ser. No. 369,964. SOURCE: CODEN: USXXAM DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 5 PATENT INFORMATION:

PATENT NO.	KIND D	ATE	APPLICATION NO.	DATE
US 5670527 EP 1227091 EP 1227091	A2 2	0020731	US 1995-473058 EP 2002-76580	19950607 < 19940715 <
R: AT, BE, IE, SI	CH, DE,	DK, ES, FR,	GB, GR, IT, LI, LU	
EP 1227092 EP 1227092			EP 2002-76582	19940715 <
			GB, GR, IT, LI, LU	J, NL, SE, MC, PT,
EP 1229035			EP 2002-76581 GB, GR, IT, LI, L	
IE, SI ZA 9600094			ZA 1996-94	
	A 2	20001121	US 1997-854223 US 1998-185059	19981103 <
AU 9944782 PRIORITY APPLN. INFO			US 1993-92733 B	2 19930716 <
			US 1995-369964 B: EP 1994-923503 A: NO 1994 US7969 A:	3 19940715 <
			WO 1994-US7969 AX US 1995-473058 AX US 1997-854223 AX	3 19950607 <
OTHER SOURCE(S):	MARP		AU 1998-71850 A	

GI




- AB Novel 1,4,5-substituted imidazole compds. I [R1 = (un)substituted alk(en/yn)yl, cycloalkyl, aralkyl, heteroaryl, wide variety of functionalized sidechains; R4 = (un)substituted Ph, naphthyl, or heteroaryl; R5 = (un)substituted 4-pyridyl, pyrimidinyl, quinolyl, isoquinolinyl, quinazolin-4-yl, 1-imidazolyl, or 1-benzimidazolyl], and their compns. for use in therapy as cytokine inhibitors, are disclosed. Approx. 100 invention compds. and a variety of intermediates were prepd. For instance, (4-fluorophenyl)(p-tolylthio)methyl isocyanide and pyridine-4-carboxaldehyde [3-(4-morpholinyl)propyl]imine (prepns. given) were cyclocondensed in the presence of 1,5,7-triazabicyclo[4.4.0]dec-5-ene to give 51% title compd. II. The latter compd. was active in a radiocompetitive, cytokine-specific binding protein assay (no data).
- IT 165806-47-3P, 1-(1-Benzylpiperidin-4-yl)-4-(4-fluorophenyl)-5-(4pyridyl)imidazole 165806-49-5P, 5-(2-Aminopyrimidin-4-yl)-4-(4fluorophenyl)-1-(1-benzylpiperidin-4-yl)imidazole RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of pyridylimidazoles and analogs as cytokine inhibitors)


RN 165806-47-3 HCAPLUS

CN Pyridine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-5-yl]- (9CI) (CA INDEX NAME)





- RN 165806-49-5 HCAPLUS
- CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)



L38 ANSWER 36 OF 44 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1997:351075 HCAPLUS DOCUMENT NUMBER: 126:317379 TITLE: Substituted imidazoles having anti-cancer and cytokine inhibitory activity

.

.

.


INVENTOR(S):	Selnick, Harold G.; Claremon, David A.; Liverton, Nigel J.
PATENT ASSIGNEE(S):	Merck and Co. Inc., USA; Selnick, Harold G.; Claremon, David A.; Liverton, Nigel J.
SOURCE:	PCT Int. Appl., 137 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3 .
PATENT INFORMATION:	


PA	FENT	NO.		KI	ND	DATE				AP	PLI	CATI	ON NO	э.	DATE				
WO	9712	876		A	1	1997	0410			WO	19	96-U	S158	80	1996	1002	<		
	W:	AL,	AM,	AU,	AZ,	BA,	BB,	BG,	BF	λ, Ι	ΒY,	CA,	CN,	CU,	CZ,	EE,	GE,	нU,	
															MG,				
															UA,				
						κz,													
	RW:											DE,	DK,	ES,	FI,	FR,	GB,	GR,	
															CM,				
				SN,			•												
CA	2234						0410			CA	19	96-2	2340	66	1996	1002	<		
	9675																		
	7021																		
	8548									ΕP	19	96-9	3765	4	1996	1002	<		
															NL,			IE,	FI
CN	1203														1996				
	1151	4353		Т	2	1999	1207			JP	19	96-5	1442	8	1996	1002	<		
	1239														1996				
	2824														1996	1002	<		
	9801														1998	0403	<		
PRIORIT												5059			1995	1006	<		
									US	19	95-	5063	Р	Р	1995	1006	<		
															1996	0213	<		
												2975			1996				
									WO	19	96-	US15	880	W	1996	1002	<		
OTHER SO	OURCE	(S):			MAR	PAT	126:	3173	79					•					

GI

.

.







Compds. of formula I and their pharmaceutically acceptable salts are AB disclosed [wherein Ar = arom. group contg. 6-10 atoms; X, X' = (CH2)mY(CH2)n; m, n = 0-4; (m+n) = 0-6; Y = bond, O, S, SO, SO2, CO, OCO,COO, NH, CONH, etc.; Het = 4- to 10-membered non-arom. heterocycle contg. .gtoreq. 1 N atom plus 0-2 addn. N and 0-1 O or S atoms; Rx = H, (un) substituted alkyl, alkoxy, or alkanoyl; R, R'' = halo, OH, (un) substituted alkyl or NH2, CF3, SH, NO2, (hetero)aryl, etc.; R' = OH, (un) substituted alkyl, heterocyclyl, amino, (hetero) aryl, etc.]. A pharmaceutical compn. is also included, as are methods of treating cancer and cytokine-mediated diseases. A total of 27 synthetic examples are given, and approx. 50 invention compds. are described and/or claimed. For instance, 4-Pyr-CH2O-TBDMS [4-Pyr = 4-pyridyl, TBDMS = SiMe2Bu-tert] in THF was treated with LDA and then with 4-FC6H4CONMeOMe to give 4-Pyr-CH(O-TBDMS)COC6H4F-4. This compd. underwent cyclocondensation with N-(tert-butoxycarbonyl)piperidine-4-carboxaldehyde and NH4OAc in the presence of Cu(OAc)2 to give title compd. II. In an in vitro test for Ras kinase activity, I had IC50 values in the range of 0.001 mM to 1.5 mM (no specific data).

IT 189442-12-4P 189442-26-0P 189442-60-2P 189442-61-3P 189442-70-4P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of substituted imidazoles with anti-cancer and cytokine inhibitory activity)


- RN 189442-12-4 HCAPLUS
- CN Pyridine, 4-[5-(4-fluorophenyl)-2-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-4-yl]- (9CI) (CA INDEX NAME)




- RN 189442-26-0 HCAPLUS
- CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-4-yl]- (9CI) (CA INDEX NAME)




- RN 189442-60-2 HCAPLUS
- CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-(2-phenylethyl)-4-piperidinyl]-1Himidazol-4-yl]- (9CI) (CA INDEX NAME)



- RN 189442-61-3 HCAPLUS
- CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-(3-phenylpropyl)-4-piperidinyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



- RN 189442-70-4 HCAPLUS
- CN Pyridine, 4-[5-(3,4-dichlorophenyl)-2-[1-[[4-(phenylmethoxy)phenyl]methyl]-4-piperidinyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




	CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:	1997:244377 HCAPLUS
DOCUMENT NUMBER:	126:225212
TITLE:	Preparation of arylpyrroles as cytokine inhibitors
INVENTOR(S):	De Laszlo Stephen E.; Mantlo, Nathan B.; Ponticello,
	Gerald S.; Selnick, Harold G.; Liverton, Nigel J.
PATENT ASSIGNEE(S):	Merck and Co., Inc., USA; De Laszlo, Stephen E.;
	Mantlo, Nathan B.; Ponticello, Gerald S.; Selnick,
	Harold G.; Liverton, Nigel J.
SOURCE:	PCT Int. Appl., 172 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:


PATENT NO).	KI	ND	DATE			A	PPLI	CATI	ON NC	э.	DATE			
WO 970587	77	A	1	1997	0220		W	D 19	96-U	s129	17	19960	8080	<	
W: A	AL, AM	, AU,	ΑZ,	BB,	BG,	BR,	BY,	CA,	CN,	CU,	CZ,	EE,	GE,	ΗU,	IL,
]	IS, JP	, KG,	KR,	ΚZ,	LK,	LR,	LT,	LV,	MD,	MG,	MK,	MN,	MX,	NO,	ΝZ,
I	PL, RO	, RU,	SG,	SI,	SK,	ΤJ,	ΤM,	ΤR,	ΤT,	UA,	US,	UΖ,	VN,	AM,	ΑZ,
	ЗY, KG														
RW: H	KE, LS	, MW,	SD,	SZ,	UG,	ΑT,	BE,	CH,	DE,	DK,	ΕS,	FI,	FR,	GB,	GR,
.]	IE, IT	, LU,	MC,	NL,	ΡT,	SE,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GA,	GN,	ML,
1	MR, NE	, SN,	ΤD,	ΤG											
CA 222813	36	А	A	1997	0220		C.	A 19	96-2	2281	36	1996	8080	<	

Searched by Susan Hanley 305-4053

AU 9667689 AU 705082	A1 19970305 B2 19990513	AU 1996-67689	19960808 <
EP 863757	A1 19980916	EP 1996-92809	7 19960808 <
R: AT, BE,	CH, DE, DK, ES,	FR, GB, GR, IT, LI,	LU, NL, SE, PT, IE, FI
JP 11510510	T2 19990914	JP 1996-50865	9 19960808 <
JP 3294616	B2 20020624	JP 1997-50865	9 19960808 <
PRIORITY APPLN. INFO	.:	US 1995-2093P	P 19950810 <
		US 1996-14181P	P 19960326 <
		GB 1996-7254	A 19960404 <
		GB 1996-9264	A 19960502 <
		WO 1996-US12917	W 19960808 <
OTHER SOURCE(S): GI	MARPAT 126:2	25212	




- AB Title compds. [I; R1 = H, alkyl, aryl, heterocyclyl, etc.; R2 = (heteroatom-interrupted) alk(en)yl, heterocyclyl, etc.; R3 = H, cyano, alkyl, alkoxycarbonyl, etc.; R4 = (un)substituted heteroaryl; R5 = substituted (hetero)aryl] were prepd. Thus, pyridine-4-carboxaldehyde was condensed with MeCOCMe3 and 4-FC6H4CHO added to the unsatd. product to give 4-FC6H4COCHR4CH2COCMe3 (R4 = 4-pyridyl) which was cyclocondensed with NH4OAc to give title compd. II. Data for biol, activity of I were given. IT 188343-89-7P 188344-17-4P 188344-44-7P
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of arylpyrroles as cytokine inhibitors)
- RN 188343-89-7 HCAPLUS
- CN Pyridine, 4-[2-(4-fluorophenyl)-5-[1-(phenylmethyl)-4-piperidinyl]-1Hpyrrol-3-yl]- (9CI) (CA INDEX NAME)




RN 188344-17-4 HCAPLUS

```
CN Pyridine, 4-[5-[1-(phenylmethyl)-4-piperidinyl]-2-[3-
(trifluoromethyl)phenyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)
```



RN 188344-44-7 HCAPLUS CN Ethanone, 1-[5-(4-fluorophenyl)-2-[1-(phenylmethyl)-4-piperidinyl]-4-(4pyridinyl)-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



HCAPLUS COPYRIGHT 2002 ACS L38 ANSWER 38 OF 44 1997:70354 HCAPLUS ACCESSION NUMBER: 126:171596 DOCUMENT NUMBER: TITLE: Novel 1,4,5-substituted imidazole compounds useful as cytokine inhibitors INVENTOR(S): Adams, Jerry L.; Sheldrake, Peter W.; Gallagher, Timothy F.; Garigipati, Ravishanker PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA SOURCE: U.S., 42 pp., Cont.-in-part of U.S. Ser. No. 369, 964, abandoned. CODEN: USXXAM DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 5 PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
US 5593992	A 19970114	US 1995-472366	19950607 <
EP 1227091	A2 20020731	EP 2002-76580	19940715 <
EP 1227091	A3 20020807		
R: AT, BE,	CH, DE, DK, ES,	FR, GB, GR, IT, LI, LU,	NL, SE, MC, PT,
IE, SI			
EP 1227092	A2 20020731	EP 2002-76582	19940715 <
EP 1227092	A3 20020807		
R: AT, BE,	CH, DE, DK, ES,	FR, GB, GR, IT, LI, LU,	NL, SE, MC, PT,
IE, SI			
EP 1229035	A1 20020807	EP 2002-76581	19940715 <


Searched by Susan Hanley 305-4053


IL 116455 A1 20010724 IL 1995-116455 19951219 < IL 134322 A1 20010913 IL 1995-134322 19951219 < IL 134322 A1 20010913 IL 1995-134322 19951219 < ZA 9600094 A 19960724 ZA 1996-94 19960108 < CA 2209938 AA 19960718 CA 1996-2209938 19960111 < W0 9621452 A1 19960718 W0 1996-U5546 19960111 < W0 9621452 A1 19960731 AU 1996-45572 19960111 < AU 9646572 A1 19960731 AU 1996-46572 19960111 < EF 809499 A1 19971021 BR 1996-6904 19960111 < EF 809499 A1 19971021 BR 1996-6904 19960111 < IF, SI CN 1177299 A 19980325 CN 1996-192298 19960111 < IF, SI CN 1177297 A 19980325 CN 1996-192298 19960111 < JP 10512555 T2 19981202 JP 1996-521862 19960111 < IF 9702901 A 19971021 BR 1996-702250 19960111 < IF 9702901 A 1997090 US 1996-192298 19960111 < IF 9702901 A 1997090 US 1996-192298 19960111 < FI 9702901 A 19970908 FI 1997-3167 19970708 < FI 9702901 A 19970908 FI 1997-3167 19970708 < FI 9702901 A 19970908 N0 1997-3167 19970708 < FI 9702901 A 19970908 N0 1997-3167 19970708 < FI 9702901 A 19970908 N0 1997-3167 19970708 < EP 1997-2530 119940705 < W0 1994-U5766 A 19970908 N0 2001-6225 20011219 < US 1995-369964 N2 19970708 < EF 1997-2530 A3 19940715 < W0 1994-U5766 A 1997090 < US 1995-369964 A2 19950101 < US 1995-369964 A2 19950109 < US 1995-369964 A2 19950109 < US 1995-369964 A2 19950109 < US 1995-47236 A3 19940715 < W0 1994-U5766 A 19970317 < US 1995-72250 A3 19960111 < US 1995-72250 A3 19960111 < US 1995-72250 A3 19960111 < US 1995-72250 A3 19960111 < US 1995-72250 A3 19960211 < US 1997-7156 A1 1997037 < US 1997-715645 A3 19960111 < US 1997-7156 A1 1997037 < US 1997-7156 A1		R:			CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	ΡT,
<pre>IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG AU 9646572 A1 19960731 AU 1996-46572 19960111 < AU 705207 B2 19990520 BR 9606904 A 19971021 BR 1996-6904 19960111 < EP 809499 A1 19971203 EP 1996-902151 19960111 < IE, SI CN 1177299 A 19980325 CN 1996-192298 19960111 < JP 10512555 T2 19981202 JP 1996-521862 19960111 < US 5663334 A 19970902 US 1996-702250 19960821 < US 6103936 A 2000815 US 1997-819619 19970317 < FI 9702901 A 19970908 FI 1997-2901 19970708 < NO 9703167 A 19970908 FI 1997-2901 19970708 < NO 9703167 A 19970908 NO 1997-3167 19970708 < NO 2001006225 A 19970908 NO 1997-3167 19970708 < NO 2001006226 A 19970908 NO 2001-6225 2001219 < NO 2001006226 A 19970908 NO 2001-6225 2001219 < EP 1994-923503 A3 19940715 < EP 1994-923503 A3 19940715 < EP 1994-923503 A3 19940715 < US 1995-369964 A2 19950109 < EP 1994-923503 A3 19940715 < US 1995-116455 A3 19950119 < NO 2001006226 A 19970908 NO 2001-6226 A 19950109 < EP 1994-923503 A3 19940715 < US 1995-369964 A2 19950109 < EP 1994-923503 A3 19940715 < US 1995-116455 A3 19950219 < JP 1996-521862 A3 19960111 < WO 1994-US7969 A2 19940715 < US 1995-116455 A3 19950119 < JP 1996-521862 A3 19960111 < US 1995-7163619 A3 19960111 < WO 1996-US546 W 19960111 < US 1995-7163619 A3 1996002 <</pre>	IL IL IL ZA CA	1343 1343 1343 9600 2209 9621 W:	24 22 23 094 938 452 AM, KG, RO,	AU, KP, RU,	A A A A A BB, KR, SD,	1 1 BG, KZ, SG,	20010 20010 20010 19960 19960 BR, LK, SI,	0826 0913 1125 0724 0718 0718 BY, LR, SK,	LT, TJ,	I I Z C W CN, LV, TM,	L 19 L 19 L 19 A 19 A 19 O 19 CZ, MD, TT,	95-1 95-1 95-1 96-9 96-2 96-0 EE, MG, UA,	3432 3432 3432 4 2099 5546 FI, MN, US,	4 2 3 38 GE, MX, US,	1995 1995 1995 1996 1996 1996 HU, NO, UZ,	1219 1219 1219 0108 0111 0111 IS, NZ, VN	< < < JP, PL,	ΡΤ,
AU 9646572 A1 19960731 AU 1996-46572 19960111 < AU 705207 B2 19990520 BR 9606904 A 19971021 BR 1996-6904 19960111 < EP 809499 A1 19971203 EP 1996-902151 19960111 < R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI CN 1177299 A 19980325 CN 1996-192298 19960111 < JP 2002105047 A2 20020410 JP 2001-215404 19960111 < US 5663334 A 19970902 US 1996-70250 19960821 < US 6103936 A 2000815 US 1997-7819619 19970708 < FI 9702901 A 19970908 FI 1997-2901 19970708 < NO 9703167 A 19970908 NO 1997-3167 19970708 < NO 2001006225 A 19970908 NO 1997-3167 19970708 < NO 2001006225 A 19970908 NO 2001-6225 20011219 < NO 2001006226 A 19970908 NO 2001-6225 20011219 < NO 2001006226 A 19970908 NO 2001-6225 20011219 < EP 1994-923503 A3 19940715 < US 1995-369964 A2 19950109 < EP 1994-923503 A3 19940715 < WO 1994-US7969 A2 19950109 < EP 1994-923503 A3 19940715 < US 1995-472366 A 1995009 < EP 1994-923503 A3 19940715 < US 1995-472366 A 19950009 < EP 1994-923503 A3 19940715 < US 1995-472366 A 19950009 < EP 1994-923503 A3 19940715 < HI 1995-116455 A3 19951219 < JP 1996-521862 A3 19960821 < US 1997-819619 A3 19970317 < AU 1998-71850 A3 19980602 <		1	IT,	LU,	MC,	NL,												
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI CN 1177299 A 19980325 CN 1996-192298 19960111 < JP 10512555 T2 19981202 JP 1996-521862 19960111 < JP 2002105047 A2 20020410 JP 2001-215404 19960111 < US 5663334 A 19970902 US 1996-702250 19960821 < US 6103936 A 20000815 US 1997-819619 19970317 < FI 9702901 A 19970908 FI 1997-2901 19970708 < NO 9703167 A 19970908 NO 1997-3167 19970708 < AU 9944782 A1 19991111 AU 1999-44782 19990827 < US 6222036 B1 20010424 US 2000-502763 20000211 < NO 2001006225 A 19970908 NO 2001-6225 20011219 < NO 2001006226 A 19970908 NO 2001-6226 20011219 < US 1993-92733 B2 19930716 < US 1995-472366 A 19950607 < US 1995-472366 A 19950607 < IL 1995-116455 A3 19951219 < JP 1996-521862 A3 19960111 < WO 1994-US7969 A2 19940715 < US 1995-472366 A 19950607 < IL 1995-116455 A3 19951219 < JP 1996-521862 A3 19960111 < WO 1996-US546 W 19960111 < WO 1996-US546 W 19960111 < WO 1996-T0250 A3 1996022 < X0 1997-819619 A3 19970317 < AU 1998-71850 A3 19980602 <	AU BR	7052 9606	572 07 904	SN,	A B A	1 2	1999 1997	0520 1021		В	R 19	96-6	904		1996	0111	<	
IE, SI CN 1177299 A 19980325 CN 1996-192298 19960111 <	. EP			BE.														PT.
US 1996-702250 A3 19960821 < US 1997-819619 A3 19970317 < AU 1998-71850 A3 19980602 <	JP US US FI NO AU US NO	1051 2002 5663 6103 9702 9703 9944 6222 2001 2001	IE, 299 2555 1050 334 936 901 167 782 036 0062 0062	SI 47 25 26	A A A A A A A A A A	2 2 1 1	1998 1998 2002 1997 2000 1997 1997 2001 1999 2001	0325 1202 0410 0902 0815 0908 0908 1111 0424 0908		CJJUUFNAUNN11 USP01111 JP1	N 19 P 19 S 19 S 19 I 19 U 19 U 200 993 995 995 995	96-1 96-5 01-2 96-7 97-8 97-2 97-3 99-4 00-5 01-6 9273 3699 9235 US79 4723 1164 5218	9229 2186 1540 0225 1961 901 167 4782 0276 225 226 3 64 03 69 66 55 62	8 2 4 0 9 3 3 82 A3 A2 A3 A3 A3	1996 1996 1996 1997 1997 1997 2000 2000 2001 2001 1993 1995 1994 1995 1995 1995	0111 0111 0821 0708 0708 0708 0708 0708 0708 0708 070	< < < < < < < <	
										US 1	996-	7022	50	A3 A3	1996 1997	0821 0317	< <	
OTHER SOURCE(S): MARPAT 126:171596	OTHER S	OURCE	:(S):			MAR	PAT	126:			998-	7185	0	А3	1998	0602	<	

OTH GI

.

Searched by Susan Hanley 305-4053






Novel 1,4,5-substituted imidazole compds. I and compns. for use in therapy AB as cytokine inhibitors are disclosed [wherein R1 = (un)substituted 4-pyridyl, pyrimidinyl, quinolyl, isoquinolinyl, quinazolin-4-yl, 1-imidazolyl, 1-benzimidazolyl; R2 = N3, heterocyclyl, heterocyclylalkyl, alk(en/yn)yl, aryl, aralkyl, wide variety of N-contg. and O-contg. groups; R4 = (un) substituted Ph, naphthyl, heteroaryl]. The subset of I [R1 = (un) substituted pyrimidinyl; R4 = (un) substituted Ph or naphthyl] is claimed. Examples include approx. 100 syntheses and several bioassays. For instance, cyclization of the isocyanide 4-FC6H4CH(N.tplbond.C)SC6H4Me-4 with the imine II (prepns. given), in CH2Cl2 in the presence of the base 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), gave 51% title compd. III. The latter compd. was active in an in vitro test for inhibition of LPS-induced prostaglandin endoperoxide synthase-2 (PGHS-2) protein expression in human monocytes.

IT 165806-47-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of imidazole derivs. as cytokine inhibitors)

```
RN 165806-47-3 HCAPLUS
```

CN Pyridine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-5-yl]- (9CI) (CA INDEX NAME)






IT 165806-49-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of imidazole derivs. as cytokine inhibitors)

RN 165806-49-5 HCAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)




÷

L38ANSWER 39 OF 44HCAPLUSCOPYRIGHT 2002 ACSACCESSION NUMBER:1997:70353HCAPLUSDOCUMENT NUMBER:126:171595TITLE:Imidazole compounds, use as cytokine inhibitors, and
process of making themINVENTOR(S):Adams, Jerry L.; Boehm, Jeffrey C.PATENT ASSIGNEE(S):Adams, Jerry L., USA; Boehm, Jeffrey C.

Searched by Susan Hanley 305-4053

U.S., 38 pp., Cont.-in-part of U.S. Ser. No. 369, 964. SOURCE: CODEN: USXXAM Patent DOCUMENT TYPE: English LANGUAGE: FAMILY ACC. NUM. COUNT: 5 PATENT INFORMATION: KIND DATE APPLICATION NO. DATE PATENT NO. _____ _____ _____ ____ _____ US 5593991 А 19970114 US 1995-476934 19950607 <--EP 1227091 EP 2002-76580 19940715 <--A2 20020731 20020807 EP 1227091 A3 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI A2 19940715 <--20020731 EP 2002-76582 EP 1227092 A3 20020807 EP 1227092 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, R: IE, SI 20020807 EP 2002-76581 19940715 <--EP 1229035 A1 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, R: IE, SI 19960108 <--ZA 1996-94 ZA 9600094 А 19960724 19990827 <--AU 1999-44782 AU 9944782 A1 19991111 B2 19930716 <--US 1993-92733 PRIORITY APPLN. INFO .: A2 19950109 <--US 1995-369964 A3 19940715 <--EP 1994-923503 AU 1998-71850 A3 19980602 <--OTHER SOURCE(S): MARPAT 126:171595 GΙ



AB Novel 1,4,5-substituted imidazole compds. I and compns. for use in therapy as cytokine inhibitors are disclosed [wherein R1 = (un)substituted

Searched by Susan Hanley 305-4053

4-pyridyl, pyrimidinyl, quinolyl, isoquinolinyl, quinazolin-4-yl, 1-imidazolyl, 1-benzimidazolyl; R2 = N3, heterocyclyl, heterocyclylalkyl, alk(en/yn)yl, aryl, aralkyl, wide variety of N-contg. and O-contg. groups; R4 = (un)substituted Ph, naphthyl, heteroaryl]. The subset of I [R1 = (un)substituted quinolyl or isoquinolinyl; R4 = (un)substituted Ph or naphthyl] is claimed. Examples include approx. 100 syntheses and several bioassays. For instance, cyclization of the isocyanide 4-FC6H4CH(N.tplbond.C)SC6H4Me-4 with the imine II (prepns. given), in CH2Cl2 in the presence of the base 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), gave 48% title compd. III. Another compd. I, namely the analog of III with R1 = 4-pyridyl, was active in an in vitro test for inhibition of LPS-induced prostaglandin endoperoxide synthase-2 (PGHS-2) protein expression in human monocytes.

IT 165806-47-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of imidazole derivs. as cytokine inhibitors)


- RN 165806-47-3 HCAPLUS
- CN Pyridine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-5-yl]- (9CI) (CA INDEX NAME)

F R R CH₂-Ph



IT 165806-49-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic
use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazole derivs. as cytokine inhibitors)

- RN 165806-49-5 HCAPLUS
- CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)



US 1995-472366 A2 19950607 <--B2 19930716 <--US 1993-92733 WO 1996-US546 W 19960111 <--

OTHER SOURCE(S): GI

CASREACT 125:212675; MARPAT 125:212675


Ι

Imidazole derivs. I [R1 = (substituted) 4-pyridyl, pyrimidinyl, quinolyl, AB isoquinolyl, quinazolin-4-yl, 1-imidazolyl, 1-benzimidazolyl; R2 = (substituted) C1-10 alkyl, C2-10 alkenyl or alkynyl, N3, cycloalkyl, heterocyclyl, etc.; R4 = (substituted) Ph, 1- or 2-naphthyl, heteroaryl] are prepd. which inhibit mitogen-activated protein kinase and the secretion of interleukin 1 and tumor necrosis factor and are useful in treatment of cytokine-mediated inflammatory diseases. Thus, 1-[3-(4-morpholinyl)propyl]-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole (II) inhibited lipopolysaccharide-induced prostaglandin endoperoxide synthase-2 expression in human monocytes with a potency similar to that of dexamethasone. II was prepd. by condensation of pyridine-4-carboxaldehyde with 4-(3-aminopropyl)morpholine and reaction of the product with 4-fluorophenyl-tolylthiomethylisocyanide (prepd. from pfluorobenzaldehyde, thiocresol, and HCONH2).

IΤ 165806-49-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (trisubstituted imidazoles useful as cytokine suppressors)

165806-49-5 HCAPLUS RN


2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-CN 1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)



L38 ANSWER 41 OF 44 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: DOCUMENT NUMBER:	1996:86798 HCAPLUS 124:202282
TITLE:	Preparation of dihydrobenzoxazinone derivatives as phospholipase A2 and interleukin 1 inhibitors
INVENTOR(S):	Kawakita, Takeshi; Kuroita, Takanobu; Murozono, Takahiro; Terasawa, Michio; Okamoto, Hitoshi
PATENT ASSIGNEE(S):	Yoshitomi Pharmaceutical, Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 35 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	
PATENT NO. KI	ND DATE APPLICATION NO. DATE

PAIENI NO.	KIND DATE	AFFLICATION NO.	DAIL
JP 07242662 OTHER SOURCE(S): GI	A2 19950919 MARPAT 124:202282	JP 1994-31631	19940301 <




AB The title compds. I [R1 = H, alkyl, etc.; R2 = H, Cl, etc.; R3, R4 = H, alkyl; Het = 5,6-dihydroimidazo[2,1-b]thiazol-3-yl, etc.] are prepd. The title compd. II.HBr at 10 .mu.M gave 40% in vitro inhibition of phospholipase A2.

IT 173084-19-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of dihydrobenzoxazinone derivs. as phospholipase A2 and interleukin 1 inhibitors)

RN 173084-19-0 HCAPLUS

CN 2H-1, 4-Benzoxazin-3(4H)-one, 6-chloro-4-methyl-8-[2-[[1-(2-phenylethyl)-4piperidinyl]amino]-4-thiazolyl]-, monohydrobromide (9CI) (CA INDEX NAME)




and a substance which substantially prevents the irritant-inactivating agent from binding to the surface. A suspension of 12% corn starch and 4%

Searched by Susan Hanley 305-4053

chlorhexidine gluconate stirred for 24h at 28-30.degree., then centrifuged, washed, and dried at 100.degree. for 2 h. The above mixt. was suspended in water at a concn. of 20% and tested against Staphylococcus aureus. The compn. inactivated the microbial pathogen within 2 min upon fluid contact.

- IT 68844-77-9, Astemizole
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. for inactivating irritants in fluids contg.
 antimicrobial agents)
- RN 68844-77-9 HCAPLUS
- CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



L38 ANSWER 43 OF 44 ACCESSION NUMBER: DOCUMENT NUMBER:	HCAPLUS COPYRIGHT 2002 ACS 1995:856174 HCAPLUS 123:246794
TITLE:	Method for preventing or reducing photosensitivity
	and/or phototoxicity reactions to medications
INVENTOR(S):	Klimstra, Paul Dale; Roniker, Barbara; Swabb, Edward
	Allen
PATENT ASSIGNEE(S):	G. D. Searle and Co., USA
SOURCE:	PCT Int. Appl., 137 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT	: 1
PATENT INFORMATION:	

PATENT NO. KIND DATE APPLICATION NO. DATE _ _ _ _ _____ ------------19950112 <--A1 19950803 WO 1995-US213 WO 9520387 AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, W: GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, MC, NL, TD, TG US 1994-188296 19940128 <--US 5668134 А 19970916 AU 1995-15605 19950112 <--19950815 AU 9515605 A1 EP 1995-907337 19950112 <--19961113 EP 741570 A1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE 20010109 US 6172069 US 1997-936572 19970924 <--В1 US 1994-188296 A1 19940128 <--PRIORITY APPLN. INFO.: 19950112 <--WO 1995-US213 W B1 19950509 <--US 1995-438002 A method for preventing or reducing a photosensitivity and/or AB


phototoxicity reaction which may be caused by a once-per-day dose of a medication comprises administering the prescribed or suggested dose of the medication to the patient during the evening or early morning hours. The present invention also provides a method for treating an infection in a patient in a manner which prevents or reduces a photosensitivity and/or phototoxicity reaction which method comprises orally administering to the patient a once-a-day dose of 25-700 mg of lomefloxacin HCl during the evening or early morning hours. The present invention also provides an article of manuf. comprising: (1) a packaging material, and (2) a once-a-day medication which causes a photosensitivity and/or a phototoxicity reaction in a patient contained within said packaging material and wherein said packaging material comprises a label which indicates that such a reaction is prevented or reduced by administering the medication to the patient during the evening or early morning hours. **68844-77-9**, Astemizole

ΙT

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for preventing or reducing photosensitivity and/or phototoxicity reactions to drugs in humans)

- RN 68844-77-9 HCAPLUS
- CN 1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



	CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:	1995:719167 HCAPLUS
DOCUMENT NUMBER:	123:112061
TITLE:	Preparation of substituted imidazoles as cytokine inhibitors
INVENTOR(S):	Adams, Jerry Leroy; Sheldrake, Peter William;
	Gallagher, Timothy Francis; Garigipati, Ravi Shanker;
	Bender, Paul Elliot; Boehm, Jeffrey Charles
PATENT ASSIGNEE(S):	SmithKline Beecham Corp., USA
SOURCE:	PCT Int. Appl., 72 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5
PATENT INFORMATION:	

PATENT NO.				KII	ND	DATE			A	PPLI	CATI	ON NC	ο.	DATĒ			
														- .			
WO 9502591				A	1	1995	0126		W	D 19	94-U	s796	9	1994	0715	<	
	W:	AU,	BB,	BG,	BR,	ΒY,	CA,	CN,	CZ,	FI,	HU,	JP,	KΡ,	KR,	KΖ,	LK,	MG,
		MN,	MW,	NO,	ΝZ,	PL,	RO,	RU,	SD,	SI,	SK,	UA,	US,	VN			
	RW:	ΑT,	ΒE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IE,	IΤ,	LU,	MC,	NL,	PΤ,	SE,
														ΤD,			
IL 110296 A1 19991231							I	L 19	94-1	1029	6	1994	0712	<			


Searched by Susan Hanley 305-4053

CA 2167311		AA	19950126		С	A 19	994-2	16731	11	1994	0715	<		
AU 9473354		A1	19950213		A	AU 19	994-7	3354		1994	0715	<		
AU 694130		В2	19980716											
ZA 9405193		А	19950420		Z	LA 19	994-5	193		1994	0715	<		
EP 708768		A1	19960501					23503		1994				
R: AT,	BE,	CH, DE	, DK, ES,	FR,	GB,	GR,	, IE,	IT,	LI,	LU,	MC,	NL,	PΤ,	SE
CN 1129447	•	A	19960821	-				93161						
CN 1050126		В	20000308											
BR 9407079		Ā	19960827		В	BR 19	994-7	079		1994	0715	<		
JP 09500137		т2	19970107					04744		1994				
HU 75313		A2	19970528				995-3			1994				
RU 2140918		C1	19991110					.03386		1994				
PL 181705		B1	20010928		-			812614						
		B1 B1	20010928					32405	-	1994 1994 1994	0715	2		
PL 181723								3240	5	1004	0715	~		
PL 181694		B1	20010928					32408	•	1994	0.10	•		
PL 181721		B1	20010928											
SK 282342			20020107		5	SK IS	996-4	17		1994				
EP 1227091		A2	20020731		Ł	SP 20	002-7	6580		1994	0/15	<		
EP 1227091		A3	20020807											
		CH, DE	, DK, ES,	FR,	GB,	GR,	, IT,	LI,	LU,	NL,	SE,	MC,	PΤ,	
	SI													
EP 1227092		A2	20020731		E	CP 20	002-7	6582		1994	0715	<		
EP 1227092		A3	20020807											
R: AT,	BE,	CH, DE	, DK, ES,	FR,	GB,	GR,	, IT,	LI,	LU,	NL,	SE,	MC,	ΡT,	
	SI													
EP 1229035		A1	20020807		F	EP 20	002-7	6581		1994	0715	<		
R: AT,										NL,			PΤ,	
	ΒĒ,		, DK, ES,							NL,			ΡT,	
IE,		CH, DE	, DK, ES,	FR,	GB,	GR,	, IT,		LU,	NL, 1996	SE,	MC,	ΡT,	
IE, FI 9600177	ΒĒ,		, DK, ES, 19960115	FR,	GB, F	GR, 51 19	, IT, 996-1	LI, .77	LU,		SE, 0115	мс, <	PT,	
IE, FI 9600177 NO 9600173	ΒĒ,	CH, DE A A	, DK, ES, 19960115 19960115	FR,	GB, F	GR, 71 19 10 19	, IT, 996-1 996-1	LI, .77 .73	LU,	1996 1996	SE, 0115 0115	MC, <	ΡT,	
IE, FI 9600177 NO 9600173 US 6103936	ΒĒ,	CH, DE A A A	, DK, ES, 19960115 19960115 20000815	FR,	GB, F N U	GR, 71 19 NO 19 JS 19	, IT, 996-1 996-1 997-8	LI, .77 .73 819619	LU,	1996 1996 1997	SE, 0115 0115 0317	MC, < <	ΡT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184	ΒĒ,	CH, DE A A A A	, DK, ES, 19960115 19960115 20000815 19991019	FR,	GB, F N U	GR, 71 19 NO 19 JS 19 JS 19	, IT, 996-1 996-1 997-8 997-8	LI, 77 73 19619 54223	LU, 9 3	1996 1996 1997 1997	SE, 0115 0115 0317 0509	MC, < < <	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850	ΒĒ,	CH, DE A A A A A A1	, DK, ES, 19960115 19960115 20000815 19991019 19980827	FR,	GB, F N U	GR, 71 19 NO 19 JS 19 JS 19	, IT, 996-1 996-1 997-8 997-8	LI, .77 .73 819619	LU, 9 3	1996 1996 1997	SE, 0115 0115 0317 0509	MC, < < <	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568	ΒĒ,	CH, DE A A A A A1 B2	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527	FR,	GB, F N U A	GR, 7I 19 NO 19 JS 19 JS 19 AU 19	, IT, 996-1 996-1 997-8 997-8 997-8 998-7	LI, 77 73 319619 354223 71850	LU,	1996 1996 1997 1997 1997	SE, 0115 0115 0317 0509 0612	MC, < < <	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801	ΒĒ,	CH, DE A A A A1 B2 A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609	FR,	GB, F N U A C	GR, 71 19 NO 19 JS 19 JS 19 AU 19 CN 19	, IT, 996-1 996-1 997-8 997-8 997-8 998-7 998-1	LI, 77 73 319619 354223 71850	LU, 9 3 2	1996 1996 1997 1997 1998	SE, 0115 0115 0317 0509 0612 0617	MC, < < < <	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557	ΒĒ,	CH, DE A A A A A B2 A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121	FR,	GB, F N U U A C C	GR, FI 19 NO 19 JS 19 JS 19 AU 19 CN 19 JS 19	, IT, 996-1 996-1 997-8 997-8 998-7 998-1 998-1	LI, 77 73 19619 54222 71850 15012 85059	LU, 9 3 2 9	1996 1997 1997 1997 1998 1998	SE, 0115 0115 0317 0509 0612 0617 1103	MC,	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782	ΒĒ,	CH, DE A A A A A B2 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111	FR,	GB, F U U A C C C C C C C C C C C C C C C C C	GR, FI 19 NO 19 JS 19 JS 19 AU 19 CN 19 JS 19 JS 19 AU 19	, IT, 996-1 997-8 997-8 997-8 998-7 998-1 998-1 999-4	LI, 77 73 319619 354222 71850 .15012 .85059 4782	LU, 9 3 2 9	1996 1997 1997 1997 1998 1998 1998 1998	SE, 0115 0115 0317 0509 0612 0617 1103 0827	MC, < < < <	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036	ΒĒ,	CH, DE A A A A A B 2 A A A A 1 B 1	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424	FR,	GB, F U U A C U A U U	GR, 71 19 70 19 75 19 75 19 75 19 740 19 75 19 740 19 75 20	, IT, 996-1 997-8 997-8 998-7 998-1 998-1 998-1 999-4 000-5	LI, .77 .73 .19619 .54222 .15012 .85059 .4782 .02763	LU, 9 3 2 9	1996 1997 1997 1997 1998 1998 1998 1998 1999 2000	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0211	MC, < < < < <	ΡΤ,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837	ΒĒ,	CH, DE A A A A B2 A A A A A B1 A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115	FR,	GB, F U U A C U A U U N	GR, 71 19 10 19 15 19 15 19 AU 19 CN 19 15 19 AU 19 15 20 AU 20	, IT, 996-1 997-8 997-8 998-7 998-1 998-1 998-1 999-4 000-5 001-8	LI, .77 .73 .19619 .54222 .15012 .85059 .4782 .02763 .37	LU, 9 3 2 9 3	1996 1997 1997 1998 1998 1998 1998 2000 2001	SE, 0115 0317 0509 0612 0617 1103 0827 0211 0219	MC, < < < < < <	ΡΤ,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838	ΒĒ,	CH, DE A A A A B 2 A A A A 1 B 1 A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F N U U A C U A U U N N N	GR, FI 19 NO 19 JS 19 JS 19 AU 19 JS 19 AU 19 JS 20 NO 20 NO 20	, IT, 996-1 997-8 997-8 998-7 998-1 998-1 999-4 000-5 001-8 001-8	LI, .77 .73 .19619 .54222 .1850 .15012 .85059 .4782 .0276 .337 .338	LU, 9 3 2 9	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219	MC,	ΡΤ,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115	FR,	GB, F U U A C U A U U N N N N N	GR, FI 19 JO 19 JS 19 JS 19 JS 19 JS 19 JS 19 JS 19 JS 20 JS 20 JO 20 JO 20 JO 20	, IT, 996-1 997-8 997-8 997-8 998-7 998-7 998-1 998-1 999-4 000-5 001-8 001-8 001-8	LI, 77 73 319619 354222 71850 .15012 85059 4782 602763 37 338 39	LU, 9 3 2 9 3	1996 1997 1997 1998 1998 1998 2000 2001 2001 2001	SE, 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219	MC,	ΡΤ,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F U U A C U U U N N N U S 1	GR, FI 19 JO 19 JS 19 JS 19 JS 19 JS 19 JS 20 JS 20 JO 20 JO 20 JO 20 JO 20 JO 20 JO 20 JO 20	, IT, 996-1 997-8 997-8 998-7 998-1 998-1 999-4 000-5 001-8 001-8 001-8 -9273	LI, .77 .73 .19619 .54222 .1850 .15012 .85059 .4782 .02763 .338 .339 .33	LU, 9 3 2 9 3 3	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 2001 1993	SE, 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219 0219 0716	MC,	ΡΤ,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F U U A C U A U U N N N N U S 1 EP 1	GR, FI 19 JO 19 JS 19 JS 19 JS 19 JS 19 JS 20 JS 20 JO 20 JS 19 JS 20 JS 19 JS 20 JS 19 JS 20 JS 19 JS 20 JS	, IT, 996-1 997-8 997-8 998-7 998-1 998-1 999-4 000-5 001-8 001-8 001-8 -9273 -9235	LI, .77 .73 .19619 .54222 .15012 .85059 .4782 .02763 .37 .38 .39 .33 .39 .33 .33	LU, 9 3 2 9 3 3 A A3	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 2001 1993 1994	SE, 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219 0219 0219 0716 0715	MC,	ΡΤ,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F U U U U U U U U U U U U U U U U S 1 E P 1 WO 1	GR, FI 19 JS 19 JS 19 JS 19 JS 19 JS 19 JS 20 JS	, IT, 996-1 997-8 997-8 998-7 998-1 998-1 999-4 000-5 001-8 001-8 001-8 001-8 -9273 -9235 -US79	LI, 77 319619 354222 21850 15012 85059 4782 502763 337 338 339 33 503	LU, 9 3 3 3 A A3 W	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 2001 1993 1994 1994	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219 0219 0219 0219 0715 0715	MC,	ΡΤ,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F U U U U U U U U U U U U U U U U U U	GR, FI 19 JS 19 JS 19 JS 19 JS 19 JS 19 JS 20 JS	, IT, 996-1 997-8 997-8 998-1 998-1 998-1 999-4 000-5 001-8 001-8 001-8 -9273 -9235 -0579 -3699	LI, 77 319619 354223 71850 15012 85059 4782 502763 338 339 33 503 969 964	LU, 9 3 3 4 3 8 8 8 8 8 8	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 2001 1993 1994 1994 1995	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219 0219 0219 0219 0219	MC,	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F U U U U U U U U U U U U U U S 1 U S 1 U S 1 U S 1 U S 1 U S 1 U S 1 U S 1 U S 1 U U U U	GR, FI 19 JS 19 JS 19 JS 19 JS 19 JS 19 JS 20 JS	, IT, 996-1 997-8 997-8 998-1 998-1 998-1 999-4 000-5 001-8 001-8 001-8 001-8 -9273 -9235 -0259 -3699 -3699 -4723	LI, 77 73 319619 354223 71850 .15012 .85059 44782 502763 338 339 33 339 33 339 33 339 33 339 33 339 33 33	LU, 9 3 3 4 3 8 9 3 3 8 9 9 3 8 9 9 9 9 9 9 9 9 9 9	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 1993 1994 1994 1995 1995	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219 0219 0219 0219 0716 0715 0715 0109 0607	MC,	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F U U U U U U U U U U U U U U U U S 1 U U S 1 U S 1 U U S 1 U U S 1 U U S 1 U U U U	GR, FI 19 JO 19 JS 19 JS 19 JS 19 JS 19 JS 20 JS 2	, IT, 996-1 997-8 997-8 998-7 998-1 998-1 999-4 000-5 001-8 001-8 001-8 001-8 -9273 -9235 -02579 -3699 -4723 -4730	LI, 77 73 319619 354223 71850 15012 85059 44782 502763 338 339 338 339 339 33 339 339 339 339	LU, 9 3 3 4 3 8 9 3 3 8 2 9 3 3 8 2 9 3 8 2 9 9 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 1993 1994 1995 1995 1995	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219 0219 0219 0716 0715 0715 0109 0607 0607	MC,	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, FNUUUU AUUUUA UUUUUUUUUUUUUUUUUUUUUUUUU	GR, 11 19 10 19 15 19 15 19 15 19 15 19 15 19 19 19 19 94 19 94 19 94 19 94 19 94 19 95 19 95 19 95 19 95 19 95 19 95 19 95	, IT, 996-1 997-8 997-8 997-8 998-1 998-1 998-1 999-4 000-5 001-8 001-8 001-8 001-8 -9273 -9235 -0273 -4723 -4730 -7022	LI, 77 73 319619 354223 71850 .15012 .85059 4782 502763 338 339 33 339 33 339 339 33 339 33 339 339 33 33	LU, 9 3 2 9 3 3 A A 3 W B2 A1 A3 A3	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 1993 1994 1995 1995 1995 1995	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219 0219 0219 0716 0715 0715 0715 0109 0607 0607	MC,	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F N U U A C U A U U A U U N N N N U S 1 EP 1 WO 1 US 1 US 1 US 1 US 1 US 1	GR, 1 19 10 19 15 19 15 19 15 19 15 19 10 19 15 19 19 19 19 94 19 94 19 94 19 94 19 94 19 95 19 19 19 19	, IT, 996-1 997-8 997-8 997-8 998-1 99235 -4723 -4723 -4722 -4722 -8196 -8196 -8196 -8196 -9273 -9773 -9775 -9	LI, 77 73 319619 354223 71850 15012 85059 44782 502763 337 338 339 33 339 33 339 339 339 339 339 3	LU, 3 3 4 3 3 4 3 8 2 9 3 3 8 2 9 3 8 2 9 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 1993 1994 1995 1995 1995 1995 1995	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0211 0219 0219 0219 0219 0219 0716 0715 0715 0715 0109 0607 0607 0821 0317	MC,	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A A B 2 A A A A B 1 A A A A A A	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F N U U U U U U U U U U U U U U S 1 U U S 1 U U S 1 U U S 1 U U S 1 U U S 1 U U S 1 U U S 1 U U U U	GR, 1 19 10 19 15 19 15 19 15 19 15 19 10 19 10 20 10 20	, IT, 996-1 997-8 997-8 998-7 998-1 99235 -4723 -4722 -47302 -8196 -85422 -85552 -85555 -85555 -85555 -85555	LI, 77 73 319619 554223 71850 15012 85059 4782 602763 337 338 339 33 339 339 339 3603 964 866 958 250 519 223	LU, 3 3 4 3 3 4 3 8 2 9 3 3 8 2 9 3 8 2 9 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	1996 1997 1997 1998 1998 1998 1998 2000 2001 2001 2001 2001 1993 1994 1995 1995 1995 1995 1995	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0219 0219 0219 0219 0219 0716 0715 0715 0715 0109 0607 0607 0821 0317 0509	MC,	PT,	
IE, FI 9600177 NO 9600173 US 6103936 US 5969184 AU 9871850 AU 705568 CN 1218801 US 6150557 AU 9944782 US 6222036 NO 10837 NO 10838 NO 10839	BE, SI	CH, DE A A A A B A A A A A A .:	, DK, ES, 19960115 19960115 20000815 19991019 19980827 19990527 19990609 20001121 19991111 20010424 19960115 19960115	FR,	GB, F N U U U U U U U U U U U U U U S 1 U U S 1 U U S 1 U U S 1 U U S 1 U U S 1 U U S 1 U U S 1 U U U U	GR, 1 19 10 19 15 19 15 19 15 19 15 19 10 19 10 20 10 20	, IT, 996-1 997-8 997-8 997-8 998-1 99235 -4723 -4723 -4722 -4722 -8196 -8196 -8196 -8196 -9273 -9773 -9775 -9	LI, 77 73 319619 554223 71850 15012 85059 4782 602763 337 338 339 33 339 339 339 3603 964 866 958 250 519 223	LU, 3 3 4 3 3 4 3 8 2 9 3 3 8 2 9 3 8 2 9 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	1996 1997 1997 1998 1998 1998 1999 2000 2001 2001 1993 1994 1995 1995 1995 1995 1995	SE, 0115 0115 0317 0509 0612 0617 1103 0827 0219 0219 0219 0219 0219 0716 0715 0715 0715 0715 0715 0715 0607 0607 0821 0317 0509	MC,	PT,	

OTHI GI

.

-



AB Title compds. [I; R1 = 4-pyridyl, pyrimidinyl, quinolyl, etc.; R2 = (cyclo)alkyl, heterocyclyl(alkyl), (hetero)aryl, etc.; R4 = Ph, naphthyl, heteroaryl, etc.] were prepd. as cytokine inhibitors (no data). Thus, 4-FC6H4CH(SR)NC (R = cresyl) was cyclocondensed with R1CH:NR2 (R1 = 4-pyridyl, R2 = 3-morpholinopropyl)(prepn. each given) to give title compd. II.

IT 165806-47-3P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted imidazoles as cytokine inhibitors) RN 165806-47-3 HCAPLUS

CN Pyridine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1Himidazol-5-yl]- (9CI) (CA INDEX NAME)


F R R CH2-Ph



IT 165806-49-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of substituted imidazoles as cytokine inhibitors)

```
RN 165806-49-5 HCAPLUS
CN 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(phenylmethyl)-4-piperidinyl]-
1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)
```




Searched by Susan Hanley 305-4053


=> d ibib abs fordref 144 1-2

. .

EACT COPYRIGHT 2002 ACS
135:162081 CASREACT
Discovery of a novel CCR3 selective antagonist
Naya, A.; Kobayashi, K.; Ishikawa, M.; Ohwaki, K.;
Saeki, T.; Noguchi, K.; Ohtake, N.
Banyu Tsukuba Research Institute, Tsukuba, Ibaraki,
300-2611, Japan
Bioorganic & Medicinal Chemistry Letters (2001),
11(9), 1219–1223
CODEN: BMCLE8; ISSN: 0960-894X
Elsevier Science Ltd.
Journal
English
-



 $I = R^{1}=R^{2}=H$ III = R^{1}=NH_{2}, R^{2}=C1




AB In searching for a novel CCR3 receptor antagonist, we designed a library that included a variety of carboxamide derivs. based on the structure of our potent antagonists for human CCR1 and CCR3 receptors, and screened the new compds. for inhibitory activity against 125I-Eotaxin binding to human CCR3 receptors expressed in CHO cells. Among them, two 2-(benzothiazolethio)acetamide derivs. (I and II) showed binding affinities with IC50 values of 750 and 1000 nM, resp., for human CCR3 receptors. I and II also possessed weak binding affinities for human CCR1 receptors. We selected I as a lead compd. for derivatization to improve in vitro potency and selectivity for CCR3 over CCR1 receptors. Derivatization of I by incorporating substituents into each benzene ring of the benzothiazole and piperidine side chain resulted in the discovery of a compd. (III) exhibiting 820-fold selectivity for CCR3 receptors (IC50=2.3 nM) over CCR1 receptors (IC50=1900 nM). III also showed potent

Searched by Susan Hanley 305-4053


functional antagonist activity for inhibiting Eotaxin (IC50=27 nM)- or RANTES (IC50=13 nM)-induced Ca2+ increases in eosinophils.

а,

RX(1) OF 9 4-ClC6H4CHO, S-CH2 - NH Na. (AcO) 3BH, CH2C12 – s– сн₂– с– NH CH2 90% REF: Bioorganic & Medicinal Chemistry Letters, 11(9), 1219-1223; 2001 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS 6 REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L44 ANSWER 2 OF 2 CASREACT COPYRIGHT 2002 ACS 134:295821 CASREACT ACCESSION NUMBER: Imidazole compounds useful as cytokine TITLE: inhibitors. Adams, Jerry Leroy; Gallagher, Timothy Francis; Sisko, INVENTOR(S): Joseph; Osifo, Irennegbe Kelly; Boehm, Jeffrey Charles Smithkline Beecham Corporation, USA PATENT ASSIGNEE(S): U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 636,779, SOURCE: fabandoned. CODEN: USXXAM DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: 5 PATENT INFORMATION: KIND DATE APPLICATION NO. DATE PATENT NO. ____ -----------_____ _____ US 1998-973594 19980513 US 6218537 B1 20010417 ZA 1996-4723 ZA 9604723 А 19970617 19960606 WO 1996-US10039 19960607 A1 19961219 WO 9640143 AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, W: KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG US 1995-473396 19950607 PRIORITY APPLN. INFO.: US 1996-636779 19960419 WO 1996-US10039 19960607 OTHER SOURCE(S): MARPAT 134:295821 GI



Novel 1,4,5-trisubstituted imidazole compds. I and their compns. for use AB in therapy as cytokine inhibitors are disclosed [wherein R1 = 4-pyridyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolin-4-yl, 1-imidazolyl, 1-benzimidazolyl, all bearing a substituted amino group, plus an optional addnl. substituent; R2 = alkyl, N3, heterocyclyl, alk(en/yn)yl, haloalkyl, etc.; R4 = (un)substituted Ph, 1- or 2-naphthyl, heteroaryl]. I are useful for treating a variety of cytokine -mediated diseases, particularly those mediated by CSBP/RK/p38 kinase, and may also be useful as antivirals (no data). For example, 2-(methylthio)pyrimidine-4-carboxaldehyde (prepn. given) was condensed with 4-amino-1-methylpiperidine-2HCl to give the imine (98%), which was cyclized with the tosylmethyl isocyanide deriv. 4-FC6H4CH(Tos)N.tplbond.C (50%) to give imidazole deriv. II [R = SMe]. This underwent S-oxidn. with K persulfate to give 83% II [R = S(O)Me], which was condensed with PhCH2NH2 (82%) to give title compd. II [R = NHCH2Ph].



REF: U.S., 6218537, 17 Apr 2001

52

REFERENCE COUNT:

.


THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d ibib abs fcrdref 146 1-28


L46 ANSWER 1 OF 28 CAS	REACT COPYRIGHT 2002 ACS -137:125087 CASREACT
TITLE:	Preparation of .alphasulfonylhydroxamic acid
	derivatives from sulfonyl fluorides and carbonyl compounds in the presence of metal hydrides or amides
	and their use as TACE inhibitors. Sandanayaka, Vincent P.; Zask, Arie; Venkatesan,
INVENTOR(S):	Aranapakam M.; Baker, Jannie L.; Krishnan, Lalitha;
	Megati, Sreenivasulu; Zeldis, Joseph
PATENT ASSIGNEE(S):	USA
SOURCE :	U.S. Pat. Appl. Publ., 39 pp.
	CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO. KIND DATE APPLICATION NO. DATE	
US 2002099035 A1 20020725 US 2001-769107 20010124 OTHER SOURCE(S): MARPAT 137:125087	
<pre>OTHER SOURCE(S): MARPAT 137:125087 AB ZCOCRIR2SO2R3 [Z = H, OH, NYOX, OR5, NR5R6; X = H, alkyl, PhCH2, hydroxyethyl, Me3CMe2Si, Me3Si, tetrahydropyranyl; Y = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl; R1, R2 = H, (substituted) aryl, heteroaryl, cycloalkyl, cycloheteroalkyl; R3 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl], were prepd. by reaction of R31SO2F (R31 as for R3 above, except that it does not contain a group that can form an anion under basic conditions) with ZCOCHR1R2 (variables as above) in the presence of a metal hydride or amide base in an ether solvent at -78.degree. to 30.degree Thus, a soln. of LDA in THF at -78.degree. was treated with Me 1-tert-butoxycarbonylpiperidine-4-carboxylate (prepn. given) in THF and then with 4-but-2-ynyloxybenzenesulfonyl fluoride (prepn. given) followed by stirring at room temp. to give 4-(4-but-2-ynyloxybenzenesulfonyl)piperi dine-1,2-dicarboxylic acid tert-Bu ester Me ester. The latter was sapond. with LiOH (100%) and the acid was treated with (COCl)2 and NH2OH.HCl to give 61% hydroxamate. Stirring of the latter with aq. HCl in CH2Cl2/dioxane to give 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-4- piperidinecarboxamide hydrochloride.</pre>	

RX(22) OF 403








CASREACT COPYRIGHT 2002 ACS L46 ANSWER 2 OF 28 ACCESSION NUMBER: 137:78809 CASREACT Method of preparation of novel purine derivatives and TITLE: their use as antifungal medicines INVENTOR(S): Bordon-Pallier, Florence; Haesslein, Jean-Luc Aventis Pharma S.A., Fr. PATENT ASSIGNEE(S): PCT Int. Appl., 87 pp. SOURCE: CODEN: PIXXD2 Patent DOCUMENT TYPE: LANGUAGE: French FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

 PATENT NO.
 KIND DATE
 APPLICATION NO.
 DATE


 WO 2002051843
 A1
 20020704
 WO 2001-FR4051
 20011219

 W:
 AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK,

LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, TN, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG RW: GH, GM, CY, DE, BF, BJ, 20020628 FR 2000-17009 20001226 FR 2818642 A1 PRIORITY APPLN. INFO.: FR 2000-17009 20001226 MARPAT 137:78809 OTHER SOURCE(S): GΙ



AB The invention concerns novel purine products I [Rx = (Z)NR1; Z = CH2, SO2, CO, CO2, CONH, (CH2)2-NR6; n = 0, 1; R1 = H, Ph, CH2Ph, pyridyl, alkyl, piperidinyl (optionally substituted); Ry = (un)substituted Ph, Rz; D1, D2 = H, (un)substituted NH2], in all the isomeric forms and pharmaceutically acceptable salts, for use as antifungal medicines. Thus, trans-N2-(4-aminocyclohexyl)-N6-(3,4-dichlorophenyl)-9H-purin-6-amine (I; Rx = 4-aminocyclohexyl, Ry = 3,4-dichlorophenyl) was prepd. from 2,6-dichloropurine via amination with 3,4-dichloroaniline in BuOH followed by fusion with trans-1,4-diaminocyclohexane at 70.degree.. I (Rx = 4-aminocyclohexyl, Ry = 3,4-dichlorophenyl) was shown to be an active inhibitor of CIV-CDK (CIV1) [IC50 = 2.9 .mu.M] and Candia albicans [CMI = 25 .mu.g/mL].



3 HCl

REF: PCT Int. Appl., 2002051843, 04 Jul 2002 NOTE: 1st stage: thermal (140.degree., 4 h)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 3 OF 28 CASREACT COPYRIGHT 2002 ACS ACCESSION NUMBER: 136:134793 CASREACT TITLE: Preparation of benzylpiperidine derivatives as serotonin reuptake inhibitors INVENTOR(S): Kodo, Toru; Masumoto, Shuji; Koyama, Koji; Kinomura, Naoya Sumitomo Pharmaceuticals Co., Ltd., Japan PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 113 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent Japanese LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

 PATENT NO.
 KIND
 DATE
 APPLICATION NO.
 DATE


 WO 2002006231
 A1
 20020124
 WO 2001-JP6195
 20010717


 W:
 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

 RW:
 GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,


Searched by Susan Hanley 305-4053

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.: JP 2000-216967 20000718 MARPAT 136:134793 OTHER SOURCE(S): GI





Title compds. [I; R = H, halogeno, alkyl, OH, alkoxy; R1 = H; Y = AB alkylene; Z = H, cycloalkyl, aryl; n = 1, 2, 3;], prodrugs thereof, and pharmaceutically acceptable salts of both are prepd. as serotonin reuptake inhibitors for treatment of sleep disorder, high blood pressure, obesity, etc. Thus, the title compd. II was prepd. from 4-piperidine hydrochloride, 2-bromo-5-methoxytoluene, and phenethyl bromide and II was in vitro tested for citalopram and 8-OH-DPAT binding inhibition effects.





THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L46 ANSWER 4 OF 28 ACCESSION NUMBER:	CASREACT COPYRIGHT 2002 ACS 135:266639 CASREACT
TITLE:	The first potent and selective inhibitors of
11105.	the glycine transporter type 2
AUTHOR(S):	Caulfield, Wilson L.; Collie, Iain T.; Dickins, Rachel
	S.; Epemolu, Ola; McGuire, Ross; Hill, David R.;
	McVey, Gillian; Morphy, J. Richard; Rankovic, Zoran;
	Sundaram, Hardy
CORPORATE SOURCE:	Lead Discovery Unit, Organon Laboratories Ltd.,
	Newhouse, ML1 5SH, UK
SOURCE:	Journal of Medicinal Chemistry (2001), 44(17),
	2679-2682
	CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English

Glycine is one of the major inhibitory neurotransmitters in the spinal AB cord and brain stem of vertebrates. The inhibitory actions of glycine are mediated by the strychnine-sensitive glycine receptor , a ligand-gated chloride channel distributed throughout the spinal cord and brain stem. Glycine is also known to potentate the action of glutamate acting as an essential co-agonist on postsynaptic N-methyl-d- aspartate (NMDA) receptors. Synaptic levels of glycine are believed to be controlled by high-affinity glycine transporters. These transporters are members of a large family of sodium/chloride-dependent transporters, which are composed of single oligomeric proteins contg. 12 hydrophobic membrane-spanning domains. There is evidence that glycine-mediated inhibition produces muscle relaxation and blockade of this inhibition produces convulsions. Therefore, we postulated that modulators of endogenous levels of glycine might provide skeletal muscle relaxation. A significant amt. of data has accumulated over recent years, indicating that glycine also has an important role in the modulation of nociceptive pathways. Thus, it was anticipated that an increase in synaptic levels of endogenous glycine by a selective inhibition of the GlyT-2 transporter in the spinal cord may offer a unique approach for developing a novel muscle relaxant, anesthetic, and/or analgesic reagent, suitable for use during surgical anesthesia. Due to the discrete localization of both ssGlyR and the GlyT-2 transporter within the spinal cord and brain stem, a glycine modulator might not be expected to lead to serious CNS side effects that are characteristic for currently used .mu.-opioid analgesics. Since testing of this hypothesis has been hampered by the lack of a suitable GlyT-2 inhibitor, we sought a potent and selective inhibitor of the transporter that would enable us to conduct proof-of-principle studies. In summary, high-throughput screening of Organon's compd. collection provided an attractive drug-like GlyT-2 inhibitor suitable for high-throughput synthesis. A detailed study of the SAR and rapid hit optimization were achieved through synthesis of a soln.-phase 2D library. This led to identification of 4-benzyloxy-3,5-dimethoxy-N-[(1-di methylaminocyclopentyl)methyl]benzamide , the first potent and selective GlyT-2 inhibitor.







Starting from 3-[2-(1-benzylpiperidin-4-yl)ethylamino]-6-phenylpyridazine AB (I), a series of pyridazine analogs, e.g. the [(piperidinylethyl)amino]pyridazines II [R = Ph, R1, R2 = H, Me, Et, Pr, Me2CH; R1 = R2 = H, R = H, Ph, Cl, MeO, 2-MeC6H4, 2-EtC6H4, 2-ClC6H4, 2-naphthyl, 3-(AcNH)C6H4, 3-AcC6H4, 4-FC6H4, 2-thienyl, 3-pyridinyl] and the tricyclic phenylpyridazines III (n = 0, 1, 2, 3) were prepd. and their AChE inhibiting structure-activity relationships were detd. Structural modifications were achieved on four different parts of I and showed that introduction of a lipophilic environment at C-5 of the pyridazine ring was favorable for AChE-inhibitory activity and AChE/BuChE selectivity, that substitution and various replacements of the C-6 Ph group are possible and led to equiv. or slightly more active derivs., and that isosteric replacements or modifications of the benzylpiperidine moiety were detrimental to the activity. III (n = 1) was the most potent inhibitor with an IC50 of 10 nM on elec. eel AChE. Compared to I, this represents a 12-fold increase in potency. Moreover, II (R = Ph, R1 =Me, R2 = H), which showed an IC50 of 21 nM, was 100-times more selective for human AChE (human BuChE/AChE ratio of 24) than the ref. compd. tacrine.



Searched by Susan Hanley 305-4053

DOCUMENT TYPE: Journal LANGUAGE: English GI





AB Pharmacophore-based discovery, synthesis, and structure-activity relation (SAR) of a series of 4-phenyl-1-arylalkyl piperidines are disclosed. These compds. have been evaluated for their ability to inhibit reuptake of dopamine (DA) into striatal nerve endings (synaptosomes). I and the most potent analog II were found to have significant functional antagonism. Pharmacophore-based discovery and synthesis of a series of 4-phenyl-1-arylalkylpiperidines are discussed. These compds. were evaluated for their ability to inhibit uptake of dopamine (DA) into striatal nerve endings (synaptosomes). Their structure-activity relation and functional antagonism studies are reported.

RX(2) OF 42



REF: Bioorganic & Medicinal Chemistry Letters, 11(4), 495-500; 2001

REFERENCE COUNT:

21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L46 ANSWER 7 OF 28	CASREACT COPYRIGHT 2002 ACS
ACCESSION NUMBER:	135:5510 CASREACT
TITLE:	Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1- piperidines as dual NK1/NK2 inhibitors
AUTHOR(S):	Ting, P. C.; Lee, J. F.; Anthes, J. C.; Shih, NY.; Piwinski, J. J.
CORPORATE SOURCE:	Schering-Plough Research Institute, Kenilworth, NJ, 07033-1300, USA
SOURCE:	Bioorganic & Medicinal Chemistry Letters (2001), 11(4), 491-494 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: DOCUMENT TYPE: LANGUAGE: GI Elsevier Science Ltd. Journal English

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4dichlorophenyl)-4(2)-(methoxyimino)pentyl-1-piperidines, e.g. I and II, were prepd. the their NK1 and NK2 receptor activity was evaluated. Compds. I and II were among 5 of the most potent inhibitors. A series of 4(2)-(methoxyimino)pentyl-1-piperidines was prepd., and their biol. activity as dual NK1/NK2 receptor antagonists detd.

RX(34) OF 119



REF: Bioorganic & Medicinal Chemistry Letters, 11(4), 491-494; 2001 NOTE: mol. sieves used


REFERENCE COUNT:	11	THERE ARE 11 CITED	REFERENCES AV	VAILABLE FOR THIS
		RECORD. ALL CITATI	ONS AVAILABLE	IN THE RE FORMAT


L46 ANSWER 8 OF 28 CASREACT COPYRIGHT 2002 ACS ACCESSION NUMBER: 134:193381 CASREACT N-Benzylpiperidine derivatives of 1,2,4-TITLE: thiadiazolidinone as new acetylcholinesterase inhibitors Martinez, Ana; Fernandez, Enrique; Castro, Ana; Conde, AUTHOR(S): Santiago; Rodriguez-Franco, Isabel; Banos, Josep-Eladi; Badia, Albert Instituto de Quimica Medica (C.S.I.C.), Madrid, 28006, CORPORATE SOURCE: Spain European Journal of Medicinal Chemistry (2000), SOURCE: 35(10), 913-922 CODEN: EJMCA5; ISSN: 0223-5234 Editions Scientifiques et Medicales Elsevier PUBLISHER: DOCUMENT TYPE: Journal English LANGUAGE: A new family of 1,2,4-thiadiazolidinones contg. the N-benzylpiperidine AB fragment was synthesized. The acetylcholinesterase (AChE) inhibitory activity of all compds. was measured using Ellman's method and some of them turned out to be as potent as tacrine. Furthermore,

4-ethyl-5-{imino[1-(phenylmethyl)-4-piperidinyl]ethyl}-2-methyl-1,2,4thiadiazolidin-3-one was as active as tacrine in reversing the blockade induced by tubocurarine at rat neuromuscular junction. Addnl., receptor binding studies provided new lead compds. for further development of .alpha.2-adrenergic and sigma-receptor antagonists. Mol. dynamic simulation using an x-ray crystal structure of AChE from Torpedo


Searched by Susan Hanley 305-4053

californica was used to explain the possible binding mode of these new compds.





A process for the prepn. of substituted piperidines I [A = arylene; R1 = AB alkyl, aryl, aralkyl, diarylalkyl, alkoxycarbonyl, halogenated alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, allyloxycarbonyl, alkylcarbonyl, halogenated alkylcarbonyl, etc.; alkoxy, cycloalkoxy, aryloxy, aralkoxy, aralkoxyalkoxy, hydroxy, lkylsulfonyloxy, arylsulfonyloxy, etc.] consisted of a reaction of II in the presence of an oxidant and a chiral osmium complex; the hydroxy groups attached to the carbon atoms 3 and 4 of the piperidine cycle I are in a cis position. E.g., 4-(4-methoxyphenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-Bu ester (prepn. given) was treated with potassium ferricyanide, (DHQ)2-PHAL, potassium osmate(VI) dihydrate, potassium carbonate, and potassium persulfate to give (S,S)-3,4-dihydroxy-4-(4methoxyphenyl)piperidine-1-carboxylic acid tert-Bu ester. E.g., 1-[2-[7-[(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidin-3yloxymethyl]naphthalen-2-yloxy]ethyl]-4-methylpiperazine was prepd. as a renin inhibitor.



CH₂- Ph 49%

OH

CH2-Ph

REF: PCT Int. Appl., 2000063173, 26 Oct 2000


REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Dig unon put to of po of	ASREACT COPYRIGHT 2002 ACS
ACCESSION NUMBER:	132:180484 CASREACT
TITLE:	Novel process and intermediates for production of
	donepezil and related compounds
INVENTOR(S):	Gutman, L. Arie; Shkolnik, Eleonora; Tishin, Boris;
	Nisnevich, Genady; Zaltzman, Igor
PATENT ASSIGNEE(S):	Finetech Ltd., Israel
SOURCE:	PCT Int. Appl., 51 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	


PATENT	NO.		KII	ND	DATE			A	PPLI	CATI	ом ис). 	DATE			
WO 2000	00948	3	A	2	2000	0224		W	0 19	99-II	L436		1999	0811		
W:	AE,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BΒ,	ΒG,	BR,	ΒY,	CA,	CH,	CN,	CR,	CU,
	CZ,	DE,	DK,	DM,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	ΗU,	ID,	IL,
													LT,			
													SE,			
	SL,	ΤJ,	ΤM,	ΤR,	ΤT,	UA,	UG,	US,	UŻ,	VN,	YU,	ZA,	ZW,	ΑM,	ΑΖ,	ΒY,
					тJ,											
RW:	GH,															
												SE,	BF,	ВJ,	CF,	CG,
	CI,															
AU 9951																
EP 1129																
R:	AT,	BE,	CH,	DE,	DK,	ΕS,	FR,	GB,	GR,	IΤ,	LI,	LU,	NL,	′SΕ,	MC,	ΡT,
					FI,											
JP 2002	252526	54	T	2	2002	0813							1999			
PRIORITY APP	PLN. I	INFO	.:					I	L 19	98-1	2580	9	1998	0817		
									0 19	99-I	L436		1999	0811		
OTHER SOURCE	C(S):			MAR	PAT	132:	1804	84								

GI

.




AB Donepezil-related compds. such as I (R1 = N-acyl-4-piperidyl, N-alkoxycarbonyl-4-piperidyl, 4-piperidyl, N-alkyl-4-piperidyl, N-benzyl-4-piperidyl, N-(.omega.-aralkyl)-4-piperidyl, 4-pyridyl; R4, R5, R6, R7 = H, alkyl, aryl, hydroxy, alkoxy, aryloxy, benzyloxy, acyloxy, alkylthio, arylthio, benzylthio, acylamino, phthalimido, halo; n = 1, 2, 3; m = 1, 2, 3, 4, 5) are prepd. as acetylcholinesterase inhibitors. I are prepd. by cyclization of compds. such as II (same R1, R4, R5, R6, R7, m, n; R2 = derivatized or nonderivatized carboxyl, cyano, N-substituted aminocarbonyl, H; R3 = derivatized or nonderivatized carboxyl, cyano, N-substituted aminocarbonyl), optionally in the presence of acids and/or solvents. One of the most potent acetylcholinesterase inhibitors of the class of compds. prepd. according to the present invention is donepezil (III).



REF: PCT Int. Appl., 2000009483, 24 Feb 2000

```
L46 ANSWER 11 OF 28 CASREACT COPYRIGHT 2002 ACS
                         130:223228 CASREACT
ACCESSION NUMBER:
TITLE:
                         Aminopyridazines as acetylcholinesterase
                         inhibitors
                         Contreras, Jean-Marie; Rival, Yveline M.; Chayer,
AUTHOR(S):
                         Said; Bourguignon, Jean-Jacques; Wermuth, Camille G.
                         Laboratoire de Chimie Organique, Faculte de Pharmacie,
CORPORATE SOURCE:
                         Universite Louis Pasteur, Illkirch, 67401, Fr.
                         Journal of Medicinal Chemistry (1999), 42(4), 730-741
SOURCE:
                         CODEN: JMCMAR; ISSN: 0022-2623
                         American Chemical Society
PUBLISHER:
DOCUMENT TYPE:
                         Journal
                         English
LANGUAGE:
GI
```

ъ1 NH



AB Following the discovery of the weak, competitive and reversible acetylcholinesterase (AChE)-inhibiting activity of minaprine I (R1 = Me, R2 = H, X = O) (IC50 = 85 .mu.M on homogenized rat striatum AChE), a series of 3-amino-6-phenylpyridazines I [R1 = H, Me, CH2OH, etc., R2 = H, 4-Cl, 3,4-(OCH2O), X = O, CH2] and II (R = morpholino, piperidino,

Ι

N(Me)CH2Ph, etc., n = 0-5) was synthesized and tested for inhibition of AChE. A classical structure-activity relationship exploration suggested that, in comparison to minaprine, the crit. elements for high AChE inhibition are as follows: (i) presence of a central pyridazine ring, (ii) necessity of a lipophilic cationic head, (iii) change from a 2- to a 4-5-carbon units distance between the pyridazine ring and the cationic head. Among all the derivs. investigated, 3-[2-(1-benzylpiperidin-4-yl)ethylamino]-6-phenylpyridazine, which shows an IC50 of 0.12 .mu.M on purified AChE (elec. eel), was found to be one of the most potent anti-AChE inhibitors, representing a 5000-fold increase in potency compared to minaprine.

RX(19) OF 47 CH2-Ph HN 1. NH4Cl, BuOH 2. K2CO3, Water 3. AcOEt (step 1) CH2-CH2-NH2 (step 1) CH2-Ph NH-CH2-- CH2 328 REF: Journal of Medicinal Chemistry, 42(4), 730-741; 1999 **REFERENCE COUNT:** 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L46 ANSWER 12 OF 28 CASREACT COPYRIGHT 2002 ACS ACCESSION NUMBER: 127:121641 CASREACT TITLE: Processes and intermediates for preparing 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2yl]methylpiperidine as acetylcholinesterase inhibitor Devries, Keith M. INVENTOR(S): Pfizer Inc., USA; Devries, Keith M. PATENT ASSIGNEE(S): PCT Int. Appl., 28 pp. SOURCE: CODEN: PIXXD2 Patent DOCUMENT TYPE: English LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: DAME ADDI TOATTON NO

PA'	LENL	NO.		KT	ND	DATE			A	55PT(CATIO	ON NO	0.	DATE			
									-								
WO	9722	584		A	1	1997	0626		W	D 19	96-I	B107	6	1996	1011		
	W:	AU,	BG,	BR,	·ΒΥ,	CA,	CN,	CZ,	нU,	IL,	IS,	JP,	KR,	KΖ,	LK,	LV,	MX,
		NO,	NZ,	PL,	RO,	RU,	SG,	SI,	SK,	UA,	US,	UZ,	VN				
	RW:	ΑT,	BE,	CH,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IΤ,	LU,	MC,	NL,	PΤ,
		SE,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GA,	GN,	ML,	MR,	NE,	SN,	ТD,	ΤG	
AU	9670	925		A	1	1997	0714		A	U 19	96-7	0925		1996	1011		
AU	7164	62		B	2	2000	0224										


Searched by Susan Hanley 305-4053


EP	883607	A	1 1998	1216	EP	1996-9	31937	19961011		
	R: AT,	BE, CH,	DE, DK,	ES, FR,	GB, C	GR, IT,	LI, LU,	NL, SE,	ΡT,	IE,
	SI,	LV, FI								
CN	1204319	P	1999	0106	CN	1996-1	99018	19961011		
BR	9612018	P	1999	0217	BR	1996-1	2018	19961011		
JP	3066083	E	2 2000	0717	JP	1997-5	22607	19961011		
JP	11500756	Г	2 1999	0119						
RÜ	2160731	C	2 2000	1220	RU	1998-1	11204	19961011		
TW	414787	E	2000	1211	ΤŴ	1996-8	5112515	19961014		
ZA	9610533	P	1998	0615	ZA	1996-1	0533	19961213		
NO	9802712	P	1998	0612	NO	1998-2	712	19980612		
PRIORITY	APPLN.	INFO.:			US	1995-8	753P	19951215		
					WO	1996-I	B1076	19961011		
				107 1010						


OTHER SOURCE(S):














The title compd I [R1 = PhCH2], useful in the treatment of, e.g., senile AB dementia of the Alzheimer's disease, was prepd. by reacting the piperidine II [R1 = R2OC(0), R3C(0) (wherein R2 = C1-4 alkyl; R3 = C1-4 alkyl, (un) substituted Ph)] with a methenylation agent followed by cyclization of the intermediate III [R1 = R2OC(O), R3C(O) (wherein R2 = C1-4 alkyl; R3 = C1-4 alkyl, (un)substituted Ph)] with a strong acid, treatment of the indanone I [R1 = R2OC(O), R3C(O) (wherein R2 = C1-4 alkyl; R3 = C1-4 alkyl, (un)substituted Ph)] with hydroxide, and reacting the indanone I [R1 = H] with a benzyl halide and a base. Compd. I showed IC50 of 0.0053 .mu.M against acetylcholinesterase.


Searched by Susan Hanley 305-4053








The invention relates to a process for prepg. title compd. I, a known AB cholinesterase inhibitor useful for enhancing memory in patients suffering from dementia or Alzheimer's disease (no data). The method involves heating an oxime deriv. II [R3 = R4 or CH2Ph; R4 = R5CO, R5OCO, R5SO2; R5 = C1-6 alkyl or C6-10/C1-6 arylalkyl] at an elevated temp. in the presence of a base. In the case where R3 = R4, the product is further hydrolyzed with an aq. mineral acid at an elevated temp., followed by benzylation, either with a benzylating agent in the presence of a base, or with benzaldehyde in the presence of a reducing agent and an acid. For instance, pyridine-4-carboxaldehyde was converted in 6 steps to the oxime II [R3 = CO2Me, R4 = H]. Treatment of this with Ac2O and AcONa in THF at room temp. gave 92% II [R3 = CO2Me, R4 = Ac]. The latter was cyclized by 2,6-lutidine in THF at 65.degree. (72%), followed by hydrolysis of the ester with 6N HCl at 100.degree. (78%), and N-benzylation with either PhCH2Br and N(CH2CH2OH)3 (74%), or PhCHO, NaBH(OAc)3, and AcOH, to give I.






AB Chromans I [A = H, OH, C1-8 alkoxy; R1 = R2 = H, or R1R2 = O; D =

Ι


NR3CONR4R5; R3, R4 = H, C1-6 alkyl, or R3R4 = o-phenylene; R5 = (substituted) C6-10 aryl] are HIV protease inhibitors and are useful in treatment of HIV infections. Thus, 4-amino-1-benzylpiperidine was condensed with Ph isocyanate, and the product was debenzylated with HCO2NH4 over Pd/C at 50.degree. and condensed with 8- methoxychromancarboxylic acid to form I (A = OMe, R1R2 = O, D = NHCONHPh) (II). II inhibited HIV protease by 99% at 200 .mu.g/mL.

RX(3) OF 10




REF: Eur. Pat. Appl., 628310, 14 Dec 1994

L46 ANSWER 15 OF 28	CASREACT COPYRIGHT 2002 ACS
ACCESSION NUMBER:	121:9124 CASREACT
TITLE:	Synthesis and x-ray structure of a potent
	superpositional analog of the enantiomeric forms of
	fluoxetine
AUTHOR(S):	Corey, E. J.; Reichard, Gregory A.; Sarshar, Sepehr
CORPORATE SOURCE:	Dep. Chem., Harvard Univ., Cambridge, MA, 02138, USA
SOURCE:	Bioorganic & Medicinal Chemistry Letters (1993),
	3(12), 2635-6
	CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE:	Journal
LANGUAGE:	English
GI	




AB 4-Phenyl-4-(p-trifluoromethylphenoxy)piperidine (I), a mol. which approximates a superimposition of the enantiomers of fluoxetine (II), has been synthesized and is somewhat more active than II as an inhibitor of serotonin uptake. I was prepd. in 3 steps from N-benzyl-4-piperidinone. X-ray anal. of I shows a strong resemblance to the 3-D structure of sertraline, a potent serotonin uptake inhibitor. RX(1) OF 6




REF: Bioorganic & Medicinal Chemistry Letters, 3(12), 2635-6; 1993

L46 ANSWER 16 OF 28 CF ACCESSION NUMBER: TITLE:	11 Pr in hy	danon-2-yl)meth		asymmetric
INVENTOR(S):	Su		ajima, Takashi; A ; Kiyofuji, Nobuo	
PATENT ASSIGNEE(S): SOURCE:	Jp	sai Co., Ltd., o n. Kokai Tokkyo DEN: JKXXAF		erfumery Co., Ltd.
DOCUMENT TYPE:	Pa	tent		
LANGUAGE:	Ja	panese		
FAMILY ACC. NUM. COUNT:	1			
PATENT INFORMATION:				
PATENT NO. KI	ND	DATE	APPLICATION NO.	DATE
JP 04187674 F	42 32	19920706 19991018	JP 1990-320055	19901121

GI



AB The title compd. (I), a known acetylcholine esterase inhibitor useful for the treatment of Alzheimer-type senile dementia, is prepd. by asym. hydrogenation of (piperidylmethylene)indanone deriv. II in the presence of an optically active Ru-phosphine complex, preferably III [A = RuX4, B = NEt3; A = RuHX, B = null; A = null, B = RuAlZ; X = halo; Y = H, NH2, AcNH, SO3H; R1 = H, linear or branched lower alkyl; Al, Z = ClO4, PF6, BF4, R2CO2; R2 = alkyl, haloalkyl, (lower alkyl)phenyl, .alpha.-aminoalkyl, .alpha.-aminophenylalkyl]. Thus, a soln. of 2.0 g II and 42.3 mg RuCl4.[(S)-(-)-2,2'-bis(diphenylphosphino)-1,1'binaphthyl]2.NEt3 complex in 30 mL CH2Cl2 was stirred at H 77 kg/cm2 and 50.degree. for 30 min and then at room temp. for 140 h, evapd. in vacuo, treated with 180 mL 0.1 N HCl (pH 2.0), extd. twice with EtOAc to remove the catalyst, adjusted to pH 9 with aq. NaHCO3, and extd. with CH2Cl2 to give 85.4% (-)-I of 97.3% ee.



REF: Jpn. Kokai Tokkyo Koho, 04187674, 06 Jul 1992, Heisei NOTE: stereoselective, 50.degree. for 30 min, and room temp. for 140 h

L46 ANSWER 17 OF 28 ACCESSION NUMBER: TITLE:	CASREACT COPYRIGHT 2002 ACS 118:80924 CASREACT Heterocyclic-cyclic amine derivatives, [(1-benzyl-4-piperidinyl)alkyl]benzisoxazoles and heteroaryl analogs, a method for their preparation and their use as cholinesterase inhibitors
INVENTOR(S):	Villalobos, Anabella; Nagel, Arthur Adam; Chen, Yuhpyng Liang
PATENT ASSIGNEE(S):	Pfizer Inc., USA
SOURCE:	PCT Int. Appl., 120 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT	: 3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE		APPLICATION NO.	DATE
WO 9217475 W: AU, BR,	A1 CA, CS	19921015 , DE, FI,	HU,	WO 1992-US1605 JP, KR, NO, PL, RU, GB, GR, IT, LU, MC,	19920309 , US
KW: AI, DE,		19920929	£Γ,	CA 1992-2107105	19920309
ALL 9219782	AA 31	19921102		AU 1992-18782	19920309
AU 658194				A0 1992 10/02	19920309
TP 06500794	<u>ሆ</u> ረ	19940127		JP 1992-510182	19920309
BR 9205811	Δ	19940628		JP 1992-510182 BR 1992-5811	19920309
EP 646115	A1	19950405		EP 1992-921695	19920309
R: AT. BE.	CH. DE	DK. ES.	FR,	GB, GR, IT, LI, LU,	NL, SE
		19950628	·	HU 1993-2733	19920309
HU 68357 PL 170567	B1	19970131		PL 1992-300711	19920309
PL 171915	B1	19970630		PL 1992-313811	19920309
PL 171914		19970630		PL 1992-313812	19920309
RU 2119920		19981010		RU 1993-55137	19920309
JP 2000154185	A2	20000606		JP 1999-368302	19920309
CZ 289756		20020417		CZ 1992-3958	19920309
IL 101327	A1	19980615		IL 1992-101327	19920322
IL 116122	A1	19981030			
IL 116122 CN 1065267	А	19921014		CN 1992-102178	19920327
CN 1044242	В	19990721			
ZA 9202239	А	19930927		ZA 1992-2239	19920327
NO 9303445	А	19930927		NO 1993-3445	19930927
AU 9521788	A1	19950907		AU 1995-21788	19950620
AU 674477		19961219			
JP 10158264		19980616		JP 1997-52097	19970306
JP 3051076		20000612			
	B1	20011204		US 2000-615690	20000714
US 2002028834		20020307		US 2001-955818	20010919
ORITY APPLN. INFO	.:			US 1991-676918	19910328
				US 1991-676918P	19910328
				JP 1992-510182	19920309
				JP 1997-52097	19920309

OTHER SOURCE(S):

.

.

MARPAT 118:80924

Searched by Susan Hanley 305-4053

WO 1992-US1605

IL 1992-101327

US 1993-127847

US 1997-855028

US 2000-615690


19920309

19920322

19930928


19970513

20000714




AB Heterocyclic amine derivs., such as [(1-benzyl-4piperidinyl)alkyl]benzisoxazoles, -isoquinolines, -benzisothiazoles, -quinazolines and analogs and derivs. thereof are claimed. These compds. are useful as memory enhancers and for the treatment or prevention of Alzheimer's disease; these compds. are cholinesterase inhibitors (no data). Thus 3-[2-[(1-benzyl)-4-piperidinyl]ethyl]-1,2-benzisoxazole (I) was prepd. from Et isonipecotate and 3-methyl-1,2-benzisoxazole in a multistep synthesis. The biol. activity of I was not tested.

RX(1) OF 36








REF: PCT Int. Appl., 9217475, 15 Oct 1992

L46 ANSWER 18 OF 28 ACCESSION NUMBER:	CASREACT COPYRIGHT 2002 ACS 115:8793 CASREACT
TITLE:	Preparation of antiallergic 2-(4-
	piperidylamino)benzimidazoles
INVENTOR(S):	Vejdelek, Zdenek; Kmonicek, Vojtech; Krepelka, Jiri
PATENT ASSIGNEE(S):	Czech.
SOURCE:	Czech., 7 pp.


Searched by Susan Hanley 305-4053


DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUN PATENT INFORMATION:	CODEN: CZXXA9 Patent Czech T: 1		
PATENT NO.	KIND DATE	APPLICATION NO.	DATE
CS 268485 OTHER SOURCE(S): GI	B1 19900314 MARPAT 115:8793	CS 1988-7626	19881121



AB The title compds. (I; R1 = H, 4-FC6H4CH2; R2 = PhCH2, 4-MeOC6H4CH2CH2, 4-MeOC6H4CH2CO) and their hydrochloride salts, specifically the antiallergic (no data) astemizole and 3 of its analogs, were prepd. by amination of 2-(methylsulfonyl)benzimidazoles with 4-amino-(1substituted)piperidines at 100-170.degree., followed by neutralization with alc. HCl. Thus, a mixt. of 3.0 g 1-(4-fluorobenzyl)-2methylsulfonylbenzimidazole (prepd. in 5 steps from 2-nitroaniline and 4-fluorobenzyl bromide) and 3.5 g 4-amino-1-(4-methoxyphenethyl)piperidine (prepd. in 5 steps from 4-MeOC6H4CH2CH2OSO2Me and 1,4-dioxa-8azaspiro[4.5]decane) in 25 mL DMF was heated 6 h at 160-170.degree. to give title compd. I (R1 = 4-FC6H4CH2, R2 = 4-MeOC6H4CH2CH2) (astemizole).

RX(7) OF 13





NH₂


Na2CO3

REF: Czech., 268485, 31 Aug 1990


L46 ANSWER 19 OF 28	CASREACT COPYRIGHT 2002 ACS
ACCESSION NUMBER:	113:23641 CASREACT
TITLE:	Novel piperidine derivatives. Synthesis and
•	anti-acetylcholinesterase activity of
	1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine
	derivatives
AUTHOR(S):	Sugimoto, Hachiro; Tsuchiya, Yutaka; Sugumi, Hiroyuki;
	Higurashi, Kunizo; Karibe, Norio; Iimura, Yoichi;

Searched by Susan Hanley 305-4053

Sasaki, Atsushi; Kawakami, Yoshiyuki; Nakamura, Takaharu; et al. CORPORATE SOURCE: Tsukuba Res. Lab., Eisai Co., Ltd., Tsukuba, 300-26, Japan SOURCE: Journal of Medicinal Chemistry (1990), 33(7), 1880-7 CODEN: JMCMAR; ISSN: 0022-2623 DOCUMENT TYPE: Journal LANGUAGE: English GI



AB The title compd. I (R = H, 2-Me, 4-NO2, 4-MeO, 4-CHO, 4-Cl, 4-PhCH2SO2; R1 = Bz, CH2Ph, CH2CH:CHPh, CH2CH2Ph, CH2C6H4Me-4, CH2C6H4NO2-2; R2 = H, Me, Et, Ph) were prepd. and evaluated for antiacetylcholinesterase activity. Substituting the benzamide group with a bulky moiety in the para position led to a substantial increase in activity. Introduction of an alkyl or Ph group at the benzamide nitrogen atom dramatically enhanced the activity. The basicity of the piperidine nitrogen atom appears to play an important role in the increased activity, since the N-benzoylpiperidine deriv. was almost inactive. I (R = 4-PhCH2SO2, R1 = CH2Ph, R2 = Me, R)(II) were the most potent inhibitors of acetylcholinesterase and produced significant increases in acetylcholine content in the cerebral cortex and hippocampus of rats. II was chosen for development as an antidementia agent.




REF: Journal of Medicinal Chemistry, 33(7), 1880-7; 1990


L46 ANSWER 20 OF 28	CASREACT COPYRIGHT 2002 ACS
ACCESSION NUMBER:	112:35803 CASREACT
TITLE:	Studies on the synthesis of antiulcer agents. V.
	Synthesis and antiulcer activity of
	dihydrobenzofuranone derivatives
AUTHOR(S):	Kitazawa, Makio; Akahane, Masuo; Nakano, Yasushi;
	Hayakawa, Kazuhide; Sato, Kazuaki; Kobayashi,
	Michihiro
CORPORATE SOURCE:	Res. Lab., Kissei Pharm. Co., Ltd., Matsumoto, 399,

	Japan
SOURCE:	Yakugaku Zasshi (1989), 109(4), 241-9
	CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE:	Journal
LANGUAGE:	Japanese
GI	

CONH₂ O Ι

AB Dihydrobenzofuranonepropionic acid derivs. and oxyacetic acid derivs. were prepd. and tested for antiulcer activities. [3-Oxospiro[benzofuran-2(3H)-1'-cyclopropan]-5-yloxy]acetamide (I) exhibited significant antiulcer activities. Structure-activity relationship was discussed.







93%

REF: Yakugaku Zasshi, 109(4), 241-9; 1989

L46 ANSWER 21 OF 28	CASREACT COPYRIGHT 2002 ACS
ACCESSION NUMBER:	111:232532 CASREACT
TITLE:	Synthesis of 1-benzyl-4-[(5,6-dimethoxy[2-14C]-1-
	indanon)-2-yl]methylpiperidine hydrochloride
	(E2020-14C)
AUTHOR(S):	Iimura, Youichi; Mishima, Mannen; Sugimoto, Hachiro
CORPORATE SOURCE:	Tsukuba Res. Lab., Eisai Co., Ltd., Tsukuba, 300-26,
	Japan
SOURCE:	Journal of Labelled Compounds and Radiopharmaceuticals
	(1989), 27(7), 835-9
	CODEN: JLCRD4; ISSN: 0362-4803
DOCUMENT TYPE:	Journal
LANGUAGE:	English




AB The title compd. (I) (E2020-14C), an acetylcholinesterase inhibitor for studying the pharmacokinetic profiles of E2020, was synthesized from 5,6-dimethoxy[2-14C]-1-indanone (II) as the labeled starting material.



1. Pd, H2, THF 2. HC1, CH2C12, AcOEt

RX(1) OF 15



HC1

REF: Journal of Labelled Compounds and Radiopharmaceuticals, 27(7), 835-9; 1989


L46 ANSWER 22 OF 28	CASREACT COPYRIGHT 2002 ACS
ACCESSION NUMBER:	109:37821 CASREACT
TITLE:	Preparation of 4-[(bicyclic
	heterocyclyl)methyl]piperidines and analogs as antihistaminics
INVENTOR(S):	Janssens, Frans E.; Kennis, Ludo E. J.; Hens, Jozef F.; Torremans, Joseph L. G.; Diels, Gaston S. M.

Searched by Susan Hanley 305-4053

PATENT NO. KIND DATE APPLICATION NO. DATE	PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUN PATENT INFORMATION:	. Ser. No. 571,135,			
	PATENT NO.	KIND		APPLICATION NO.	DATE
US 4695575 A 19870922 US 1985-747754 19850624				US 1985-747754	19850624
ES 539281 A1 19870616 ES 1984-539281 19841231	US 4090070	ה ב	19870616	FS 1984 - 539281	19841231
ES 539281 A1 19870616 ES 1984-539281 19841231 AU 8537364 A1 19850912 AU 1985-37364 19850107	ES JJ9201	אב או	19850912	AU 1985-37364	19850107
AU 573673 B2 19880616	AU 0007004	B2	19880616	NO 1903 37304	19030107
CA 1259609 A1 19890919 CA 1985-471589 19850107	CD 1259609	۵2 ۵1	19890919	CA 1985-471589	19850107
FI 8500079 A 19850710 FI 1985-79 19850108	ET 9500079	Δ	19850710		
FI 83867 B 19910531	FT 93967	R	19910531	11 1903 /9	19000100
FI 83867 C 19910910	FT 03007	C	19910910		
FI 8500079 A 19850710 FI 1985-79 19850108 FI 83867 B 19910531 FI 19850700 19850108 FI 83867 C 19910910 NO 19850108 NO 8500085 A 19850710 NO 1985-85 19850108	NO 8500085	Δ	19850710	NO 1985-85	19850108
NO 160849 B 19890227	NO 160849	B	19890227	NO 1900 00	10000100
NO 160849 C 19890607		Ċ			
DK 8500089 A 19850710 DK 1985-89 19850108		Δ	19850710	DK 1985-89	19850108
JP 60185777 A2 19850921 JP 1985-479 19850108	TP 60185777	A2	19850921		
JP 07068240 B4 19950726	JP 07068240	R4	19950726	01 1900 179	10000100
HU 36471 A2 19850930 HU 1985-61 19850108	HI 36471	D7 D7		HU 1985-61	19850108
HU 200338 B 19900528					
ZA 8500187 A 19860827 ZA 1985-187 19850108				ZA 1985-187	19850108
RO 90622 B3 19861210 RO 1985-117252 19850108	BO 90622	B3			
SU 1396964 A3 19880515 SU 1985-3836858 19850108	SU 1396964	A3			
IL 74018 A1 19880831 IL 1985-74018 19850108	TI. 74018	A1	19880831		
PL 145710 B1 19881031 PL 1985-251488 19850109			19881031	PL 1985-251488	
US 4839374 A 19890613 US 1987-94987 19870910					
PRIORITY APPLN. INFO.: US 1984-569369 19840109					

GI

. .



The title compds. [I; 3 of A1-A4 = (un)substituted CH, the 4th = N, (un)substituted CH; B = CH2, O, SO, SO2; R = substituted C1-6 alkyl, AB

Searched by Susan Hanley 305-4053

US 1984-671135


US 1985-747754


19841113

19850624

alkoxy, alkylthio, amino, pyrrolidinyl, piperidinyl, hexahydroazepinyl, etc.; R1 = H, alkyl, cycloalkyl, (un)substituted aryl, heteroaryl, (hetero)aralkyl; R2 = H, alkyl] and their stereoisomers and acid salts were prepd. as antihistaminics and serotonin antagonists. 1-[(4-Fluorophenyl)methyl]-2-(4-piperidinylmethyl)-1H-benzimidazol-5-ol and PhSCH2CH2Br were refluxed 2 h in Me2CHCH2COMe contg. Na2CO3 to give 27.8% benzimidazole deriv. (II). I inhibited compd. 48/80-induced lethality in rats, caused by histamine release, with ED50 of 0.005-0.16 mg/kg s.c. or orally. I also inhibited gastric lesions caused by simultaneous release of serotonin.


RX(5) OF 105






AB The piperidinomethanamines I (m = 0, 1, 2, 5; n = 1-6; R = H, p-ClC6H4,

2-naphthyl; R1 = H, Me; R2 = H, MeO, C1; R3, R4 = H, MeO) (21 compds.) were prepd. as platelet aggregation inhibitors. Thus, 1-(4-cyano-4-phenylpiperidino)-2-(4-chlorophenyl)-1-ethanone, prepd. from 4-phenyl-4-cyanopiperidine and p-ClC6H4CH2COC1, was reduced with LiAlH4 to give I (m = 0, n = 2, R = R1 = R3 = R4 = H, R2 = Cl) (II). The most potent compd. II had an platelet aggregation inhibiting IC50 of 5.5 .times. 10-6 mol/L.




Ph, or styryl], C(:NH)NH2, CH:Z (Z = O, S), SO2R2 (R2 = alkyl), Q (dashed line = residue of a heterocyclic ring); R3 = H, halo, CF3, alkoxy], useful as inhibitors of Ca-induced contraction of tracheal smooth muscle or vascular tissue, were prepd. A mixt. of I (.DELTA.10 present, R = R3 = H), 4-Me2NC6H4CHO, NaB(CN)H3, and EtOH was stirred 24 h at room temp. to give I (R = 4-Me2NC6H4CH2) which, at 10-7 M, showed 69% inhibition of Ca-induced contraction described above. The most effective compds. for this inhibition were those in which the C of the R group attached to the piperidine N at the point of attachment is in the reduced form, e.g., CH2R7 (R7 = remainder of substituent). The most active compds. are those where the C of R7 attached to the reduced C was part of an unsatd. grouping.

RX(1) OF 5



<u>4-(Me2N)C6H4CHO</u>, NaBH3CN




REF: Eur. Pat. Appl., 157399, 09 Oct 1985

L46 ANSWER 25 OF 28	CASREACT COPYRIGHT 2002 ACS
ACCESSION NUMBER:	104:5787 CASREACT
TITLE:	3-Indolecarboxamide compounds
INVENTOR(S):	Tahara, Tetsuya; Ikebe, Tsuguo; Maruyama, Yutaka;
	Yaoka, Osamu; Miura, Yohji
PATENT ASSIGNEE(S):	Yoshitomi Pharmaceutical Industries, Ltd. , Japan
SOURCE:	Eur. Pat. Appl., 24 pp.
	CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT	: 1
PATENT INFORMATION:	

PAT	CENT NO.	KIND	DATE	APPLICATION NO.	DATE
ΕP	150505	A2	19850807	EP 1984-116372	19841227
ΕP	150505	A3	19850821		
ΕP	150505	в1	19870401	,	
	R: AT, BE,	CH, DE	, FR, GB,	IT, LI, NL, SE	
JP	60142981	A2	19850729	JP 1983-251149	19831228
JP	64000396	B4	19890106		
US	4581355	А	19860408	US 1984-680727	19841212


CA 1230600 ES 539123	A1 A1	19871222 19860316	CA 1984-470179 ES 1984-539123	19841214 19841227
AT 26273	E	19870415	AT 1984-116372	19841227
PRIORITY APPLN. INFO.:			JP 1983-251149	19831228
			EP 1984-116372	19841227

GI



AB N-Heterocyclylindolecarboxamides I (R1,R4,R6 = H, alkyl; R2,R3 = H, alkyl, alkoxy, alkanoyloxy, OH, halo; R5 = H, halo, Z = O, S, bond; n = 1,2; m, k = 1-3) were prepd. Thus, 5-acetoxy-2-methylindole-3-carboxylic acid was converted to its acid chloride and treated with 4-amino-1- phenethylpiperidine to give carboxamide II (R7 = Ac). This was sapond. to give II (R7 = OH) (III). III inhibits 5-lipoxygenase with an IC50 of 0.44 .mu.M and I are more effective cardiotonics than ouabain.


RX(1) OF 1 $CH_2 - CH_2 - Ph$ N H H H H CO_2H CO_2H




REF: Eur. Pat. Appl., 150505, 07 Aug 1985

L46 ANSWER 26 OF 28 CASREACT COPYRIGHT 2002 ACS ACCESSION NUMBER: 103:178235 CASREACT


TITLE:	Synthesis and pharmacological evaluation of piperidine derivatives with various heterocyclic rings at the
AUTHOR(S):	4-position Takai, Haruki; Obase, Hiroyuki; Nakamizo, Nobuhiro; Teranishi, Masayuki; Kubo, Kazuhiro; Shuto, Katsuichi; Hashimoto, Tamotsu
CORPORATE SOURCE:	Tokyo Res. Lab., Kyowa Hakko Kogyo Co., Ltd., Tokyo, 194, Japan
SOURCE :	Chemical & Pharmaceutical Bulletin (1985), 33(3), 1104-15 CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: LANGUAGE: GI	Journal English



AB A series of piperidine derivs. with various heterocyclic rings at the 4-position, e.g. I, II, was prepd. and tested for antihypertensive activity and other biol. activities. The antihypertensive effects of the present compds. in the spontaneous hypertensive rat were less potent than those of previously reported compds. However, some exhibited antiulcer and/or antiinflammatory activity. Structure-activity relationships are discussed.



(NH2)2SO2, Pyridine



REF: Chemical & Pharmaceutical Bulletin, 33(3), 1104-15; 1985


L46 ANSWER 27 OF 28	CASRE	ACT COPYRIGHT	2002 ACS			
ACCESSION NUMBER:	103	3:123369 CASRE	ACT			
TITLE:	Ise	ochroman deriva	tives			
PATENT ASSIGNEE(S):	Eat	rth Chemical Co	., Ltd., Japan			
SOURCE:	Jpi	n. Kokai Tokkyo	Koho, 10 pp.			
	COL	DEN: JKXXAF				
DOCUMENT TYPE:	Pat	tent				
LANGUAGE:	Jaj	panese				
FAMILY ACC. NUM. COUNT: 1						
PATENT INFORMATION:						
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
JP 60097975	A2	19850531	JP 1983-206260	19831101		
JP 06057696	В4	19940803				

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I (R = H, halo, alkyl; X = NR1, CR1R2; R1, R2 = H, alkyl, alkenyl, Ph, aralkyl, cyclohexyl) and their salts, useful as antiallergic agents, were prepd. Thus, stirring 17.6 g II and 14 g III in the presence of 3.6 g 50% NaH gave 26 g IV (R3 = CO2Me), which (25 g) was reduced to give 20 g IV (R3 = CH2OH), which (10 g) was cyclized in the presence of p-MeC6H4SO3H to give 5 g V. Redn. of 1.5 g V over 5% Pd/C gave 1.2 g VI, which inhibited induced histamine release from rat peritoneal mast cells at 50% in vitro.


RX(1) OF 1



REF: Jpn. Kokai Tokkyo Koho, 60097975, 31 May 1985, Showa

L46 ANSWER 28 OF 28 ACCESSION NUMBER: TITLE:	CASREACT COPYRIGHT 2002 ACS 102:95509 CASREACT Syntheses and biological activities of 1,4-disubstituted piperidines
AUTHOR(S):	Gupta, Krishna A.; Saxena, Anil K.; Jain, Padam C.; Anand, Nitya
CORPORATE SOURCE:	Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, 226001, India
SOURCE:	Archiv der Pharmazie (Weinheim, Germany) (1984), 317(12), 1010–17 CODEN: ARPMAS; ISSN: 0365–6233
DOCUMENT TYPE: LANGUAGE:	Journal English

GI




OMe

III

AB Isoquinolines I (R = CH2Ph, Me) were prepd. from piperidones II in 5 steps via cyclization of acylphenethylamines III, then acylated with R2COCl (R2 = Me, Ph) to give IV. The amebicidal, antileishmanial, and antileukemia activities of the compds. prepd. were described. None of the compds. tested were active against leukemia.

RX(7) OF 24



REF: Archiv der Pharmazie (Weinheim, Germany), 317(12), 1010-17; 1984

PATEL 10/069,215

=> d ibib abs hitstr


٦

Miuts

L47 ANSWER 1 OF 1 HCAP ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:	US COPYRIGHT 2002 ACS 2001:152644 HCAPLUS 134:207822 Preparation of substituted piperidines as modulators
INVENTOR(S):	of chemokine receptor activity Thom, Stephen; Baxter, Andrew;
INVENIOR(3):	Kindon, Nicholas; McInally, Thomas;
	Springthorpe, Brian; Perry, Matthew; Harden,
PATENT ASSIGNEE(S):	David; Evans, Richard; Marriott, David Astrazeneca UK Limited, UK
SOURCE:	PCT Int. Appl., 133 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT: PATENT INFORMATION:	1
FAILINI INFORMATION.	
PATENT NO. KI	ND DATE APPLICATION NO. DATE

			11110 01110														
WO	WO 2001014333				A1 20010301			WO 2000-GB3179					9	20000818			
	W:	AE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	ΒA,	ΒB,	BG,	BR,	ΒY,	CA,	CH,	CN,	CR,
		CU,	CΖ,	DE,	DK,	DM,	DZ,	ΕE,	ΕS,	FI,	GB,	GD,	GΕ,	GH,	GM,	HR,	ΗU,
		ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	ΚP,	KR,	KΖ,	LC,	LΚ,	LR,	LS,	LT,	LU,
		LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	NO,	ΝZ,	ΡL,	ΡТ,	RO,	RU,	SD,	SE,
		SG,	SI,	SK,	SL,	ТJ,	ΤM,	ΤR,	ΤT,	ΤΖ,	UA,	UG,	US,	UΖ,	VN,	YU,	ZA,
		ZW,	AM,	AZ,	ΒY,	KG,	ΚΖ,	MD,	RU,	ΤJ,	TM						
	RW:						•	-	-					ΑT,			
		DE,	DK,	ΕS,	FI,	FR,	GB,	GR,	ΙĖ,	IT,	LU,	MC,	NL,	PΤ,	SE,	BF,	ΒJ,
		CF,	CG,	CI,	CM,	GA,	GN,	GW,	ML,	MR,	NE,	SN,	ΤD,	TG			
EP 1212299					EP 2000-951768												
	R:	ΑT,	ΒE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IΤ,	LI,	LU,	NL,	SE,	MC,	ΡT,
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL							
CORITY APPLN. INFO.		. :				SE 1999-2987			А	1999	0824						
								1	WO 2	000-0	GB31	79	W	2000	0818		
HER SC	DURCE	(S):			MAR	PAT	134:	2078	22								
HER SO	DURCE	(S):			MAR	PAT	134:			000-0	GB31	79	W	2000	0818		

GI



· · · · · · ·


The title compds. [I; Z = CR4R5, CO, CR4R5Z1; Z1 = alkylene, alkenylene, AB CONH; R1 = (un)substituted alkyl, alkenyl, 3-14 membered (un)satd. ring system which optionally further comprises up to two ring carbon atoms that form carbonyl groups and which optionally further comprises up to 4 ring heteroatoms selected from N, O, and S; m = 0-1; Q = 0, S, CO, etc.; n = 00-6 (when n = 0, then m = 0); R2, R3 = H, alkyl; (CR2R3) n = cycloalkyloptionally substituted by alkyl; T = NR10, CONR10, NR11CONR10, etc.; X1-X4 = CH2, CHR12 (wherein R12 = alkyl, cycloalkyl(alkyl), CO, etc.); R4, R5 = H, alkyl; R6 = (un)substituted aryl, heterocyclyl; R10-R11 = H, alkyl, haloalkyl, etc.] and their pharmaceutically acceptable salts, useful in therapy, esp. for the treatment of chemokine receptor related diseases (such as inflammatory disease) and conditions, were prepd. E.g., a 3-step synthesis of the piperidine II was given. The exemplified compds. I were found to be antagonists of the eotaxin mediated [Ca2+]i in human eosinophils and/or antagonists of the MIP-1.alpha. mediated [Ca2+]i in human monocytes (no data). Certain compds. I were found to be antagonists of the eotaxin mediated human eosinophil chemotaxis (no data).

```
IT
    328082-04-8P 328082-05-9P 328082-10-6P
     328082-34-4P 328082-35-5P 328082-37-7P
     328082-48-0P 328082-52-6P 328082-53-7P
     328082-65-1P 328082-66-2P 328082-71-9P
     328082-72-0P 328082-73-1P 328082-74-2P
     328082-81-1P 328082-83-3P 328082-86-6P
     328082-87-7P 328082-88-8P 328082-94-6P
     328082-95-7P 328082-96-8P 328082-98-0P
     328083-00-7P 328083-02-9P 328083-04-1P
     328083-07-4P 328083-09-6P 328083-21-2P
     328083-32-5P 328083-39-2P 328083-41-6P
     328083-44-9P 328083-49-4P 328083-50-7P
     328083-57-4P 328083-59-6P 328083-68-7P
     328083-70-1P 328083-75-6P 328083-76-7P
     328083-77-8P 328084-34-0P 328084-35-1P
     328248-70-0P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (prepn. of substituted piperidines as modulators of chemokine receptor
        activity)
```


.

```
RN 328082-04-8 HCAPLUS
```

CN 4-Piperidinamine, 1-[(3,4-dichlorophenyl)methyl]-N-[[1-[(4methylphenyl)methyl]-1H-pyrazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 328082-05-9 HCAPLUS
CN 4-Piperidinamine, 1-[(3,4-dichlorophenyl)methyl]-N-[(2-phenyl-1H-imidazol4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 328082-10-6 HCAPLUS

CN 3H-Pyrazol-3-one, 4-[[[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]amino]methyl]-1,2-dihydro-1,5-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)

٠




PAGE 1-A


PAGE 2-A



RN 328082-34-4 HCAPLUS CN 1,2,4-Oxadiazole-5-butanamide, N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




- RN 328082-35-5 HCAPLUS
- CN Propanamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2-[[5-[1,2dihydro-2-oxo-1-(phenylmethyl)-3-pyridinyl]-4-methyl-4H-1,2,4-triazol-3yl]thio]- (9CI) (CA INDEX NAME)




RN 328082-37-7 HCAPLUS

• • • •

CN 4-Quinolinecarboxamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)




- RN 328082-48-0 HCAPLUS
- CN 1,2-Benzenedicarboxamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-N'-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 328082-52-6 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[5-[[[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]amino]carbonyl]-2-methoxyphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 328082-53-7 HCAPLUS


..

CN 3-Pyrrolidinecarboxamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-5-oxo-1-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A







CN 4,6-Pyrimidinediamine, 2-chloro-N-cyclopropyl-N'-[2-[[1-[(3,4dichlorophenyl)methyl]-4-piperidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 328082-66-2 HCAPLUS
CN 1,2-Ethanediamine, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-N'-(4phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 328082-71-9 HCAPLUS CN 2,4-Pyrimidinediamine, N4-cyclopropyl-N2-[2-[[1-[(3,4dichlorophenyl)methyl]-4-piperidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 328082-72-0 HCAPLUS


.

. .


CN 1,2-Ethanediamine, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-N'-[4-(3-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 328082-73-1 HCAPLUS CN 1,2-Ethanediamine, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-N'-[4-(3-thienyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 328082-74-2 HCAPLUS CN 1,2-Ethanediamine, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-N'-[4-(2-thienyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 328082-81-1 HCAPLUS

.

. .


CN 1H-Pyrazole-4-acetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-5-methyl-1-phenyl- (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 2-A

RN 328082-83-3 HCAPLUS
CN 4-Thiazoleacetamide, 2-(4-chlorophenyl)-N-[1-[(3,4-dichlorophenyl)methyl]4-piperidinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 328082-86-6 HCAPLUS

CN 4-Thiazoleacetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2pyrazinyl- (9CI) (CA INDEX NAME)




RN 328082-87-7 HCAPLUS CN Acetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2-[(5-phenyl-2pyrimidinyl)thio]- (9CI) (CA INDEX NAME)




RN 328082-88-8 HCAPLUS CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Searched by Susan Hanley 305-4053

Page 9



RN 328082-94-6 HCAPLUS CN 1,2,4-Oxadiazole-5-propanamide, 3-(4-bromo-1-methyl-1H-pyrazol-3-yl)-N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 328082-95-7 HCAPLUS


, .

.

CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]-3-pyrazinyl- (9CI) (CA INDEX NAME)




- RN 328082-96-8 HCAPLUS
- CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]-3-[(2-thienylsulfonyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



```
RN 328082-98-0 HCAPLUS
```


• • • •

CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




- RN 328083-00-7 HCAPLUS
- CN Cyclopropanecarboxamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



- RN 328083-02-9 HCAPLUS
- CN 1H-1,2,4-Triazole-3-propanamide, N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




- RN 328083-04-1 HCAPLUS
- CN 1H-1,2,4-Triazole-3-acetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]-5-phenyl- (9CI) (CA INDEX NAME)


Searched by Susan Hanley 305-4053

`.

. .


.





- RN 328083-32-5 HCAPLUS
- CN 1,2,4-Oxadiazole-5-propanamide, N-[(3-endo)-8-[(3,4-dichlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]-3-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



• HCl


- RN 328083-39-2 HCAPLUS
- CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(1R)-1-(4-bromophenyl)ethyl]-4piperidinyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




. RN 328083-41-6 HCAPLUS CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(1S)-1-(4-bromophenyl)ethyl]-4piperidinyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 328083-44-9 HCAPLUS CN Acetamide, 2-([1,1'-biphenyl]-4-yloxy)-N-[1-[(3,4-dichlorophenyl)methyl]-4piperidinyl]- (9CI) (CA INDEX NAME)




RN 328083-49-4 HCAPLUS

. .


CN Acetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2-[(5-phenyl-2pyrimidinyl)oxy]- (9CI) (CA INDEX NAME)




RN 328083-50-7 HCAPLUS CN Acetamide, N-[1-[(4-iodophenyl)methyl]-4-piperidinyl]-2-[(5-phenyl-2pyrimidinyl)thio]- (9CI) (CA INDEX NAME)




RN 328083-57-4 HCAPLUS
CN 1H-Pyrrole-2-propanamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]5-phenyl- (9CI) (CA INDEX NAME)




RN 328083-59-6 HCAPLUS CN 1,2-Ethanediamine, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-N'-(5phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




- RN 328083-68-7 HCAPLUS
 CN 4-Piperidinamine, 1-[(3,4-dichlorophenyl)methyl]-N-[3-[3-(2-pyridinyl)-
 - 1,2,4-oxadiazol-5-yl]propyl]- (9CI) (CA INDEX NAME)



RN 328083-70-1 HCAPLUS CN 1H-1,2,4-Triazole-3-propanamide, 5-(4-chlorophenyl)-N-[1-[(3,4dichlorophenyl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 328083-75-6 HCAPLUS
CN 2-Thiazoleacetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-4phenyl- (9CI) (CA INDEX NAME)




RN 328083-76-7 HCAPLUS

÷ -,


CN 4-Thiazoleacetamide, N-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-2phenyl- (9CI) (CA INDEX NAME)




- RN 328083-77-8 HCAPLUS
- CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(3,4-difluorophenyl)methyl]-4piperidinyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



- RN 328084-34-0 HCAPLUS
- CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(3-chloro-4-fluorophenyl)methyl]-4piperidinyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



- RN 328084-35-1 HCAPLUS
- CN 1,2,4-Oxadiazole-5-propanamide, N-[1-[(4-chloro-3-fluorophenyl)methyl]-4piperidinyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 328248-70-0 HCAPLUS

. .

CN 1,2,4-Oxadiazole-5-propanamide, N-[(3-exo)-8-[(3,4-dichlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




13

REFERENCE COUNT:

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTO



(57) Abstract: The invention compounds of formula (I) wherein \mathbb{R}^1 , Z, Q, m, n, X¹, X², X³, X⁴ and T are as the specification, processes for their p pharmaceutical compositions contain and their use in therapy, especiall treatment of chemokine receptor relate

ions.

and a second

2-2-12-22

A

L6 AN DN TI IN

.

1

- ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN 1998:631744 CAPLUS 129:310895 Benzamide compounds and their use as neovascularization inhibitors Inaba, Takayuki; Tada, Hiroki; Iwamura, Hiroyuki

.... · :

and and merel was a strend to be suggested water water